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1. Zusammenfassung
Weltweit steigt die Prävalenz kutaner Plattenepithelkarzinome (cSCCs), während die an der 
Tumorentstehung beteiligten Mechanismen noch nicht vollständig verstanden sind. Das Ziel dieser 
Studie war es, den Einfluss der Wnt/Beta-catenin und Ras-Raf-MEK-ERK MAPK-Signalwege an cSCC 
Entstehung und Wachstum mit Hilfe von 2D kultivierten Keratinozyten, 3D organotypischen Kulturen 
der Haut (OTCs) sowie primären humanen cSCC-Biopsien zu untersuchen.
Eine Deregulierung des Wnt Signalwegs, welche durch eine nukleäre Translokation von Beta-catenin 
detektiert werden kann, wurde bereits für cSCC Tumorzellen beschrieben. Wir konnten nicht nur eine 
abnormale Wnt/Beta-catenin-Aktivierung im Tumor, sondern auch oder ausschließlich in Fibroblasten 
des Stromas nachweisen, was eine zusätzliche Rolle eines deregulierten Wnt-Signalwegs impliziert. 
In Fibroblasten identifizierte eine Genexpressionsanalyse Interleukin-8 (IL-8), C-C motif chemokine 
2 (CCL-2) und Matrix metalloproteinase-1 (MMP-1) als Wnt/Beta-catenin induzierte Gene. Darüber 
hinaus wurden IL-8 und CCL-2 durch Wnt-3a-stimulierte Fibroblasten in OTCs sezerniert und konnten 
ebenso in humanen cSCCs nachgewiesen werden. Funktionell führte IL-8 und CCL-2 Stimulation von 
nicht-tumorigenen HaCaT-Zellen zu Hyperproliferation und ersten Invasionsmerkmalen. Die zusätzliche 
Behandlung von OTCs mit neutralisierenden Antikörpern gegen IL-8 und CCL-2 verhinderte diese Wnt-
abhängigen Effekte. MMP-1 wurde ebenfalls in Wnt-3a-stimulierten OTCs sowie in humanen cSCCs 
exprimiert und aktiviert. Ein Basalmembran-Abbau begünstigte invasives Wachstum von gutartig-
tumorigenen H-RasG12V transfizierten HaCaT-RAS A-5-Zellen, was zusätzlich die Bedeutung einer Wnt-
abhängige Interaktion zwischen Fibroblasten und Keratinozyten in der Karzinogenese aufzeigte.
Der Ras-Raf-MEK-ERK MAPK Signalweg ist in den meisten Melanomen aufgrund einer B-RafV600E-
Mutation konstitutiv aktiv und führt zu erhöhtem Wachstum und Überleben der Tumorzellen. Klinische 
Studien von Melanom-Patienten, die mit B-RafV600E-Inhibitoren, wie Vemurafenib, behandelt wurden, 
zeigen eine deutliche Wachstumsreduktion dieser Tumore. Andererseits führte diese Therapie zu einer stark 
beschleunigten Entwicklung von cSCCs und legte daher eine direkte Beteiligung von Vemurafenib in der 
Progression bestehender Läsionen nahe. Vemurafenib-Stimulation von B-RafV600E A375 Melanomzellen 
bestätigte einen Block des MEK-ERK-Signalwegs, führte allerdings in Fibroblasten und verschiedenen 
Keratinozyten zu einer MEK-ERK Hyperaktivierung. Trotz der stark erhöhten MAPK-Aktivität, waren 
weder Proliferation noch das Überleben der Keratinozyten verändert. Bei kontinuierlicher Vemurafenib-
Behandlung von HaCaT-Zellen kam es zu einem selektiven Wachstumsvorteil von Sub-Populationen. 
Um die Rolle einer abnormalen B-Raf-Aktivierung im Gewebe zu untersuchen, wurden OTCs 
kontinuierlich mit Vemurafenib behandelt. Zum einen erhöhte Vemurafenib direkt die Differenzierung 
von normalen und transformierten Keratinozyten, was auch als hyperkeratotische Haut in vielen 
Melanom-Patienten beobachtet wurde. Zum anderen verursachte Vemurafenib in HaCaT-RAS A-5-
Zellen eine hohe MMP-1 und MMP-3-Expression, die mit Collagen-Umbau und Invasion verbunden 
war. Da sowohl Differenzierung, als auch Invasion durch eine zusätzliche Behandlung mit dem MEK-
Inhibitor Cobimetinib verhindert wurden und dies auch bei Melanom-Patienten zu einer verminderten 
cSCC-Anzahl führte, zeigte, dass die Phänotypen in vitro sowie die sich rasch entwickelnden und gut 
differenzierten cSCCs in vivo eine Folge der Vemurafenib-induzierten ERK-Aktivierung darstellen.
Diese Arbeit beschreibt Wnt/Beta-catenin Deregulierung im Stroma sowie eine abnomale Raf-MEK-
ERK MAPK Aktivität in Keratinozyten als unabhängige Aspekte die zur cSCC-Progression beitragen.
2. Summary
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2. Summary
The prevalence of cutaneous squamous cell carcinoma (cSCC) is constantly increasing worldwide, 
however, the mechanisms driving tumorigenesis are not yet understood. The aim of this study was 
to understand the contribution of the Wnt/Beta-catenin and the Ras-Raf-MEK-ERK mitogen-activated 
protein kinase (MAPK) signaling pathways in cSCC development and progression using 2D keratinocyte 
monolayer cultures, 3D organotypic cultures of the skin (OTCs) as well as primary human cSCC samples.
Deregulated canonical Wnt signaling in tumor cells, as detected by nuclear translocation of Beta-
catenin, is well described for a number of human cSCCs. Here, we found that aberrant Wnt/Beta-
catenin activation is not restricted to tumor cells, but was additionally or exclusively detected in stromal 
fibroblasts. This suggested a second role of aberrant Wnt signaling in the stroma of developing cSCCs. 
Gene expression analysis of fibroblasts identified Interleukin-8 (IL-8), C-C motif chemokine 2 (CCL-2) 
and Matrix metalloproteinase-1 (MMP-1) as targets of Wnt/Beta-catenin. In agreement, IL-8 and CCL-2 
were secreted by Wnt-3a-stimulated fibroblasts in OTCs and could also be detected in human cSCCs in 
situ. As consequence, IL-8 and CCL-2 caused hyper-proliferation and early invasion of non-tumorigenic 
HaCaT keratinocytes. Importantly, neutralizing antibodies against IL-8 and CCL-2 abolished these Wnt-
dependent effects in OTCs. MMP-1 was also highly expressed in Wnt-3a-stimulated OTCs as well as 
in human cSCCs and was shown to be active. Furthermore, degradation of the basement membrane 
correlated with invasive growth of benign-tumorigenic H-RasG12V-transfected HaCaT-RAS A-5 cells, 
demonstrating the importance of the Wnt-dependent fibroblast-keratinocyte cross-talk for skin cancer 
progression.
Ras-Raf-MEK-ERK MAPK signaling is constitutively active in most melanomas due to a B-RafV600E-
mutation leading to increased proliferation and survival. Clinical trials targeting oncogenic B-Raf in 
melanoma by mutation-specific inhibitors like Vemurafenib displayed high response rates, but caused 
at the same time development of cSCCs. This suggested a direct involvement of Vemurafenib in the 
progression of pre-existing lesions. Vemurafenib stimulation of B-RafV600E-mutant A375 melanoma 
cells confirmed a block in MEK-ERK signaling, while all B-Rafwild-type cells, such as dermal fibroblasts 
and different keratinocytes, revealed MEK-ERK hyper-activation. Despite MAPK-activation, neither 
proliferation nor survival was altered in the keratinocytes. Analyses of continuously Vemurafenib 
treated HaCaT cells did not show genomic instability, but rather led to a selective growth advantage 
of genetic subpopulations. To study the role of aberrant B-Raf signaling in the tissue context, OTCs 
were treated with Vemurafenib. As result, Vemurafenib directly increased differentiation of the normal 
and transformed keratinocytes, resembling the hyperkeratotic skin phenotype of many melanoma 
patients. Remarkably, Vemurafenib stimulation of HaCaT-RAS A-5 cells caused high MMP-1 and 
MMP-3 expression, which correlated with Collagen remodeling and invasion into the stroma. Since both, 
differentiation and invasion were abolished by co-treatment with the MEK-inhibitor Cobimetinib and as 
patients receiving the same therapy showed highly decreased cSCC numbers, this strongly suggests that 
the phenotypes in in vitro as well as the rapidly developing well-differentiated cSCCs in vivo are direct 
results of Vemurafenib-induced ERK-activation.
Taken together, this work unraveled two novel aspects, namely Wnt/Beta-catenin deregulation in the 
tumor-stroma and aberrant Raf-MEK-ERK MAPK signaling in keratinocytes as oncogenic events 
driving cSCC progression.
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3. Introduction
3.1 Human skin
The Human skin covers a body surface of about 1.5-1.8 m2 and provides approximately 16% of the 
body mass. It fulfills a dual role since the skin protects the body from physical, chemical and biological 
hazards and in addition, it forms a barrier to retain fluids, thus preventing dehydration of the body. 
Furthermore, the skin also regulates temperature, electrolyte as well as water balance and has crucial 
functions in sensation and immune defense (Elias, 2005; Haake et al., 2001).
3.1.1 Compartments of the human skin
The human skin consists of three compartments: The subcutaneous fat represents the innermost layer, 
followed by the mesenchymally derived dermis and the epidermis, forming the protective body surface 
(Haake et al., 2001). The dermis is a connective tissue, mainly composed of extracellular matrix (ECM). 
This matrix mostly consists of Collagen type I + III fibrils and elastic fibers that are embedded in a 
gel of different glycosaminoglycans and proteoglycans. These proteins and polysaccharides are mainly 
secreted by fibroblasts, the major cell type of the dermis and provide the skin with tensile strength and 
elasticity. Besides fibroblasts, macrophages, mast cells, blood vessels and nerve endings are additionally 
found in the dermis (Fuchs, 2007; Haake et al., 2001). The epidermis on the other hand is a stratified 
squamous epithelium that forms the outer covering of the skin. The predominant cell type of this 
compartment are the keratinocytes but also other specialized cells like melanocytes, Langerhans cells 
and Merkel cells are present in a smaller number (Watt, 1989). Dermis and epidermis are divided by the 
basement membrane (BM), an amorphous and electron-dense structure (Kalluri, 2003), which serves as 
structural support, but has also regulatory functions (Aumailley and Timpl, 1986; Paulsson, 1992). The 
main component of the BM is Collagen type IV but also other ECM proteins like laminins and heparin-
sulphate proteoglycans (HSPGs) are present (Kalluri, 2003).
3.1.2 Epithelial proliferation and differentiation
Keratinocytes give rise to four distinct epidermal layers representing the different stages of cell 
differentiation: Stratum basale, Stratum spinosum, Stratum granulosum and Stratum corneum (Fuchs, 
1993; Green, 1977) (Fig. 1). The stratum basale harbors a single layer of highly proliferative keratinocytes 
with a cuboidal morphology. These cells are connected to the BM by hemidesmosomes, consisting 
of Integrin alpha-6 beta-4 heterodimers. In addition, keratinocytes interact laterally and suprabasally 
through desmosomes and other cell-cell junctions (Jones and Green, 1991). Both, hemidesmosomes and 
desmosomes are associated with the intracellular cytoskeleton, particularly with keratin intermediate 
filaments. Basal epidermal cells characteristically form keratin networks composed of Keratin-5 (K5) 
and Keratin-14 (K14). The suprabasal stratum spinosum is composed of several layers of keratinocytes 
that change their morphology to flattened polygonal cells. Once basal cells differentiate, the expression 
of K5/ K14 is downregulated and Keratin-1 (K1) and Keratin-10 (K10) are predominantly expressed 
within the suprabasal layers (Fuchs, 1993). Moving outwards through the 1-5 cell layers that compose 
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the stratum granulosum, keratinocytes dehydrate and thereby become further flattened. Moreover, 
cells are characterized by keratohyalin granules, which are mainly composed of pro-Filaggrin and 
synthesize the precursors of the cornified envelope such as Involucrin and Loricrin (Haake et al., 2001). 
As closer keratinocytes approach the outside, they prepare to degrade their cell organelles. By reaching 
the outermost layer, the stratum corneum, cells terminally differentiate into dead horn squamous 
(corneocytes). In particular, these cells contain a Filaggrin-stabilized keratin filament network, which is 
covalently linked to the proteinous cornified envelope that replaces the plasma membrane. Embedded 
in a lipid matrix and interconnected by modified desmosomes, the corneocytes form the permeability 
barrier of the skin (Fuchs, 1990; Nemes and Steinert, 1999).
The epidermis is a continuously renewing tissue. However, cell proliferation is limited to cells within 
the stratum basale that gives rise to the entire epidermis (Watt and Hogan, 2000). In this layer most 
cells are rapidly dividing progenies of stem cells, referred to as transiently amplifying cells. These 
keratinocytes undergo a limited number of cell divisions (Fuchs and Raghavan, 2002; Watt et al., 2006), 
before detaching from the basal layer, stop dividing and induce a program of terminal differentiation. 
Ultimately, they form the barrier of the skin and thereby replace cells which are constantly shed off 
(Fuchs, 1990).
3.2 Skin cancer
Skin cancer is the most common cancer worldwide and the incidence steadily increases, while the age 
of the patients decreases (Molho-Pessach and Lotem, 2007). It includes a number of tumor entities 
that arise from transformation of different cells: The malignant melanoma (MM) represents the most 
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Figure 1 | Organization of the human skin.
According to organization and function, the human skin is divided into compartments. The basement membrane 
seperates dermis from epidermis. The epidermis represents a multi-layered squamous epithelium, which can be 
further subdivided into Stratum basale, Stratum spinosum, Stratum granulosum and Stratum corneum (adopted 
from Fusenig et al. 1986 and kindly provided by Karsten Böhnke).
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aggressive skin tumor, which is derived from the pigment-producing melanocytes within the epidermis, 
dermis or mucosa. Basal cell carcinoma (BCC) as well as squamous cell carcinoma (SCC) derive from 
keratinocytes and are the most frequent skin carcinomas. Merkel cell carcinoma (MCC) originates 
from neuroendocrine cells of epidermis, hair follicle and mucosa. MCCs are rare but highly aggressive 
(Boukamp, 2005; Manola et al., 2000).
3.2.1 Malignant melanoma
Melanomas are the most aggressive skin tumor entity with high invasion, metastasis and mortality rates. 
It is believed that melanomas arise from intermitted UV exposure and in particular from severe sunburns 
during childhood. The risk for developing melanoma was also associated with specific mutations in 
the melanocortin-1 receptor, which is important in determining the type of melanin that is produced 
by melanocytes. Cells harboring these mutations may not be able to synthesize the photoreactive 
eumelanin, but instead express the photosensitizing pheomelanin, which causes mutations and drives the 
transformation of melanocytes (Boukamp, 2005). The most prevalent genetic change in MMs represents 
the deregulation of the Ras-Raf-MEK-ERK mitogen-activated protein kinase (MAPK) pathway. 
In normal cells, this highly conserved signaling pathway regulates cell proliferation, differentiation, 
senescence and apoptosis (Heidorn et al., 2010), depending on environmental cues (Marshall, 1995). In 
malignant melanoma, mutations in this pathway lead to a constitutive activation accompanied by cell 
cycle progression (Heidorn et al., 2010; Libra et al., 2005). The majority of mutations are found at amino 
acid position 600 of the B-Raf kinase. In particular, B-RafV600E, B-RafV600K, B-RafV600R, B-RafV600E2, 
B-RafV600D-alterations were frequently described (Bello et al., 2013).
3.2.2 BCC and SCC in normal and immunosuppressed persons
BCCs represent the most frequent skin tumors and generally develop at sites that are strongly exposed 
to sunlight, therefore, severe sunburns during childhood and adolescence increase the risk of BCC 
development. BCCs grow locally invasive and cause massive tissue destruction but metastasize 
rarely (< 0.1%). The second most frequent skin tumors are SCCs (Boukamp, 2005). Like in BCCs, 
the development strongly correlates to UV-irradiation (Cadet et al., 2005; de Gruijl, 1999). Since the 
SCC-incidence increases with age and the tumor surrounding skin provides evidence for chronic sun 
exposure, cumulative UV-exposure seems to be a crucial factor in tumor development and progression. 
Besides sun exposure, chronic exposure to arsenic, heat, X, gamma rays or HPV infections are discussed 
to cause SCC. The metastasis potential of cutaneous SCCs is generally low (1%) (Boukamp, 2005), 
but they are capable of local expansion, lymph node metastasis and distant metastasis (Euvrard et al., 
2003). This implies that SCC is mostly associated with a low mortality rate (de Gruijl, 1999). However, 
in immunosuppressed persons, e.g. after organ transplantation, SCC is the most common cancer type, 
occurring 65-250 times more frequently compared to the general population. The incidence even 
increases with the duration of immunosuppressive therapy. Moreover, SCCs in immunosuppressed 
patients grow rapidly, are more aggressive, recur more frequently and show an increased metastasis 
potential of 5-8% (Euvrard et al., 2003).
3. Introduction
6
3.2.3 Multistep process of cSCC development
As proposed by Hanahan and Weinberg, tumorigenesis in human reflects a multistep process driven by 
several genetic alterations transforming normal cells into tumor cells (Hanahan and Weinberg, 2000). 
The development of squamous cell carcinomas is also believed to be a multistep process, arising from 
actinic keratoses (AK), Bowen’s disease also known as carcinoma in situ (CIS) or keratoacanthoma 
(KA) (Boukamp, 2005; Burnworth et al., 2007). Evidence for the progression of AK to cutaneous SCC 
(cSCC) is provided by genetic studies reporting that AKs have a similar karyotypic profile as cSCCs, but 
lack some degree of complexity, which is consistent with an earlier stage in tumor development (Ashton 
et al., 2003). KAs are also genetically incomplete, likely still controlled by the environment and may 
further develop into invasive cSCCs (Burnworth et al., 2007) (Fig. 2).
In agreement with the dependence of cSCC-development on cumulative UV exposure, these tumors 
demonstrate the highest mutation rate of all cancers (Durinck et al., 2011) and consequently, display a 
complex genetic background with large cytogenetic heterogeneity. Common chromosomal losses for 
cSCCs are 3p, 4q, 5q, 8p, 9p, 13q, 15, 17p, while common gains are 3q, 4p, 7q, 8q, 9q, 11q, 14q, 
17q, Xq (Boukamp, 2005). The genetic aberrations in cSCCs seem to be a prerequisite for altered 
cellular functions contributing to carcinogenesis. One example for a characteristic and well-investigated 
aberration in cSCCs are mutations in the gene coding for p53 (TP53). TP53 shows UV-specific 
mutations in about 50% of all cSCCs, which impair its function to mediate cell cycle arrest in G1-
phase, repair damage or finally induce apoptosis. p53 mutations are supposed to represent the first 
step in the course of skin carcinogenesis by destabilizing the genome, as lack of functional p53 allows 
the transmission of non-lethal chromosomal damage to daughter cells (Boukamp, 2005; Brash, 2006; 
Brash et al., 1996). Furthermore, NOTCH1 and NOTCH2 were also identified to be mutated at an 
CIS
KA
simple karyotype
complex karyotype
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V-A / U
V-B
normal skin cSCC
p53
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Figure 2 | Progression model of squamous cell carcinoma.
Cutaneous squamous cell carcinoma (cSCC) derives from transformed keratinocytes, which is believed to be a 
multistep process. Cumulative UV irradiation causes specific mutations that inactivate p53 and cause additional 
genetic alterations further driving tumorigenic transformation. In course of skin carcinogenesis, carcinoma in situ 
(CIS) is a pre-invasive stage of SCCs. Keratoacanthoma (KA) represents a benign cutaneous squamous neoplasia. 
Both are genetically incomplete cSCCs that are likely to develop into invasive cSCCs with highly complex karyotypes 
(modified from Boukamp 2005/ Burnworth et al., 2007).
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early stage of cSCC development and are also detected in a high percentage tumors. In normal cells, 
Notch receptors transduce signals in response to ligands on neighboring cells regulating development 
through cell fate determination, growth and survival (Durinck et al., 2011; South et al., 2014; Wang 
et al., 2011). Another example for a frequent aberration in cSCCs is the amplification of chromosome 
11q13, which was associated with overexpression of Cyclin D1 in KAs and cSCCs. Cyclin D1 together 
with the Cyclin-dependent kinases 4 and 6 are essential in cell cycle progression during G1/S-phase. 
Accordingly, enhanced expression of this gene was reported to increase proliferation but also to disturb 
tissue homeostasis in vitro (Burnworth et al., 2007; Burnworth et al., 2006; Utikal et al., 2005). In 
contrast, mutations in the GTPase Harvey RAS viral oncogene (H-Ras) that are likely caused by UV-
radiation represent less frequent alterations. As mutations of this gene are found in only 5-15% of cSCCs, 
its contribution to skin cancer development is controversially discussed. Besides H-Ras, the GTPase 
neuroblastoma RAS viral oncogene (N-Ras) and Kirsten RAS viral oncogene (K-Ras) are also members 
of the Ras-family. These oncogenes encode small GTP-binding proteins, which transduce mitogenic 
signals, thereby playing a central role in regulating cell proliferation and apoptosis (Barbacid, 1987; 
Boukamp, 2005). In cSCCs, mutations in H-Ras seem to be an early event, since these were already 
described in precancerous lesions such as KAs. Thus, H-Ras likely exerts its oncogenic potential only 
in cooperation with other genetic changes that manifested in a step-wise fashion (Boukamp et al., 1995; 
Boukamp et al., 1990).
3.2.4 Role of the tumor microenvironment in cSCC formation
Besides the multistep tumor progression model that is driven by the accumulation of genetic alterations 
(Hanahan and Weinberg, 2000), it was hypothesized that the tumor surrounding tissue, the tumor 
stroma, plays an additional role in the carcinogenesis of keratinocytes. The normal stroma provides 
the connective tissue framework and consists of a specific ECM as well as cellular components like 
fibroblasts, leukocytes and blood-vessel cells (Mueller and Fusenig, 2002, 2004) (Fig. 3a). During 
tumor progression, tumor and stromal cells are in an intensive cross-talk with each other through cell-
cell interaction or the secretion of soluble factors (Mueller and Fusenig, 2004). Such factors involve 
chemokines, a subfamily of cytokines, which are structurally related small signaling molecules (Rollins, 
1997). Chemokines are secreted in response to signals like pro-inflammatory cytokines and mediate the 
chemoattraction of especially inflammatory cells in a paracrine manner. Moreover, chemokines play 
a role in other biological functions including cell proliferation, migration, angiogenesis and protease 
induction, which demonstrates their pro-tumorigenic potential (Bergers and Benjamin, 2003; Coussens 
and Werb, 2002; Deshmane et al., 2009; Gillitzer and Goebeler, 2001). On the other hand, cancer cells 
themselves can alter their surrounding stroma to a permissive and supportive environment by secreting 
stroma-modulating factors like interleukins (ILs), granulocyte-macrophage colony-stimulating factors 
(CSFs), Transforming growth factor-beta (TGF-beta) or Vascular endothelial growth factor (VEGF) 
(Mueller and Fusenig, 2004).
Tumor and stromal cells are also capable of secreting proteases like matrix metalloproteases (MMPs), 
which are capable of remodeling and degrading ECM and BM. The MMP family consists of over 24 
zinc-dependent enzymes that are usually induced in wound-edge basal keratinocytes at positions of 
disrupted BM. This MMP expression allows keratinocytes to migrate across the dermal or provisional 
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matrix in order to repair damaged skin. However, MMPs also play a key role in virtually every step 
of tumorigenesis. They promote tumor cell invasion, stimulate blood vessel infiltration, metastasis, 
and release numerous growth factors by ECM degradation (Bergers et al., 2000; Brooks et al., 1996; 
Giannelli et al., 1997; Kalluri, 2003; Lynch and Matrisian, 2002; Mueller and Fusenig, 2004; Rohani 
et al., 2014). Therefore, it is not surprising that MMP expression is elevated in nearly all solid tumors, 
including breast, colon, pancreas and melanoma, which is often correlated with decreased survival 
(Egeblad and Werb, 2002).
The release of growth factors by tumor cells can activate stromal cells such as fibroblasts, smooth-muscle 
cells and adipocytes that in turn secrete paracrine factors involved in tumorigenesis (Kalluri, 2003; Lynch 
and Matrisian, 2002; Mueller and Fusenig, 2004). Moreover, these factors allow transdifferentiation of 
fibroblasts into myofibroblasts. These cells show a spindle-shaped morphology and share characteristics 
of fibroblasts and smooth-muscle cells. In association with cancer cells, myofibroblasts are also known 
as carcinoma-associated fibroblasts (CAFs). The presence of this cell type in the tumor stroma has been 
observed in many cancer types, such as breast, prostate and skin cancer. CAFs were often associated 
with tumor growth, onset of invasion and metastasis. The secretion of MMPs is frequently involved in 
later stages of tumor progression (Egeblad and Werb, 2002; Mishra et al., 2011; O-Charoenrat et al., 
2001). Additionally, growth factors and cytokines such as Hepatocyte growth factor (HGF), VEGF or 
chemokine (C-C motif) ligand 2 (CCL2) further activate tumor as well as stroma and recruit inflammatory 
Figure 3 | Tumor microenvironment and cSCC development.
a | A normal epithelium is composed of keratinocytes in the epidermis that are separated by the basement 
membrane (BM) from the dermal or stromal compartment. The latter is composed of collagen, fibroblasts, blood 
vessels and a few leukocytes. b | During transition to pre-malignant dysplasia, differentiation of keratinocytes is 
disturbed, leading to a hyperplastic epithelium with an intact BM. Fibroblasts become activated and the number of 
macrophages increases. c | Further progression to a carcinoma is associated with an increase in inflammatory cells 
and angiogenesis resulting in a high number of leaky tumor vessels. Fibroblasts differentiate into myofibroblasts 
(known as carcinoma-associated fibroblasts, CAFs) resulting in the expression of growth factors, matrix components 
and proteases like MMPs that degrade ECM components such as Collagen. Following BM degradation, tumor cells 
invade the underlying dermis (adopted from Mueller and Fusenig 2004).
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cells (Fig. 3b-c). Thus, genetic alterations in combination with a tumor-supportive microenvironment 
seem to mediate initiation, progression and invasive growth of SCCs (Kalluri and Zeisberg, 2006; 
Mueller and Fusenig, 2004; Orimo et al., 2001).
3.3 Signaling pathways in cSCC progression
As cSCC demonstrates a high genetic complexity arising from a mutation rate of approximately 
1 mutation per 30 kbp coding sequence (Durinck et al., 2011), definite driver events or signaling 
pathways involved in carcinogenesis remain largely elusive. In many diseases, signaling cascades are 
inappropriately regulated and contribute to carcinogenesis. Accordingly, deregulated Wnt signaling 
has been observed in numerous cancer types (Klaus and Birchmeier, 2008), such as colorectal cancer, 
hepatocellular carcinoma, leukemia or hair follicle tumors (Clevers, 2006; Vermeulen et al., 2010). The 
fact that cSCCs show frequent amplifications of the chromosomes 7q, 8q, 11q, or 17q (Burnworth et 
al., 2006; Popp et al., 2002; Popp et al., 2000) that carry genes of the Wnt signaling pathway like Wnt 
ligands or Frizzled receptors, points to a role of deregulated Wnt signaling also in cSCC development 
and/ or progression. Besides canonical Wnt signaling, additional pathways are likely to be involved in 
cSCC tumorigenesis. Deregulation of MAPKs has been reported for a wide range of diseases including 
different types of human cancer (Mebratu and Tesfaigzi, 2009). In melanoma, especially the Ras-Raf-
MEK-ERK MAPK pathway is frequently mutated and essential for tumorigenesis (Heidorn et al., 
2010). As a novel melanoma therapy specific B-Raf inhibitors are used. Unexpectedly, this led to the 
development of cSCCs as adverse effect, suggesting an involvement of the Ras-Raf-MEK-ERK MAPK 
pathway also in SCCs progression (Bollag et al., 2010).
3.3.1 The canonical Wnt signaling pathway
The highly conserved Wnt/Beta-catenin signaling pathway plays a crucial role in virtually every aspect 
of embryonic development of all animal species and controls homeostatic self-renewal in a wide range 
of adult tissues. In particular, this pathway regulates proliferation, migration, cell fate determination and 
organogenesis (Clevers, 2006; Klaus and Birchmeier, 2008; Logan and Nusse, 2004; Reya and Clevers, 
2005; Watt and Collins, 2008). In skin, the Wnt pathway is involved in development and maintenance of 
hair follicles (Gat et al., 1998) as well as in epidermal bulge stem cell renewal and linage selection (Watt 
et al., 2006). Moreover, the canonical and non-canonical Wnt pathways are critical in cutaneous wound 
repair (Fathke et al., 2006). The central player of the signal transduction is the protein Beta-catenin, 
which is an additional component of adherens junctions in epithelia. There, it is an essential and highly 
stable binding partner for the cytoplasmic tail of E-cadherin (Peifer et al., 1992).
In absence of Wnt ligands, cytoplasmic Beta-catenin is recruited to a destruction complex. This 
complex consists of Adenomatous polyposis coli (APC), Axins as well as Casein kinase 1 alpha (CK1-
alpha) and Glycogen synthase kinase-3 beta (GSK-3 beta). Subsequently, Beta-catenin is N-terminally 
phosphorylated by both kinases, ubiquitinated by Beta-transducin repeat-containing protein (Beta-
TrCP) and finally proteasomally degraded. As consequence, cytoplasmic Beta-catenin levels are low 
and Wnt pathway target genes are not expressed (Fig. 4a). Canonical Wnt signaling is initiated by Wnt 
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ligands released from signaling cells that lead to the formation of a trimeric complex with Frizzled 
(Fz) transmembrane receptors and Low-density lipoprotein receptor-related protein 5/ 6 (LRP-5/ -6) 
co-receptors in target cells. Thereafter, LRP-5/ 6 are phosphorylated by GSK-3 beta, CK1-alpha and 
possibly other yet not identified kinases. Dishevelled (DSH) is recruited to Fz at the plasma membrane 
and polymerizes with other DSH molecules. These events serve as mediators to tether Axin molecules 
to the plasma membrane, which finally inactivate the destruction complex. As consequence, cytoplasmic 
Beta-catenin is stabilized, translocates into the nucleus and forms a transcriptionally active complex 
with LEF/ TCF transcription factors by replacing the protein Groucho. This complex interacts with 
co-activators like B-cell CLL/ lymphoma 9 protein (Bcl-9), Pygopus or CREB-binding protein (CBP) 
Figure 4 | The canonical Wnt/Beta-catenin signaling pathway.
a | In absence of Wnt ligands or in presence of inhibitors like Dickkopf (DKK), Beta-catenin is recruited into the 
destruction complex, consisting of Adenomatous polyposis coli protein (APC), Axins and two kinases: Following 
N-terminal phosphorylation by Casein kinase I isoform alpha (CKI-alpha) as well as by Glycogen synthase kinase-3 
beta (GSK-3 beta) and subsequent ubiquitylation by Beta-transducin repeat-containing protein (beta-TrCP), Beta-
catenin is proteasomally degraded. The co-repressor Groucho ensures transcriptional repression of Wnt target 
genes by binding to Lymphoid enhancer-binding factor (LEF)-T-cell factor (TCF) transcription factors. b | In the 
presence of Wnt ligands, Low-density lipoprotein receptor-related protein 5 (LRP-5) and LRP6 are phosphorylated 
by CKI-gamma and GSK-3 beta. Dishevelled (DSH/ DVL) proteins are recruited to the plasma membrane and 
interact with Frizzled (Fz/ FZD) receptors and further Dishevelled molecules. Interaction of Axin with phosphorylated 
LRP-5, LRP-6 and the Dishevelled polymer inactivates the destruction complex. This stabilizes Beta-catenin, which 
forms a transcriptionally active complex with LEF and TCF by displacing Grouchos in the nucleus. B-cell CLL/
lymphoma 9 protein (Bcl-9), Pygopus and CREB-binding protein (CBP) serve as co-activators, while MYC, CYCD1 
(Cyclin D1), MMPs and AXIN2 are direct target genes (adopted from Klaus and Birchmeier 2008).
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in order to mediate gene expression of Wnt target genes (Fig. 4b). A large number of Wnt/Beta-catenin 
target genes have been identified and include players of the pathway itself like AXIN2, providing 
positive- and negative feedback controls during signaling. Additional direct Wnt target genes include 
MYC, CYCD1 (Cyclin D1), different MMPs as well as angiogenic factors like VEGF, pointing to a 
direct role of this pathway in carcinogenesis. However, most of the target genes are not universal but 
rather tissue and cell type specific (Clevers, 2006; Klaus and Birchmeier, 2008).
3.3.2 Wnt/Beta-catenin signaling in cSCC development and progression
By analyzing 32 human cSCCs and in agreement with other laboratories (Brasanac et al., 2005; Doglioni 
et al., 2003; Liu et al., 2008; Lyakhovitsky et al., 2004; Malanchi et al., 2008; Papadavid et al., 2001; 
Papadavid et al., 2002), we could detect nuclear Beta-catenin, a hallmark for Wnt pathway activity, in 
cSCC tumor cells in situ. Interestingly and different from studies performed by others, we could detect 
nuclear Beta-catenin also in cells of the surrounding tumor stroma (Fig. 5b), while normal skin was 
negative (Fig. 5a, c, e). These cells were positive for the mesenchymal marker Vimentin and stained 
negative for the epidermal Keratin-14 (Fig. 5d) as well as for the leukocyte marker CD45 (Fig. 5f). 
This argued that the Beta-catenin-positive stromal cells are likely fibroblasts. Besides the direct effect 
of the Wnt signaling pathway on tumor cells, this observation suggested an additional indirect effect 
through fibroblasts. These stromal cells may be activated by Wnt as well and thus, contribute to cSCC 
progression in a paracrine manner (Wischermann, 2009).
This hypothesis was further substantiated by functional studies in vitro. We could show that fibroblasts are 
more sensitive to Wnt-3a stimulation compared to the spontaneously immortalized and non-tumorigenic 
HaCaT keratinocytes. Moreover, global gene expression analysis revealed that Wnt-3a stimulation of 
dermal fibroblasts results in the upregulation of cytokines including Interleukin-8 (IL-8/ CXCL-8) and 
C-C motif chemokine 2 (CCL-2/ MCP-1) as well as of ECM remodelers like MMP-1 (Fig. 5g). Thus, 
IL-8, CCL-2 and MMP-1 might be involved in development or progression of cSCCs (Sobel, Tham 
et al., 2015). While MMP-1 can directly influence invasion by degrading ECM and BM components 
(Lynch and Matrisian, 2002), the upregulation of the cytokines IL-8 and CCL-2 suggested a Wnt-
induced cross-talk between stromal fibroblasts and HaCaT keratinocytes. IL-8, a member of the CXC 
chemokine subfamily, is known to be expressed by leukocytes, fibroblasts, endothelial and different 
tumor cells. Upon secretion, this chemokine plays an important role in inflammation, chemoattraction and 
angiogenesis but most importantly in tumor growth and metastasis (Li et al., 2005; Waugh and Wilson, 
2008). It was also shown that IL-8 stimulates proliferation of cultured keratinocytes (Steude et al., 2002; 
Tuschil et al., 1992). CCL-2 belongs to the CC chemokine subfamily and is secreted by a variety of 
cells including epithelial, endothelial, smooth-muscle, meningeal, astrocyte, microglial cells, fibroblasts 
as well as tumor cells (Conti and Rollins, 2004; Deshmane et al., 2009). However, the major cell types 
secreting CCL-2 are monocytes and macrophages (Yoshimura et al., 1989). It regulates migration and 
infiltration of different leukocytes but was shown to also increase proliferation of endothelial cells. 
There is evidence that IL-8 and CCL-2 act in tumor-stroma communication in several malignancies 
(Mishra et al., 2011). Moreover, both factors belong to the IL-6-induced cytokine network promoting 
malignant tumor growth in the HaCaT skin carcinogenesis model (Lederle et al., 2011). In order to 
understand the contribution of Wnt/Beta-catenin in cSCC tumorigenesis, it was crucial to study the role 
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of IL-8, CCL-2 and MMP-1 in more detail.
3.3.3 Ras-Raf-MEK-ERK MAP kinase pathway
Besides Wnt/Beta-catenin the Ras-Raf-MEK-ERK MAPK pathway might also be involved in cSCC 
progression. This highly conserved signaling cascade regulates cell responses to environmental cues 
(Marshall, 1995) regulating cell proliferation, differentiation, senescence and apoptosis (Heidorn et al., 
2010). In general, extracellular stimuli such as cytokines, mitogens, hormones, oxidative stress or heat 
induce the signaling cascade by interacting with receptor complexes. These receptors include receptor 
tyrosine kinases (RTKs) like Epithelial growth factor receptor (EGFR), Mast/stem cell growth factor 
receptor Kit (c-Kit) or G protein-coupled receptors. Downstream signaling from RTKs is mediated 
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Figure 5 | Nuclear Beta-catenin is found in stromal fibroblasts of human cSCCs and direct Wnt-3a 
stimulation of NHDF induces cytokines and matrix modulation factors in fibroblasts.
a, b | Beta-catenin IHC (brown) of normal human skin shows Beta-catenin staining at the plasma membrane of 
keratinocytes, but not in fibroblasts (a). In SCCs, Beta-catenin was additionally detected in nuclei of tumor cells 
(upper arrow) as well as of cells within the tumor-stroma (lower arrow, b). c, d | IIF for Vimentin (green) and 
Keratin-14 (K14, red) identified the majority of cells within the ECM of normal skin (c) and the tumor-stroma (d) 
as mesenchymal cells. e, f | CD45 IHC (brown) showed no accumulation of inflammatory cells within the ECM of 
normal skin (e) or the tumor-stroma (f). g | NHDF were stimulated with Wnt-3a (100 ng/ml) for 8 and 24 h. Global 
gene expression analyses followed by hierarchical cluster analyses revealed 50 (8 h) and 87 (24 h) differentially 
expressed genes (yellow/upregulation, blue/downregulation). Wnt/Beta-catenin regulated genes were summarized 
in functionally related groups: direct Wnt target genes (AXIN2, APCDD1), cytokines (IL8, CCL2, CXCL6, CXCL10, 
CCL8, IL32) and ECM/cytoskeleton remodeling genes (TNFAIP6, PDPN, MMP1) (modified from Sobel, Tham et 
al. 2015).
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by the Ras-activating guanine nucleotide exchange factor Son of sevenless (SOS). The GDP to GTP 
conversion leads to the activation of the small guanine nucleotide binding protein Ras, which initiates 
MAPK signaling through the kinase Raf. Subsequently, this serine/ threonine kinase phosphorylates and 
thereby activates the kinase MEK that further phosphorylates the kinase ERK, leading to the activation 
of downstream transcription factors (Chang et al., 2003; Mebratu and Tesfaigzi, 2009). However, the 
pathway is more complex, as there are three Ras (H-Ras, K-Ras and N-Ras), three Raf (A-Raf, B-Raf, 
C-Raf/ Raf-1), two MEK (MEK1, MEK2) and two ERK (ERK1, ERK2) proteins with non-redundant 
function. In addition, the MAP kinase pathway is not linear. In normal cells, B-Raf forms homodimers 
or heterodimers with C-Raf in a Ras-dependent manner initiating downstream signaling via MEK and 
ERK (Heidorn et al., 2010). Moreover, cross-talks between this pathway and the Phosphatidylinositol 
4,5-bisphosphate 3-kinase (PI3K)-Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-
specificity protein phosphatase (PTEN)-Akt pathway occur at multiple levels (Vultur et al., 2011; 
Zaravinos et al., 2009) (Fig. 6).
In malignant melanoma (MM) mutations in KIT, NRAS and especially BRAF were detected in either 
3-5%, 15-20% or 30-70% of tumors (Davies et al., 2002; Dong et al., 2003; Heidorn et al., 2010; Libra 
et al., 2005; Tap et al., 2010). Among different BRAF mutations, the substitution of glutamic acid to 
valine at position 600 (B-RafV600E, T to A missense transversion at nucleotide 1799) accounts for about 
90% of B-Raf mutations. As consequence, the auto-inhibitory state of B-Raf is prevented allowing 
Figure 6 | Ras-Raf-MEK-ERK signaling, key mutations and therapeutical targets in melanoma.
Extracellular stimuli such as cytokines, mitogens, hormones, oxidative stress or heat induce the signaling cascade 
by interacting with receptor complexes including the receptor tyrosine kinases (RTKs) Epithelial growth factor 
receptor (EGFR), Mast/stem cell growth factor receptor Kit (c-Kit) or G protein-coupled receptors. RTK-activity leads 
to downstream signaling via Ras-activating guanine nucleotide exchange factor Son of sevenless (SOS) and Ras. 
Subsequently, Ras stimulates MAPK signaling through Raf, MEK and ERK leading to the activation of transcription 
factors (TFs) and gene regulation. Cross-talks between Ras-Raf-MEK-ERK signaling and the PI3K-PTEN-Akt 
pathway occur at multiple levels. Especially the Ras-Raf-MEK-ERK pathway is frequently associated with mutations 
in cancer. BRAF is the most commonly activated oncogene in melanomas, followed by NRAS and KIT. Drugs with 
a potential therapeutic impact on melanoma are listed in the purple boxes (adopted from Ji et al. 2012).
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B-Raf signaling as monomeric protein with a 500-fold increased activity, thus constitutively stimulating 
MEK-ERK signaling (Heidorn et al., 2010). This prevents apoptosis and induces cell cycle progression 
(Libra et al., 2005) demonstrating the need for inhibitors targeting different components of the pathway 
(Fig. 6).
3.3.4 B-Raf kinase inhibitors in therapy of malignant melanoma
Since melanomas highly depend on Ras-Raf-MEK-ERK pathway activity, the inhibition of B-Raf 
represented an attractive target for small molecule inhibitors (Vultur et al., 2011). Two very promising 
and highly selective ATP-competitive B-RafV600E-inhibitors are Vemurafenib/ PLX4032 (Plexxikon, 
Roche) and Dabrafenib/ GSK2118436 (GlaxoSmithKline). During clinical trials of B-RafV600E-mutant 
melanoma patients, both inhibitors showed superior response rates of 50% (Bollag et al., 2010; 
Flaherty et al., 2010; Menzies et al., 2012; Robert et al., 2011). Compared to the former standard care, 
chemotherapy with Dacarbazine, Vemurafenib and Dabrafenib increased progression free survival 
(PFS) from 1.6-2.7 to 6.9 months and overall survival (OS) from 9.7-15.6 to either 13.6 or 18.2 months 
in Phase III clinical trials (Queirolo et al., 2015). Intriguingly, responses to Vemurafenib were seen 
at all sites of metastatic disease, including liver, small bowel and bone (Menzies et al., 2012). While 
treatment of tumors harboring B-RafV600E resulted in many cases in partial or complete tumor regression, 
no tumor regression was observed in cells carrying B-Rafwild-type. This rendered both B-Raf inhibitors 
as promising treatment strategy exclusively for B-Raf mutant melanomas. In contrast, traditional 
approaches or broad-spectrum kinase inhibitors like Sorafenib (Nexavar, Bayer) showed disappointing 
results in melanoma therapy, likely due to the non-specific broad-spectrum kinase inhibitory activity and 
the associated toxicity (Vultur et al., 2010, 2011). Therefore, Vemurafenib was approved by the FDA for 
the treatment of malignant melanoma in 2011 and is sold as Zelboraf, while Dabrafenib was approved 
in 2013 and is traded as Tafinlar (Press releases by FDA in August 2011 and May 2013). Besides MM, 
Vemurafenib was also employed to treat patients suffering from B-RafV600E mutant stage IV non-small-
cell lung cancer (Peters et al., 2013) and in combination with the chemotherapeutic Vinblastine to treat 
ganglioglioma (Rush et al., 2013).
However, as melanomas develop resistance against Vemurafenib within 2-18 months after onset of 
treatment, major research efforts focus on the mechanism of resistance development (Molina-Arcas and 
Downward, 2012). In order to prevent reactivation of Ras-Raf-MEK-ERK signaling and subsequent 
resistance, novel therapies combining B-Raf inhibitors like Vemurafenib or Dabrafenib with the 
MEK inhibitors Cobimetinib/ GDC-0973 (Roche) or Trametinib/ GSK1120212 (GlaxoSmithKline), 
respectively, are employed in clinics. In particular, Phase III trials combining Vemurafenib + Cobimetinib 
or Dabrafenib + Trametinib improved PFS from 6.9 months, achieved with B-Raf inhibitor mono-
therapy, to either 9.9 or 9.3/ 11.4 months (Queirolo et al., 2015).
3.3.5 Adverse effects by kinase inhibitors targeting B-Raf
During clinical trials of specific B-RafV600E-inhibitors adverse effects such as fatigue, photosensitivity, 
rashes, hair loss, joint pain, abnormal liver function, gastrointestinal problems but mainly cutaneous 
adverse effects including KAs and cSCCs were monitored (Flaherty et al., 2010). KAs and cSCCs 
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occurred within a median time of 8 weeks in 4-31% of MM patients treated with Vemurafenib (Anforth 
et al., 2013). Similarly, Dabrafenib led to the development of 9-19% KAs/ cSCCs in Phase I-III clinical 
trials (Flaherty et al., 2012; Long et al., 2014). Since both, KAs and cSCCs, are typical UV-induced 
tumors (Boukamp, 2005), it is not surprising that these carcinomas predominantly occur in sun-exposed 
areas of the skin. This favors the idea that pre-existing oncogenic mutations potentiate the effects of the 
kinase inhibitors, rather than leading to a de novo development (Bollag et al., 2010). Interestingly and 
different from sporadic cSCCs, the developing tumors were always well-differentiated. Besides KAs 
and cSCCs, treatment with both specific B-Raf inhibitors led to the development of verrucous keratosis 
in 29%, which is histologically characterized as hyperkeratotic papules, and hyperkeratosis in 6-51% of 
melanoma patients (Anforth et al., 2013; Anforth et al., 2015). Recently performed safety-evaluations 
of Vemurafenib on either 3,222 or 675 treated melanoma patients showed the development of KAs and 
cSCCs in 14-29% and hyperkeratosis in 19% of patients (Larkin et al., 2014b; McArthur et al., 2014). 
Hyperkeratotic mucosal lesions and one case of oral SCC upon treatment with specific B-Raf inhibitors 
was also described (Vigarios et al., 2015). In addition, one case report describes a MM patient developing 
chronic myelomonocytic leukemia (CMML) after 11 days of Vemurafenib therapy. In particular, ERK-
signaling was highly activated in N-RasG12R-mutant monocytes leading to an expansion of this population 
(Callahan et al., 2012). Besides haematopoietic tumor growth, a case of a MM patient receiving 
Vemurafenib experienced rapid growth of a pre-existing K-RasQ61L-mutant pancreatic adenocarcinoma 
as well as subsequent hepatic metastases (Grey et al., 2014). The development of new primary cutaneous 
melanomas in patients receiving either Vemurafenib or Dabrafenib was also observed. Interestingly, all 
melanocytic lesions were B-Rafwild-type (Zimmer et al., 2012). Taken together, these observations suggest 
that B-Raf-inhibitors are not only affecting B-Raf mutant melanocytes.
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Figure 7 | Vemurafenib induced block and hyper-activation of MEK-ERK signaling.
a | Melanoma cells rely on ERK-activity for tumor growth. The specific B-Raf inhibitor Vemurafenib (VEM) was 
designed to binds mutant B-RafV600E proteins as ATP-competitive inhibitor, abrogate downstream signaling via MEK-
ERK and thereby prevent tumor growth. b, c | In B-Rafwild-type cells, Vemurafenib was hypothesized to cause a 
paradoxical MEK-ERK hyper-activation. Besides B-Rafwild-type status, both hypothesized models require Ras activity 
either by Ras mutation or upstream signaling through receptor tyrosine kinases (RTKs). One proposed mechanism 
by Poulikakos et al. (2010) suggests a low local concentration of the specific B-Raf inhibitor as third requirement 
leading to a stochastic Vemurafenib binding of only one Raf protein in a C-Raf-C-Raf homodimer or C-Raf-B-Raf 
heterodimer. Subsequently, a conformational change of the bound Raf subunit hyper-actives the second (b). The 
second proposed mechanism by Heidorn et al. and Hatzivassiliou et al. (2010) suggests that a specific B-Raf 
inhibitor resolves the auto-inhibitory state of B-Raf, allowing increased Raf dimer formation in a Ras-dependent 
manner, which mediates MEK-ERK hyper-activation (c).
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In search for mechanisms leading to the described cutaneous adverse effects in melanoma therapy, it was 
suggested that the same small molecule inhibitors, which efficiently block mutant B-Raf signaling (Fig. 
7a) may also lead to a paradoxical activation of this pathway in B-Rafwild-type cells. As second requirement, 
both currently hypothesized models require Ras activity resulting from a Ras mutation or activation of 
upstream pathway components like RTKs (Hatzivassiliou et al., 2010). The first proposed mechanism 
suggests a low local concentration of a specific B-Raf inhibitor as third requirement. As consequence, the 
inhibitor stochastically binds and blocks only one Raf protein of a C-Raf-C-Raf homodimer or C-Raf-
B-Raf heterodimer. This leads to a conformational change of the bound subunit that trans-activates the 
second subunit of the complex and causes pronounced downstream signaling. Consequently, a high 
local B-Raf inhibitor concentration would lead to a block of both Raf subunits within a dimer preventing 
further downstream signaling (Fig. 7b). According to this hypothesis, a low drug-bioavailability of a 
B-Raf inhibitor in skin could be the reason for the paradoxical MEK-ERK activation by Vemurafenib 
(Poulikakos et al., 2010). The second proposed mechanism claimed that a specific B-Raf inhibitor rather 
resolves the B-Raf auto-inhibitory state allowing Raf dimer formation in a Ras-dependent manner, than 
acting on the already formed dimer itself (Hatzivassiliou et al., 2010; Heidorn et al., 2010) (Fig. 7c). 
The outcome of both models is a so called B-Raf inhibitor induced MEK-ERK hyper-activation leading 
to increased proliferation and transformation of melanoma cells. However, additional mutations may 
also play a role in tumorigenesis (Robert et al., 2011). This indicates that the development of adverse 
cutaneous effects actually depends on the RAS-RAF-MEK-ERK pathway, arguing for specific rather 
than off-target effects by the B-Raf inhibitors.
3.4 Aim of the study
The prevalence of cSCCs is constantly increasing worldwide especially in elderly or immunosuppressed 
transplant recipients, whereas the mechanism of tumor initiation and progression are not yet fully 
understood. In this thesis, I aimed to investigate two distinct signaling pathways regarding their role 
in cSCC development. First, the role of Wnt/Beta-catenin activated dermal fibroblasts was further 
analyzed, as this was identified in a subset of human cSCCs. Second, the effect of the B-RafV600E 
inhibitor Vemurafenib and particularly the relevance of Ras-Raf-MEK-ERK MAPK signaling in cSCC 
progression, observed in treated melanoma patients, was dissected. Besides a direct effect of Vemurafenib 
on keratinocytes, a stromal modulation changing the fibroblasts’ secretome may drive keratinocyte 
tumorigenesis, as well. To address these questions, experiments were conducted using primarily the 
HaCaT skin carcinogenesis progression models in monolayer cultures as well as in 3D OTCs resembling 
human skin. This allowed the analysis of interactions between tumor and stromal cells through direct 
interactions or soluble factors. Thus, the following questions were the basis for the present study.
(1) Are the Wnt-3a induced cytokines IL-8 and CCL-2 as well as the matrix remodeling factor 
MMP-1 also expressed in OTCs? What is their effect on epithelial morphology and carcinogenesis?
(2) Is Vemurafenib induced MEK-ERK hyper-activation also observed in B-Rafwild-type keratinocytes 
and dermal fibroblasts? What is the impact of Vemurafenib or Ras-Raf-MEK-ERK signaling on 
epithelial morphology and tumorigenesis?
(3) Are identified mechanisms also found in human primary cSCC samples in situ?
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4. Materials and Methods
4.1 Materials
4.1.1 Technical equipment
Table 2 | Technical equipment.
Type Name Company
Centrifuges Centrifuge 5415 R Eppendorf, Cologne, Germany
Centrifuge 5417 R Eppendorf, Cologne, Germany
Heraeus Labofuge 400 Thermo Fischer Scientific, 
Fermont, USA
Cell culture Casy Cell Counter Schärfe System GmbH, 
Reutlingen, Germany
Cell culture incubator Thermo Fischer Scientific, 
Fermont, USA
FACSCanto II Flow Cytometer BD Biosciences, Heidelberg, 
Germany
FastPrep FP120 Thermo Fischer Scientific, 
Fermont, USA
Microscopes AX-70 (Fluorescence images) Olympus Deutschland, 
Hamburg, Germany
BX-51 (Brightfield images) Olympus Deutschland, 
Hamburg, Germany
Cell Observer (Proliferation images) 
equipped with Colibri imaging system
Zeiss, Oberkochen, Germany
IX-70 (Cell culture images) Olympus Deutschland, 
Hamburg, Germany
CCD-Cameras AxioCam ERc 5s (Cell culture images) Zeiss, Oberkochen, Germany
AxioCam MRm (Proliferation images) Zeiss, Oberkochen, Germany
OSIS Color View (Brightfield images) Olympus Deutschland, 
Hamburg, Germany
OSIS F View (Fluorescence images) Olympus Deutschland, 
Hamburg, Germany
PL60 Digital Camera Samsung, Schwalbach/ Ts., 
Germany
Software BD FACSDiva Software 8.0 BD Biosciences, Heidelberg, 
Germany
cell^R/ cell^D Imaging Software 3.2 Olympus Deutschland, 
Hamburg, Germany
Creative Suite 5 Adobe Systems, San José, 
USA
GraphPad Prism 4 GraphPad Software, La Jolla, 
USA
Fiji/ ImageJ 2.0.0-rc-23 http://fiji.sc/wiki/index.php/Fiji
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FlowJo v10.0.7 FlowJo, Ashland, OR, USA
LightCycler 480 Software 1.5.0 SP3 Roche Applied Sciences, 
Mannheim, Germany
ZEN 2012 (blue edition) Zeiss, Oberkochen, Germany
Miscellaneous Cryostat Cryotome Leica, Wetzlar, Germany
Fluoroskan Ascent Thermo Fischer Scientific, 
Fermont, USA
LightCycler 480 Instrument II Roche Applied Sciences, 
Mannheim, Germany
MCK Software (M-FISH analysis) Leica, Wetzlar, Germany
Microtome Leica, Wetzlar, Germany 
Mini-PROTEAN Tetra Cell Bio-Rad, Munich, Germany
Mini Trans-Blot Module Bio-Rad, Munich, Germany
Multiskan FC Microplate Photometer Thermo Fischer Scientific, 
Fermont, USA
NanoDrop ND-1000 Thermo Fischer Scientific, 
Fermont, USA
Peltier Thermal Cycler MJ Research, San Francisco, 
USA
PowerPac HC Bio-Rad, Munich, Germany
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4.1.2 Chemicals and materials
Table 3 | Chemicals and materials.
Name Company
5’Brom-2‘-desoxyuridin/ 5‘-Brom2‘-Desoxycytidin (BrdU) Sigma-Aldrich, Taufkirchen, 
Germany 
6-well, 24-well and 96-well plates (flat bottom) Nunc, Wiesbaden, Germany 
Acrylamide / Bis-Solution (40%, 37.5:1) Bio-Rad, Munich, Germany
Agarose Biozym, Hessisch Oldendorf, 
Germany 
Alkaline Phosphatase/ Horseradish Peroxidase Block BioFX Laboratories, Owings 
Mills, MD, USA
Amersham ECL Rainbow Molecular Weight Markers GE Healthcare, Munich, 
Germany
BEMCOT M-3II Asahi Kasei, Tokyo, Japan
BioCoat Deep Well Plates (6-well) BD Biosciences, Heidelberg, 
Germany
Bovine Serum Albumin (BSA) Jackson Immuno Research, 
Suffolk, UK
Cell Culture dishes (6, 10, 15 cm) Falcon, Heidelberg, Germany 
Cell Lifter Corning, Amsterdam, 
Netherlands
Cell Strainer (70 µm) BD Falcon, Franklin Lakes, 
NJ, USA
Colcemid (KaryoMAX) Life Technologies, Frederick, 
MD, USA
Eosin G Roth, Karlsruhe, Germany 
Eukitt - Non aqueous mounting medium Sigma-Aldrich, Taufkirchen, 
Germany 
Fluorescent Mounting Medium Dako Cytomation, Hamburg, 
Germany 
Haematoxylin Roth, Karlsruhe, Germany
Hank’s balanced salt solution Biochrom, Berlin, Germany 
Hoechst 33258, pentahydrate (bis-benzimide)
(500 µg/mL)
Life Technologies, Frederick, 
MD, USA
Lambda DNA-Hind III Ladder Fermentas, St. Leon-Rot, 
Germany
Medical X-ray film FujiFilm, Düsseldorf, Germany
Microscopic slides (Histobond) Marienfeld, Lauda-
Königshofen, Germany 
Microscopic slides (Superfrost Plus) Thermo Fisher Scientific, 
Waltham, MA, USA
Nitroblue tetrazolium chloride/ 5-bromo-4-chloro-3-indolyl 
phosphate substrate tablets
Roche Applied Sciences, 
Mannheim, Germany 
Nitrocellulose membrane (Protran BA 85) Whatman, Dassel, Germany
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PBS/ PBS+ (with MgCl2, CaCl2) Serva Electrophoresis, 
Heidelberg, Germany 
PEFA-Block Serva Electrophoresis, 
Heidelberg, Germany
Pepsin Sigma-Aldrich, Taufkirchen, 
Germany 
Pepstatin Serva Electrophoresis, 
Heidelberg, Germany
Polycarbonate membrane filter inserts
(0.4 µm pore HD, PET track-etched membrane) 
Falcon, Heidelberg,
Germany 
Ponceau S, ATX Sigma-Aldrich, Taufkirchen, 
Germany 
Propidium iodide (PI, 80 mg/mL) Sigma-Aldrich, Taufkirchen, 
Germany 
Specialized fixative for anatomy and histology MORPHISTO, Frankfurt a. M., 
Germany
SYBR Green Life Technologies, Frederick, 
MD, USA
SYBR Safe DNA Gel Stain Life Technologies, Frederick, 
MD, USA
T7-RNA polymerase Roche Applied Sciences, 
Mannheim, Germany 
TEMED Roth, Karlsruhe, Germany
ThinCerts, 12 well, 0.4 µm, translucent Greiner Bio-One, 
Frickenhausen, Germany
ThinCert-Plate 12-well Greiner Bio-One, 
Frickenhausen, Germany
Tissue Tek Sakura Finetek, Zoeterwoude, 
Netherlands 
TRIzol Reagent Life Technologies, Frederick, 
MD, USA
Further basic chemicals were purchased from AppliChem (Darmstadt, Germany), Merck (Darmstadt, 
Germany), Roth (Karlsruhe, Germany) or Sigma-Aldrich (Taufkirchen, Germany).
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Table 4 | Buffers and solutions.
Name Composition Application
Blocking buffer 3% (w/v) BSA in PBS+ + 0.02% (w/v) Sodium azide IIF
Blocking buffer 2% (w/v) Milk powder (blocking grade), 
0.1% (v/v) Tween 20 in PBS
WB
Blocking solution 0.5% (v/v) Triton X-100 in 3% (w/v) BSA (IgG-free, 
in PBS+)
WM
Loading dye, 
DNA (3x)
4 M Urea, 50 mM EDTA, 50% (w/v) Sucrose, 
0.1% (w/v) Bromophenol blue
AGE
Loading dye, 
Protein (5x)
3.75 mM Tris (pH 6.8), 50% (v/v) Glycerol, 
350 mM SDS, 10% (v/v) beta-Mercaptoethanol, 
pinch of Bromophenol blue
SDS-PAGE
Lower gel buffer 1.5 M Tris (pH 8.8), 14 mM SDS SDS-PAGE
RIPA buffer 10 mM Tris-HCl (pH 7.2), 150 mM NaCl, 
5 mM EDTA, 1% (v/v) Triton X-100, 
0.1% (w/v) SDS, 1% (w/v) Sodium deoxycholate
Protein 
extraction
RIPA lysis buffer 0.2 U/mL Aprotinin, 1 ng/µL Leupeptin, 
0.1 ng/mL Pepstatin A and 50 nM PEFA-Block, 
diluted in RIPA buffer
Protein 
extraction
Running buffer 10% (v/v) Tris-Glycine (10x), 0.1% (w/v) SDS SDS-PAGE
SDS-PA collection 
gel (12%)
3.75% (v/v) Glycerol, 25% (v/v) Lower gel buffer, 
30% (v/v) Acrylamide/ Bis Solution (40%), 
0.05% (w/v) APS, 0.05% (v/v) TEMED
SDS-PAGE
SDS-PA stacking 
gel (2.8%)
25% (v/v) Upper gel buffer, 
7.8% (v/v) Acrylamide/ Bis Solution (40%), 
0.05% (w/v) APS, 0.2% (v/v) TEMED
SDS-PAGE
SSC buffer (20x) 3 M NaCl, 300 mM Trisodium citrate, pH 7.0 ISH, M-FISH
TBE pH 8.3 (10x) 890 mM Tris, 890 mM Boric acid, 32 mM EDTA AGE
Transfer buffer 10% (v/v) Tris-Glycine (10x), 20% (v/v) Methanol WB
Tris-Glycine 
Solution (10x)
330 mM Tris, 1.9 M Glycine SDS-PAGE, 
WB
Upper gel buffer 0.5 M Tris (pH 6.8), 14 mM SDS SDS-PAGE
Wash buffer 0.1% (v/v) Tween 20 in PBS WB
Wash buffer 1 0.2% (v/v) Tween 20 in PBS+ WM
Wash buffer 2 0.2% (v/v) Tween 20 in PBS WM
AGE: Agarose gel electrophoresis, IIF: Indirect immunofluorescence, ISH: In situ hybridization, 
M-FISH: Multiplex-fluorescence in situ hybridization, SDS-PAGE: SDS-Polyacrylamide gel 
electrophoresis, WB: Western-Blot, WM: Whole-mount IIF
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4.1.3 Kits
Table 5 | Kits.
Name Company
Amersham ECL Advance Western Blotting Detection Kit GE Healthcare, Munich, 
Germany
DIG-RNA Labeling Kit Roche Applied Sciences, 
Mannheim, Germany
EnzChek Gelatinase/Collagenase Assay Kit Life Technologies, Frederick, 
MD, USA
FITC Annexin V Apoptosis Detection Kit I BD Pharmingen, 
Erembodegem, Belgium
LightCycler 480 Probes Master Roche Applied Sciences, 
Mannheim, Germany
Pierce BCA Protein Assay Kit Thermo Fischer Scientific, 
Fermont, USA
qBiomarker Somatic Mutation PCR Array,
Human Skin Cancers
QIAGEN, Hilden, Germany
QIAamp DNA Mini Kit QIAGEN, Hilden, Germany
QIAshredder QIAGEN, Hilden, Germany
Quantikine Human CCL2 / MCP-1 Immunoassay R&D Systems, Wiesbaden, 
Germany
Quantikine Human IL-8 Immunoassay R&D Systems, Wiesbaden, 
Germany
Quantikine Human Pro-MMP-1 Immunoassay R&D Systems, Wiesbaden, 
Germany
Quantikine Human Total MMP-3 Immunoassay R&D Systems, Wiesbaden, 
Germany
Quantikine Human Total MMP-9 Immunoassay R&D Systems, Wiesbaden, 
Germany
REAL EnVision Detection System
Peroxidase/ DAB+, Rabbit/ Mouse
Dako, Glostrup, Denmark
RevertAid H Minus First Strand cDNA Synthesis kit Thermo Fischer Scientific, 
Fermont, USA
RNase A (20 mg/mL, Cell cycle analysis) Life Technologies, Frederick, 
MD, USA
RNase A (17,500 U, DNA isolation) QIAGEN, Hilden, Germany
RNase-free DNase Set (RNA isolation) QIAGEN, Hilden, Germany
RNeasy Mini Kit QIAGEN, Hilden, Germany
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4.1.4 Primer and probes
The following primers were used for quantitative RT-PCR (qRT-PCR) with an adequate probe from the 
Universal Probe Library (UPL, Roche).
Table 6 | qRT-PCR primer and probes.
Gene Primer sequences (5’-3’) UPL # Efficiency Cell type
alphaSMA ccctgaagtacccgatagaaca (fwd)
ggcaacacgaagctcattg (rev)
9 1.94 Fibroblasts
AXIN2 cagccattcaggaactaccc (fwd)
gaaggtgtgtggaggaaagg (rev)
3 1.93
1.99
Fibroblasts
Keratinocytes
CCL2 agtctctgccgcccttct (fwd)
gtgactggggcattgattg (rev)
40 1.97 Fibroblasts
CDKN1A tcactgtcttgtacccttgtgc (fwd)
ggcgtttggagtggtagaaa (rev)
32 1.94
1.99
Fibroblasts
Keratinocytes
CSF2 tctcagaaatgtttgacctcca (fwd)
gcccttgagcttggtgag (rev)
1 2.00 Fibroblasts
CXCL10 gaaagcagttagcaaggaaaggt (fwd)
gacatatactccatgtagggaagtga (rev)
34 2.00 Fibroblasts
CXCL12 gctggtcctcgtgctgac (fwd)
gcatgggcatctgtagctc (rev)
13 1.86 Fibroblasts
EGFR ctatgtgcagaggaattatgatcttt (fwd)
gggcaatgaggacataacca (rev)
79 2.00 Keratinocytes
FGF7 aagggacccaagagatgaaga (fwd)
cctttgattgccacaattcc (rev)
59 2.00 Fibroblasts
FGF10 gaaggagaactgcccgtaca (fwd)
ggcaacaactccgatttctact (rev)
80 2.00 Fibroblasts
FLG ggactctgagaggcgatctg (fwd)
tgctcccgagaagatccat (rev)
38 1.98 Keratinocytes
GAPDH agccacatcgctcagacac (fwd)
gcccaatacgaccaaatcc (rev)
60 1.93
1.97
Fibroblasts
Keratinocytes
HGF cagcatgtcctcctgcatc (fwd)
tcttttcctttgtccctctgc (rev)
15 1.99 Fibroblasts
IL1A ggttgagtttaagccaatcca (fwd)
tgctgacctaggcttgatga (rev)
6 2.00
1.98
Fibroblasts
Keratinocytes
IL1B tacctgtcctgcgtgttgaa (fwd)
tctttgggtaatttttgggatct (rev)
78 1.94
1.97
Fibroblasts
Keratinocytes
IL6 gatgagtacaaaagtcctgatcca (fwd)
ctgcagccactggttctgt (rev)
40 1.70 Fibroblasts
IL8 agacagcagagcacacaagc (fwd)
atggttccttccggtggt (rev)
72 1.97 Fibroblasts
IVL acccatcaggagcaaatgaa (fwd)
agctcgacaggcaccttct (rev)
16 2.00 Keratinocytes
KRT10 ccatcgatgaccttaaaaatcag (fwd)
cgcagagctacctcattctcata (rev)
64 2.00 Keratinocytes
MMP1 gctaacctttgatgctataactacga (fwd)
tttgtgcgcatgtagaatctg (rev)
7 1.94
1.98
Fibroblasts
Keratinocytes
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MMP3 cagtttgctcagcctatcca (fwd)
tcacatctttttcgaggtcgt (rev)
58 2.00
2.00
Fibroblasts
Keratinocytes
MMP9 gaaccaatctcaccgacagg (fwd)
gccacccgagtgtaaccata (rev)
6 1.89
1.70
Fibroblasts
Keratinocytes
MMP14 caggaatgaggatctgaatgg (fwd)
ccgaggggtcactggaat (rev)
45 2.00
2.00
Fibroblasts
Keratinocytes
SNAI2 tggttgcttcaaggacacat (fwd)
gcaaatgctctgttgcagtg (rev)
7 1.95 Keratinocytes
TGFA cccagattcccacactcag (fwd)
acgtacccagaatggcagac (rev)
38 2.00
1.99
Fibroblasts
Keratinocytes
TGFB1 gcagcacgtggagctgta (fwd)
cagccggttgctgaggta (rev)
72 1.98
2.00
Fibroblasts
Keratinocytes
TGFB3 aagaagcgggctttggac (fwd)
gcgcacacagcagttctc (rev)
38 2.00
1.93
Fibroblasts
Keratinocytes
Primers were synthesized by Sigma-Aldrich (Taufkirchen, Germany).
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4.1.5 Antibodies
Table 7 | Primary antibodies.
Specificity Species Dilution Company Cat. -No. Application
Akt, phospho
(Thr308)
Rabbit 1:1,000 Cell Signaling 9275 WB
alpha-SMA Mouse 1:100 Sigma-Aldrich A2547 IIF
BrdU Mouse 1:5 BD Biosciences 347580 WM + IIF
Cadherin-1 Mouse 1:20 Progen 10028 IIF
Cleaved Collagen
C1,2C
Rabbit 1:100 IBEX 
Pharmaceuticals
50-1035 IIF
Collagen IV Rabbit 1:100 Progen 10760 IIF
Collagen VII Mouse 1:400 Sigma-Aldrich C6805 IIF
ERK1/2 Rabbit 1:2,000 Cell Signaling 9102 WB
ERK1/2, phospho
(Thr202/ Tyr204)
Mouse 1:2,000 Cell Signaling 9106 WB
ERK1/2, phospho
(Thr202/ Tyr204)
Rabbit 1:400 Cell Signaling 4370 IHC
Filaggrin Mouse 1:200 Acris Antibodies AM00245 IIF
GAPDH Mouse 1:50,000 Merck Millipore MAB374 WB
Integrin beta-4 Rat 1:1,000 BD Pharmingen 33691A IIF
Keratin-10 Mouse 1:20 Progen 11414 IIF
Keratin-14 Mouse 1:50 R&D Systems MAB3164 IIF
Keratin-14 Rabbit 1:1,000 Biolegend PRB-155P IIF
Ki67 Rabbit 1:300 Abcam ab15580 IIF
MEK1/2 Mouse 1:1,000 Cell Signaling 4694 WB
MEK1/2, phospho
(Ser217/ Ser221)
Rabbit 1:1,000 Cell Signaling 9154 WB
MMP-1 Rabbit 1:100 Sigma-Aldrich M3940 IIF
p38 alpha Mouse 1:2,000 Cell Signaling 9217 WB
p38, phospho
(Thr180/ Tyr182)
Rabbit 1:1,000 Cell Signaling 9211 WB
Vimentin Mouse 1:100 Progen 61013 IIF
Wnt-3 Rabbit 1:100 Abcam ab32249 IIF
IHC: Immunohistochemistry, IIF: Indirect immunofluorescence, WB: Western-Blot, 
WM: Whole-mount IIF
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Table 8 | Secondary antibodies.
Specificity Species Conjugate Dilution Company Cat. -No.
Digoxigenin 
(DIG)
Sheep Horseradish 
peroxidase
1:300 Roche Applied 
Sciences
11207733910
Mouse-IgG Goat Alexa-488 (IIF) 1:600 Life Technologies A11029
Mouse-IgG Goat Cy3 (IIF) 1:500 Jackson 
ImmunoResearch
115-165-205
Rabbit-IgG Goat Cy3 (WM) 1:600 Dianova 111-165-144
Rat-IgG Donkey Cy3 (IIF) 1:500 Dianova 712-166-153
Mouse-IgG Donkey Horseradish 
peroxidase
1:40,000 Dianova 715-035-150
Rabbit-IgG Donkey Horseradish 
peroxidase
1:40,000 Dianova 711-035-152
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4.1.6 Cell culture supplements, media and solutions
Table 9 | Cell culture supplements.
Supplement Company
2-Phospho-L-Ascorbic Acid, trisodium salt Sigma-Aldrich, Taufkirchen, 
Germany 
Anti-human CCL-2/ MCP-1 Neutralizing Antibody
(#MAB279/ nCCL-2)
R&D Systems, Wiesbaden, 
Germany
Anti-human IL-8 Neutralizing Antibody
(#MAB208/ nIL-8)
R&D Systems, Wiesbaden, 
Germany
Celastrol Cayman Chemical, Ann Arbor, 
MI, USA
Cholera toxin Sigma-Aldrich, Taufkirchen, 
Germany 
Cobimetinib/ GDC-0973 (COBI) Adooq Bioscience, Irvine, CA, 
USA
DermaLife K Medium Complete Kit Lifeline Cell Technology, 
Frederick, MD, USA
DMEM (Dulbecco’s Modified Eagle’s Medium)
DMEM:F12, 1:1 Mixture
Lonza, Verviers, Belgium
Dimethyl Sulfoxide (DMSO) Sigma-Aldrich, Taufkirchen, 
Germany 
EDTA (0.05% (w/v) in PBS + 1 µL/mL Phenol red) Serva Electrophoresis GmbH 
Fetal Bovine Serum (FBS); Lot, 41Q7791K Gibco, Auckland, New 
Zealand
Fetal Bovine Serum (FBS) GOLD, Lot: A15112-1936 GE Healthcare, Munich, 
Germany
Fetal Bovine Serum (FBS) GOOD, Lot: P132307 PAN-Biotech, Aidenbach, 
Germany
Human recombinant CCL-2/ MCP-1 R&D Systems, Wiesbaden, 
Germany 
Human recombinant EGF Life Technologies, Frederick, 
MD, USA
Human recombinant FGF-Basic Life Technologies, Frederick, 
MD, USA
Human recombinant IL-8 R&D Systems, Wiesbaden, 
Germany 
Human recombinant TGF-alpha R&D Systems, Wiesbaden, 
Germany
Human recombinant TGF-beta-1 Life Technologies, Frederick, 
MD, USA
Hydrocortisone Sigma-Aldrich, Taufkirchen, 
Germany 
Insulin Sigma-Aldrich, Taufkirchen, 
Germany 
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Mouse recombinant Wnt-3a R&D Systems, Wiesbaden, 
Germany 
Penicillin/ Streptomycin (10,000 U/mL / 10,000 µg/mL) Biochrom, Berlin, Germany
Penicillin/ Streptomycin/ Fungizone
(500 µg/mL, 500 µg/mL, 1.25 µg/mL)
Lonza, Verviers Belgium
Tissucol Kit 1.0 Baxter, Deerfield, IL , USA
Trasylol (Aprotinin, 10,000 U/mL) Bayer, Leverkusen, Germany
Trypsin (0.1% in PBS + 1 µL/mL Phenol red) Roche Applied Sciences, 
Mannheim, Germany
Vemurafenib/ PLX4032/ RG7204 (VEM) ChemieTek, Indianapolis, USA
Table 10 | Cell culture media and solutions.
Name Composition
Growth medium DMEM with 10% FBS and 1% (v/v) Penicillin/ Streptomycin
FADcomplete DMEM + DMEM F-12 (1:1) with 5% (v/v) FBS, 1% (v/v) Penicillin/ 
Streptomycin, 24 ng/mL Adenine, 0.1 nM Cholera toxin, 1 ng/mL EGF, 
0.4 µg/mL Hydrocortisone, 5 µg/mL Insulin
FDM medium DMEM + DMEM F-12 (1:1) with 10% (v/v) FBS, 1% (v/v) Penicillin/ 
Streptomycin/ Fungizone, 200 µg/mL 2-Phospho-L-Ascorbic Acid, 2.5 
ng/mL EGF, 5 ng/mL FGF-Basic, 5 µg/mL Insulin, 1 ng/mL TGF-beta-1
Freezing Medium Adequate medium with 20% FBS and 10% (v/v) Glycerol
rFAD DMEM + DMEM F-12 (1:1) with 10% (v/v) FBS, 1% (v/v) Penicillin/ 
Streptomycin, 200 µg/mL 2-Phospho-L-Ascorbic Acid, 0.1 nM Cholera 
toxin, 0.4 µg/mL Hydrocortisone
Trypsin/ EDTA NHEK: 0.40% Trypsin/ 0.05% (w/v) EDTA
HaCaT: 0.05% Trypsin/ 0.05% (w/v) EDTA
NHDF: 0.10% Trypsin/ 0.05% (w/v) EDTA
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4.1.7 Cells and cell lines
The parental HaCaT cells (Boukamp et al., 1988), H-RasG12V transfected benign tumorigenic HaCaT-
RAS A-5 and malignant tumorigenic HaCaT-RAS II-4 cells were generated (Boukamp et al., 1982; 
Mueller and Fusenig, 1999) and routinely cultivated in the laboratory. In addition, the squamous cell 
carcinoma cell lines SCL-I (Boukamp et al., 1982), SCL-II (Tilgen et al., 1983), SCC-12, SCC-13 
(Rheinwald and Beckett, 1981), MET-1 and MET-4 (Proby et al., 2000) were cultivated. Normal human 
epidermal keratinocytes (NHEK) and normal human dermal fibroblasts (NHDF) were derived from 
human explant cultures of either epidermis or de-epidermized dermis in a routinely performed method 
(Maas-Szabowski et al., 2003; Schoop et al., 1999). B-RafV600E-mutant A375 melanoma cells were also 
cultivated. All cells and cell lines were tested for mycoplasma contamination every two weeks (Venor 
GeM Mycoplasma Detection Kit; Minerva Biolabs, Berlin, Germany). The purity of cells was validated 
using the Multiplex Cell Contamination Test by Multiplexion (Heidelberg, Germany), as described 
(Schmitt and Pawlita, 2009). No Mycoplasma, SMRV and interspecies contamination were detected. 
HaCaT cells were authenticated using Multiplex Cell Authentication by Multiplexion (Heidelberg, 
Germany), as described (Castro et al., 2013).
Table 11 | Origin of normal keratinocytes and fibroblasts.
Name Donor Body site Isolation date
NHEK 1 female, 23 years Breast 26.04.2004
NHEK 2 female, 40 years Abdomen 10.03.2008
NHEK 3 female, 41 years Abdomen 02.09.2010
NHEK 4 female, unknown age Breast 20.10.2005
NHDF 1 female, 23 years Abdomen I-04.04.2007
NHDF 2 female, 22 years Breast 08.02.1996
NHDF 3 male, 21 years Rump 09.03.1995
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4.2 Methods
4.2.1 Maintenance of cells
Keratinocytes and A375 melanoma cells were cultivated in an incubator at 37 °C with 95% humidity 
and 5% CO
2
 pressure (normoxia), while NHDF were incubated at 37 °C with 95% humidity, 5% CO
2
 
and 5% O
2
 pressure (hypoxia).
NHEK were cultivated in DermaLife K medium complete. 7 days after thawing, cells were rinsed in 
EDTA, detached using 0.4% Trypsin/ EDTA for 3-5 min and used for subsequent experiments. NHDF 
were grown in growth medium and were spilt every 7-14 days in a ratio of 1:3. Therefore, cells were 
rinsed with EDTA and incubated for 3-5 min in 0.1% Trypsin/ EDTA.
Non-tumorigenic HaCaT, benign-tumorigenic HaCaT-RAS A-5, malignant-tumorigenic HaCaT-RAS 
II-4 and A375 melanoma cells were routinely cultivated in growth medium (see Table 10, 4.1.6), which 
was replaced every 2-3 days. Cells were spilt either after 7 days at a ratio of 1:12 (A-5, II-4 and A375) 
or after 10 days at a ratio of 1:10 (HaCaT). In particular, cells were rinsed in EDTA and incubated for 10 
min with fresh EDTA. 0.05% Trypsin/ EDTA was added for 3-5 min to detach the keratinocytes and the 
Trypsin-activity was stopped with two volumes of growth medium. The cSCC cells lines SCL-I, SCL-
II, MET-1 and MET-4 cells were cultivated in growth medium, SCC-12 and SCC-13 cells in FADcomplete 
(see Table 10, 4.1.6). cSCC cell lines were split every 7 days, as described for HaCaT-RAS A-5 cells.
4.2.1.1 Freezing and thawing of cell stocks
For freezing, cells at 80% confluence were trypsinized, as described above, centrifuged for 5 min at 
1,000 rpm and resuspended in freezing medium (see Table 10, 4.1.6) at a concentration of 2x 106 cells/
mL. 1 mL aliquots were transferred into cryo-tubes placed in 2-propanol containing cryo-boxes for 
controlled freezing (1 °C/min). The cells were pre-cooled for 1 hour at 4 °C and transferred to -80 °C 
storage over night. Finally, the cell stocks were stored in the gas phase of liquid nitrogen.
To thaw cells, cryo-tubes containing cells were incubated at 37 °C and the suspension was added to a 
culture dish containing the appropriate growth medium. The medium was replaced after 1-2 days.
4.2.1.2 Harvesting of cells
Cells were trypsinized as described (see 4.2.1) and the suspension was centrifuged for 5 min at 1,000 
rpm. The pellet was resuspended in 1 mL PBS and centrifuged again for 5 min at 3,200 rpm. The 
supernatant was removed and the pellet was stored at -80 °C (harvest by trypsinization). Alternatively, 
cells were washed twice in PBS at 4 °C, detached in 1 mL PBS using a Cell Lifter (Corning) and 
transferred to a reaction tube. After centrifugation for 5 min at 3,200 rpm, the supernatant was removed 
and the pellet was stored at -80 °C (harvest by detachment).
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4.2.1.3 Stimulation of cells with different agents
Cells were stimulated with the following agents in the corresponding culture medium: human recombinant 
CCL-2 (100 ng/mL), Celastrol (2.2-8.8 µM in DMSO), Cobimetinib/ GDC-0973 (COBI, 0.01-1 µM in 
DMSO), DMSO (0.01-0.5%), human recombinant EGF (2-10 ng/mL), human recombinant IL-8 (10 ng/
mL) and Vemurafenib/ PLX4032 (VEM, 0.01-50 µM in DMSO). Depending on each solvent, either the 
appropriate medium or DMSO (0.01-0.5%) in the appropriate medium was used as controls. Medium 
containing the stimulatory factors was replaced as indicated.
4.2.1.4 Continuous cell stimulation
Long-term effects of Vemurafenib on HaCaT and HaCaT-RAS A-5 cells were investigated by continuous 
treatment with Vemurafenib for 9 weeks or 5 weeks, respectively. Therefore, 5x 105 cells were seeded 
per 10 cm tissue culture plate and treated either with growth medium and DMSO (0.05%) as controls or 
with 1 µM and 5 µM Vemurafenib. The factors were replaced by medium change every 2-3 days. HaCaT 
and HaCaT-RAS A-5 cells were split every 7 days, were counted using the Casy Cell Counter and 5x 105 
cells per 10 cm tissue culture plate and treatment condition were seeded. Cell number was plotted and 
the morphology was documented using the Olympus IX-70 microscope.
Toxicity and cellular changes were quantified by FACS-based cell cycle (see 4.2.3) and apoptosis assay 
24 h after the last Vemurafenib stimulation (see 4.2.4) as well as by multiplex fluorescence in situ 
hybridization (M-FISH) analysis. The latter was performed by Prof. Dr. Anna Jauch of the Institute of 
Human Genetics at the Heidelberg University Hospital (see 4.2.7). Moreover, RNA was isolated from 4 
weeks + 8 h and 8 weeks + 8 h continuously treated HaCaT cells (see 4.2.13.1) to analyze relative gene 
expression of target genes by qRT-PCR (see 4.2.13.3 and 4.2.13.4).
4.2.2 SYBR Green cell proliferation assay
NHEK, HaCaT and HaCaT-RAS A-5 cells were seeded in 24-well plates at a density of 104 cells in 500 
µL DermaLife K medium complete (NHEK) or growth medium (HaCaT, A-5) per well and incubated 
for 24 h before treatment. For CCL-2 and IL-8 proliferation assays, HaCaT cells were starved for 72 
h in growth medium supplemented with only 2% FBS. For quantification of cell numbers, a standard 
plate was additionally prepared with 1x, 2x, 3x, 5x, 7x and 10x 104 cells per well in triplicates. 12 h 
later, the standard plate as well as a seeding control were harvested by removing the medium and storing 
the plates at -20 °C. Then, cells were stimulated (4 wells per condition and time point) with either 
recombinant human CCL-2, IL-8, a combination of both, recombinant human EGF or with Vemurafenib 
while DMSO treatment served as control, diluted in the corresponding pre-treatment medium. Cells 
were continuously stimulated for 24-72 h without changing the medium and at each time point, one plate 
was harvested as described for the standard plate.
To determine the total cell number per well, the frozen plates were thawed and incubated with SYBR 
Green (1:2,500) in 0.1% (v/v) Triton X-100 diluted in PBS for 1 h in the dark. Thereafter, the fluorescence 
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was measured at 485 nm with Fluoroskan Ascent (Thermo Fischer Scientific). The total cell number was 
calculated using the standard plate as a reference in which a given fluorescence intensity was correlated 
to a defined cell number. Each experiment was repeated at least twice and the mean was plotted. The 
Two-way ANOVA + Bonferroni posttest, comparing each condition to the control treated cells over 
time, was used to determine statistically significant differences.
4.2.3 Cell cycle analysis by FACS
Effects of stimulation on the cell cycle progression were assessed by staining the DNA content of lysed 
cells using propidium iodide (PI), which was subsequently quantified by FACS analysis. Therefore, cells 
were harvested by trypsinization (see 4.2.1.2) 24 h or 48 h after control, DMSO or Vemurafenib (1 µM/ 
5 µM) treatment. Each cell pellet was washed once in cold PBS and fixed while vortexing by slowly 
adding 400 µL 70% (v/v) ethanol in ddH
2
O per 106 cells. After >1 h incubation at 4 °C, PBS (4 °C) was 
added followed by centrifugation for 5 min at 3,200 rpm, 4 °C to remove the ethanol. PBS washing 
was repeated when required. Cell pellets were resuspended in PBS (4 °C) and incubated with 50 µg/mL 
RNase A for 30 min at 37 °C. Thereafter, 500 µg/mL PI was added to stain the DNA for 10 min, before 
analysis by flow cytometry at a flow rate of approx. 150 events/sec employing a FACSCanto II (BD). 
Unstained cells were included into the analysis as controls and to set the voltage of forward (FSC) and 
side scatter (SSC) using the BD FACSDiva Software (PI-filter: 616/ 26 nm). Data was plotted by using 
FlowJo.
4.2.4 Apoptosis analysis by FACS
Toxicity upon stimulation of cells with Vemurafenib was assessed by performing a FACS-based apoptosis 
assay according to the FITC Annexin V Apoptosis Detection Kit I (BD Pharmingen) to detect early 
and late apoptotic cells. It relies on the principle that early apoptotic cells lose membrane asymmetry 
allowing FITC labeled Annexin V to bind the membrane phospholipid phosphatidylserine, usually 
located at the inner plasma membrane leaflet of a viable cell. Late apoptosis is additionally detected by 
PI that enters cells due to a damaged plasma membrane. Celastrol, which is known to induce apoptosis 
in HaCaT cells (Zhou et al., 2011), was used as positive control.
After control, DMSO, Celastrol or Vemurafenib treatment for 24 h or 48 h, cells were harvested by 
trypsinization (see 4.2.1.2), washed once in PBS (4 °C) and resuspended in the supplied binding buffer 
at a concentration of 106 cells/mL. 100 µL cell suspension was mixed with 5 µL FITC Annexin V and 
5 µL PI solution, vortexed and incubated for 15 min at room temperature (RT) in the dark. Then, 400 
µL binding buffer was added and the samples were analyzed by flow cytometry using a FACSCanto II 
(BD). Unstained as well as FITC Annexin V or PI single stained cells were included into the analysis 
to set the voltage of forward (FSC) and side scatter (SSC) and to perform compensation using the BD 
FACSDiva Software (FITC-filter: 530/ 30 nm, PI-filter: 616/ 26 nm). Data was plotted using FlowJo 
and statistically significance was calculated by Two-way ANOVA + Bonferroni posttest comparing each 
treatment to the corresponding control.
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4.2.5 Preparation and maintenance of organotypic co-culture (OTC) models
In this study three different organotypic co-culture models were used depending on the raised research 
question (Fig. 8). Generation, maintenance, stimulation and harvest are described in the following 
paragraphs.
4.2.5.1 Generation and maintenance of OTCs
(a) Collagen-based organotypic culture (colOTC)
Organotypic co-cultures based on collagen as dermal equivalent and scaffold were prepared following 
the method of Schoop and co-workers (Schoop et al., 1999). Accordingly, Collagen type I gels with 
embedded NHDF 3 were prepared on ice by mixing 8 volumes of a rat Collagen type I solution (5 
mg/mL in 0.1% (v/v) acetic acid, 4 °C; isolated from rat tails) with 1 volume 10x Hank’s buffered 
saline. After neutralization with 5 M NaOH, NHDF were trypsinized (see 4.2.1) and resuspended at 
5x 105 cells/mL in FBS. 3.5 mL of the resulting mixture was poured into polycarbonate membrane 
filter inserts (0.4 µm pore HD, PET track-etched, Falcon) placed in BioCoat Deep Well Plates (6-well, 
BD Biosciences). The gels were polymerized for 1 h at 37 °C. Subsequently, glass rings (Technical 
Infrastructure, DKFZ Heidelberg) were gently placed on top of the gels and incubated for additional 15-
20 min at 37 °C. Thereafter, the released liquid was aspirated and growth medium supplemented with 
200 µg/mL 2-phospho-L-ascorbic acid was added into each well plus filter insert to ensure equilibration 
of the gels over night at 37 °C. The next day, HaCaT cells were trypsinized (see 4.2.1), singularized using 
a 70 µm cell strainer and 106 cells were seeded on top of each dermal equivalent. Therefore, the medium 
within the ring was removed and 1 mL of the HaCaT cell suspension (106 cells/mL) was added into the 
ring. After 18-24 h of submersed cultivation, cells that did not adhere and the medium with the glass 
rings were carefully removed in order to allow air-exposed growth of the keratinocytes (air-lift). During 
the first week of cultivation, OTCs were incubated in growth medium supplemented with 200 µg/mL 
2-phospho-L-ascorbic acid, 2 ng/mL human recombinant EGF and 2 ng/mL human recombinant TGF-
alpha. Thereafter, OTCs were cultured in growth medium supplemented with 2-phospho-L-ascorbic 
acid only, which was replaced every 2-3 days until harvesting the cultures after 2-4 weeks (Fig. 8a).
(b) Scaffold-based organotypic culture (scaOTC)
Organotypic co-cultures based on the cellulose material BEMCOT M-3II (Asahi Kasei) as physical 
scaffold and fibroblasts embedded in a Fibrin matrix as dermal equivalent were prepared following the 
method of Böhnke and co-workers (Boehnke et al., in preparation). For the use in 6-well cell culture 
inserts, circular M-3II pieces with diameter of 22 mm were prepared using a punch and sterilized by 
autoclaving between two microscopic slides. The scaffolds were inserted onto polycarbonate membrane 
filter inserts (0.4 µm pore HD, PET track-etched, Falcon) placed in 6-well plates (Nunc). NHDF 1 
were trypsinized (see 4.2.1) and 7.5x 105 cells resuspended in 375 µL FBS were mixed with 375 µL 
Thrombin in PBS (10 I.E./mL, Tissucol Kit 1.0, Baxter) per OTC and filled into the M-3II-containing 
insert. Fibrinogen (Tissucol Kit 1.0, Baxter) was dissolved in 10 mL PBS, pH 7.0 resulting in an 8 mg/
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mL Fibrinogen solution. 375 µL Fibrinogen solution was diluted with 375 µL PBS per culture and 
additionally added into the filter insert to produce a gel with embedded fibroblasts (final concentrations: 
2.5 I.E./mL Thrombin, 2 mg/mL Fibrinogen). For the clotting reaction, dermal equivalents were incubated 
for 30 min in the incubator. Subsequently, glass rings (Technical Infrastructure, DKFZ Heidelberg) were 
gently placed on top. Liquid on the gel was removed before adding the pre-culture medium consisting 
of growth medium supplemented with 200 µg/mL 2-phospho-L-ascorbic acid and 1 ng/mL human 
recombinant TGF-beta-1 for 7 days submersed cultivation. One day before seeding keratinocytes, the 
inserts were placed in BioCoat Deep Well Plates (6-well, BD Biosciences) and the medium was shifted to 
growth medium with 200 µg/mL 2-phospho-L-ascorbic acid and Trasylol (500 U/mL, Bayer) to prevent 
degradation of the gel. HaCaT cells were trypsinized (see 4.2.1), singularized using a 70 µm cell strainer 
and 106 cells were seeded on top of the dermal equivalent. Therefore, the medium within the ring was 
removed and 1 mL of the HaCaT cell suspension (106 cells/mL) was seeded. After 18-24 h of submersed 
cultivation, cells that did not adhere and the medium with the glass rings were carefully removed in 
order to allow air-exposed growth of the keratinocytes (air-lift). During the first week of culture, OTCs 
were incubated in growth medium supplemented with 200 µg/mL 2-phospho-L-ascorbic acid, 500 U/mL 
Trasylol, 2 ng/mL human recombinant EGF and 2 ng/mL human recombinant TGF-alpha. Thereafter, 
OTCs were cultured in growth medium supplemented 2-phospho-L-ascorbic acid and Aprotinin only, 
which was replaced every 2-3 days until harvesting the cultures after 4-9 weeks (Fig. 8b).
(c) Fibroblast-derived matrix-based organotypic culture (fdmOTC)
Organotypic co-cultures based on a fibroblast-derived matrix (fdm) as dermal equivalent and scaffold 
were prepared following the method of Berning and co-workers (Berning et al., 2015). Therefore, 
ThinCerts (0.4 µm, translucent) 12-well filter inserts (Greiner Bio-One) were placed in ThinCert-Plates 
12-well (Greiner Bio-One) and 5 mL FDM medium (see Table 10, 4.1.6) was added to the bottom 
well. NHDF 1 were trypsinized (see 4.2.1), resuspended at 106 cells/mL in FDM medium. 500 µL of 
the resulting suspension was added to each filter insert (1st NHDF seeding). After 2-3 days each, this 
procedure was repeated for a 2nd and 3rd NHDF seeding of 5x 105 cells per filter insert. To generate a 
fibroblast-derived matrix, submersed cultivation was continued for four weeks with medium changes 
every 2-3 days (insert: 0.5 mL, bottom well: 5 mL). The day before seeding keratinocytes, medium 
was replaced by rFAD (see Table 10, 4.1.6). NHEK 2, HaCaT, HaCaT-RAS A-5 were trypsinized 
accordingly (see 4.2.1), singularized using a 70 µm cell strainer and resuspended at 0.5x 106 cells/mL 
in rFAD medium. 500 µL of the resulting suspension was seeded onto the fdm within the filter insert. 
After 4-5 days of submersed cultivation, the medium within the filter inserts was removed in order to 
allow air-exposed growth of the keratinocytes (air-lift). During the first week of cultivation, OTCs were 
incubated in rFAD medium supplemented with 2 ng/mL human recombinant EGF and 2 ng/mL human 
recombinant TGF-alpha. Thereafter, OTCs were cultured in rFAD only, which was replaced every 2-3 
days until harvesting the cultures after 3-7 weeks (Fig. 8c).
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4.2.5.2 Stimulation of OTCs
OTCs were stimulated with the following agents in the corresponding culture medium: Cobimetinib/ 
GDC-0973 (COBI, 0.01-1 µM in DMSO), Vemurafenib/ PLX4032 (VEM, 0.01-50 µM in DMSO) or 
recombinant mouse Wnt-3a (100 ng/mL). In order to block the effects of either CCL-2 or IL-8, OTCs 
were treated with anti-human CCL-2 neutralizing antibody (nCCL-2, 4 µg/mL) and anti-human IL-8 
neutralizing antibody (nIL-8, 1 µg/mL). Depending on each solvent, either the appropriate medium or 
DMSO (0.01-0.5%) in the appropriate medium was used as control. Medium containing the stimulatory 
factors was replaced every 2-3 days.
epithelium
rat Collagen I
medium
fibroblasts
keratinocytes
a
epithelium
Fibrin gel + scaffold
medium
fibroblasts
keratinocytes
b
epithelium
fdm
medium
fibroblasts
keratinocytes
c
2-4 weeks1 day
seeding of
keratinocytes
NHDF in
Collagen I
harvest
harvest
harvest
epithelial growthpre-cultivation
epithelial growthpre-cultivation
epithelial growthpre-cultivation
4-9 weeks1 week
seeding of
keratinocytes
NHDF in
Fibrin
3-7 weeks4 weeks
seeding of
keratinocytes
NHDF
seeding
Collagen-based organotypic culture (colOTC)
Scaffold-based organotypic culture (scaOTC)
Fibroblast-derived matrix-based organotypic culture (fdmOTC)
Figure 8 | Organotypic culture models.
To resemble human skin in vitro, organotypic cultures (OTCs) were generated by embedding fibroblasts in a matrix 
forming the dermal equivalent. Keratinocytes that are seeded on top and grown air-exposed form a multilayered 
stratifying epithelium. OTCs differ in the employed keratinocytes, the composition of the dermal equivalent and the 
scaffold. a | colOTCs base on Collagen type I with embedded fibroblasts as dermal equivalent and scaffold. They 
require a short pre-incubation time of 1 day, before seeding keratinocytes and last for 4 weeks. b | scaOTCs base 
on Cellulose as physical scaffold and fibroblasts embedded in a Fibrin matrix as dermal equivalent. They require 
a medium pre-incubation time of 1 week, before seeding keratinocytes and are stable for more than 9 weeks. 
c | fdmOTCs base on a fibroblast-derived matrix (fdm) as dermal equivalent and scaffold. They require a long 
pre-incubation of 4 weeks allowing the fibroblasts to build a matrix, before seeding keratinocytes. These OTCs are 
stable for more than 7 weeks.
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colOTCs were stimulated directly after air-lift with Wnt-3a and anti-human CCL-2/ IL-8 neutralizing 
antibodies for 2-4 weeks, while scaOTC were grown in for 2 weeks after air-lift allowing epithelial 
growth. Thereafter, scaOTCs were stimulated with Vemurafenib for 2-7 weeks. Similarly, fdmOTC were 
grown for 2 weeks after air-lift in rFAD before stimulating with Cobimetinib and/ or Vemurafenib for 
1-5 weeks. Only Wnt-3a treatment of fdmOTCs was started immediately after air-lift and was continued 
for 4 weeks.
4.2.5.3 Harvest and processing of OTCs
OTCs were incubated with BrdU (65 µM) for 5 h prior to harvest in order to label proliferating cells. 
Thereafter, OTCs were taken off the membrane and cut for further processing according to the following.
(a) Paraffin embedding
One quarter of each OTC was fixed over night using specialized fixative for anatomy and histology 
(Morphisto). Afterwards, the samples were subjected to dehydration in increasingly concentrated 
ethanol solutions and were transferred to xylene prior to paraffin embedding. Sections of formalin-
fixed paraffin-embedded (FFPE) colOTCs, scaOTCs or fdmOTCs were cut with 5 µm, 5 µm or 7 µm 
in diameter, respectively, using a microtome (Leica). Sections were mounted on uncoated microscope 
slides and were dried at 37 °C for 2 days.
(b) Cryo-conservation
One quarter to half of the OTCs was mounted in Tissue Tek, frozen in the gas phase of liquid nitrogen 
and then stored at -80 °C. For immunofluorescence staining of colOTCs, scaOTCs or fdmOTCs, 7 
µm cryo-sections were cut at -26 to -28 °C with a cryostat microtome (Leica) and were mounted on 
Histobond microscopic slides (Marienfeld). These slides were air-dried and stored at -80 °C.
(c) Whole-mount preparation
The epithelium of a quarter of an colOTC was peeled off the dermal equivalent using forceps, while 
fdmOTCs were not separated as these cultures are translucent. Each OTC was transferred into PBS and 
fixed in 3.7% (v/v) formaldehyde in PBS for 2 h at RT. After washing 3x in PBS, the epithelium was 
stored at 4 °C in PBS containing 0.02% (w/v) sodium azide until further antibody staining.
(d) RNA isolation of fdmOTCs
For RNA expression analysis comparing gene regulation in the dermal equivalent vs. the epithelium, 
one quarter of an fdmOTC was incubated with 1 mg/mL Dispase II (Roche) for 120 min at 37 °C 
to digest the BM component Collagen IV. This treatment allowed separating dermal equivalent from 
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epidermis. Each sample was transferred to a 2 mL screw cap tube containing 1 mL TRIzol Reagent (Life 
Technologies). Subsequently, the tissue was homogenized using a FastPrep FP120 (Thermo Fischer 
Scientific) for 2-3x 30 sec at speed 6.0 and further stored at -80 °C. For the subsequent RNA-isolation 
from OTCs see 4.2.13.2.
(e) Conditioned medium
The medium of OTCs was harvested 48 h after medium change. Following centrifuged for 1 min at 
3,200 rpm to remove cell debris, conditioned medium was stored at -20 °C until subsequent analysis by 
ELISA (see 4.2.15).
4.2.6 Histology staining of OTC sections
Prior to H/E staining, the FFPE and dried sections (prepared as described in 4.2.5.3a) were deparaffinized 
by immersion in xylene, followed by stepwise rehydration in graded ethanol solutions of decreasing 
concentration (100%, 96%, 80% and 70% ethanol) and finally immersed in distilled H
2
O. Subsequently, 
sections were stained with haematoxylin and eosin. A 5% (v/v) HCl in 70% (v/v) ethanol bath as well as 
extended washing steps ensured the removal of excess dye before dehydration of the sections in graded 
ethanol solutions and xylene. The stained sections were mounted with Eukitt mounting medium (Sigma-
Aldrich) and were analyzed using an Olympus BX-51 microscope equipped with a OSIS Color View 
CCD camera and the accompanying cell^D software (Olympus).
4.2.7 Multiplex fluorescence in situ hybridization (M-FISH) analysis
To investigate whether continuous Vemurafenib treatment leads to cell selection or additional chromosomal 
aberrations, M-FISH analysis was performed in collaboration with Prof. Dr. Anna Jauch at the Institute 
of Human Genetics of the Heidelberg University Hospital. To prepare metaphase spreads, continuously 
treated HaCaT cells (5 weeks, see 4.2.1.4) were split and when reaching a high proliferation rate, they 
were arrested in metaphase by incubation with 0.27 µg/mL Colcemid (KaryoMAX, Life Technologies) 
in growth medium for 4 h, 37 °C. Subsequently, HaCaT cells were trypsinized (see 4.2.1), slowly mixed 
with 15 mL KCl solution (75 mM), 37 °C and incubated for 15-20 min in order to lyse the cells by the 
osmotic pressure. The nuclei were fixed by 3x centrifugation for 10 min at 1,500 rpm, removal of the 
supernatant and slowly adding 15 mL of a 75% (v/v) methanol/ 25% (v/v) acetic acid solution, 4 °C. 
Finally, nuclei were resuspended in 0.5-1 mL of 75% (v/v) methanol/ 25% (v/v) acetic acid solution and 
dripped onto microscopic slides. For RNA and protein digestion, slides were washed in 2x SSC buffer, 
incubated in 100 µg/mL RNase A in 2x SSC buffer for 30-60 min at 37 °C, washed 3x 5 min in 2x SSC 
buffer and incubated in a 75 µg/mL Pepsin (Sigma)/ 0.01 M HCl solution for 10 min at 37 °C. Slides 
were washed 2x 5 min in PBS, incubated in a 50 mM MgCl
2
/ PBS solution for 5 min, fixed in 1% (v/v) 
formaldehyde/ 50 mM MgCl
2
/ PBS for 10 min and washed for 5 min in PBS. DNA was dehydrated in 
graded ethanol solutions of increasing concentration (70%, 90% and 100% ethanol) for 3 min each and 
was finally air-dried. DNA was denatured in 70% (v/v) formamide/ 2x SSC for 100 min at 75 °C and 
4. Materials and Methods
38
dehydrated in graded ethanol solutions of increasing concentration (70%, 90% and 100% ethanol) for 
2 min each.
According to Geigl and co-workers (Geigl et al., 2006), seven whole chromosome painting probes, 
conjugated with DEAC, FITC, Cy3, TexasRed, Cy5, Biotin dUTP or DIG-dUTP, were mixed with 50% 
(v/v) formamide in 2x SSC and Cot1-DNA. The probes were denatured for 7 min at 75 °C, pre-annealed 
for 20 min at 37 °C and finally added to the denatured metaphase preparations for hybridization (48 h at 
37 °C). Thereafter, slides were washed 2x 5 min in 2x SSC buffer at RT, 2x 7 min in 0.2 % (v/v) SSC/ 
0.2% (v/v) Tween-20 solution at 56 °C and 1x 5 min in 4x SSC/ 0.2% (v/v) Tween-20. To detect the 
Biotin and DIG labeled chromosome probes, indirect immunofluorescence was performed according to 
the following. Slides were blocked in 3% (w/v) bovine serum albumin (BSA) in 2x SSC buffer for 30 min 
at 37 °C and were briefly washed in 4x SSC/ Tween-20 solution. The following antibodies were diluted 
in 1% (w/v) BSA in 4x SSC buffer/ 0.2% (v/v) Tween-20 and added to the slides for 45 min at 37 °C. 
Primary antibody-step: anti-Streptavidin Alexa-750 (Life Technologies, S21384), secondary antibody-
step: anti-Avidin (Vector, BA-300) and anti-Digoxin (Sigma, D7782), third antibody-step: anti-rabbit 
IgG-Cy5.5 (Calbiochem, 401311) and anti-Streptavidin Alexa-750 (Life Technologies S21384). After 
the incubation, washing steps were performed 3x 5 min in 4x SSC buffer/ 0.2% (v/v) Tween-20 at 45 °C. 
Subsequently, slides were incubated with 10 µM Biotin in 4x SSC/ 0.2% (v/v) Tween-20 for 10 min at 37 
°C, washed 5 min in 4x SSC/ 0.2% (v/v) Tween-20, incubated with 0.2 mg/mL DAPI (4’,6-diamidino-
2-phenylindole) diluted in 2xSSC and mounted. Images were taken using highly specific microscope 
filters (Chroma Technology, Brattleboro, VT, USA) and were analyzed using Leica MCK Software.
4.2.8 In situ hybridization
Cryo-conserved samples of human cSCCs and skin without any pathological changes were obtained 
from several individual donors (approved by the Ethics Commission of University of Heidelberg, 
Germany; #422005 07.03.2005). For in situ hybridization a 245 bp cDNA probe of the WNT2 coding 3’-
end (nucleotide position 2473-2717) and a 261 bp cDNA probe of the WNT3 coding 3’-end (nucleotide 
position 1214-1474) were generated by PCR and cloned into a pCR2.1 vector for synthesis of a specific 
probe by using T7-RNA polymerase (Roche). As positive control, a specific probe of the KRT14 3′-coding 
region of 380 bp was used. For Digoxigenin (DIG)-labeling of the cRNA probe, the DIG-RNA labeling Kit 
(Roche) was used following the instructions of the manufacturer. To detect IL8 and CCL2 mRNA, DIG 
labeled probes were designed and ordered from Exiqon (IL8: 5’-AGGTAAGATGGTGGCTAATACT-3’, 
CCL2: 5’-ACACTAGTACCATGAAAGATA-3’). After denaturation of cryo-conserved sections of 
human skin and cSCCs at 90 °C, pre-hybridization with 2x SSC/ 50% formamide and hybridization 
with the probe was performed at 42 °C over night. Washing was performed at 50 °C including RNase 
A digestion. For detection, an Alkaline phosphatase-labeled anti-DIG antibody (Roche) was used. For 
blocking internal tissue phosphatases, samples were treated with 0.2 mg/mL Levamisole for 30 min. 
For the color substrate reaction of the phosphatase, Nitroblue tetrazolium chloride/5-bromo-4-chloro-
3-indolyl phosphate substrate tablets (Roche) were used. Positive (Keratin-14) and negative controls 
(hybridization buffer; sense probes) were included. Samples were analyzed using a BX-51 microscope 
equipped with an OSIS Color View CCD camera and the accompanying cell^D software (Olympus).
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4.2.9 Immunohistochemistry (IHC)
To investigate ERK activation in OTCs, phospho-ERK1/2 was stained by immunohistochemistry (IHC) 
following the REAL EnVision Detection System Peroxidase/ DAB+, Rabbit/ Mouse (Dako). FFPE 
OTC sections (see 4.2.5.3a) on Superfrost Plus microscopic slides (Thermo Fischer Scientific) were 
deparaffinized and rehydrated by 2x 5 min xylene, 3 min 95% (v/v) ethanol, 3 min 70% (v/v) ethanol 
and dH
2
O incubation. Antigen retrieval was performed in target retrieval solution (1:10 in ddH
2
O, Dako) 
for 20 min at 80 °C followed by 20 min at RT and 5 min in PBS. The sections were further incubated 
with Peroxidase Block (BioFX Laboratories) for 20 min at RT and were washed 3x 5 min with PBS. 
Phospho-ERK1/2 antibody (Cell Signaling; see Table 7, 4.1.5) was diluted in 3% BSA and the solution 
was incubated on the sections for 90 min at RT. Thereafter, slides were washed 3x 5 min in PBS+. Control 
slides were included which were only incubated with BSA. Afterwards, the sections were incubated with 
EnVision HRP Rabbit/ Mouse (Dako) for 30 min at RT and were subsequently washed 3x 5 min in PBS+. 
For detection, DAB+ Chromogen was diluted in DAB+ Buffer (1:50, Dako) and added to the sections 
for 10 min. Then, sections were rinsed in dH
2
O and counterstained by incubation in haematoxylin for 5 
min followed by rinsing in dH
2
O for 10 min. Slides were dehydrated by 3 min 70% (v/v) ethanol, 3 min 
100% (v/v) ethanol, 3 min xylene and were mounted using Eukitt mounting medium (Sigma-Aldrich). 
Images were taken using the AX-51 microscope equipped with a OSIS Color View CCD camera and the 
accompanying cell^D software (Olympus Microscopy).
4.2.10 Indirect immunofluorescence (IIF)
In this study different IIF-protocols were performed as described below. A list of primary and secondary 
antibodies is given in Table 7+8 (see 4.1.5).
(a) Immunofluorescence of OTC cryo-sections
After briefly washing the cryo sections (see 4.2.5.3b) in dH
2
O, sections were fixed in 80% (v/v) methanol 
for 5 min at 4 °C followed by acetone dehydration for 2 min at -20 °C. Air-dried sections were blocked 
with Blocking buffer (see Table 4, 4.1.2) for 20 min at RT followed by incubation with the primary 
antibody (see Table 7, 4.1.5), diluted in Blocking buffer, for 1 h at 37 °C + 1 h at RT or alternatively for 
30 min at 37 °C + over night at 4 °C. After washing for 5 min in 0.1% (v/v) Triton X-100/ PBS+ solution 
and 2x 5 min in PBS+, sections were incubated with fluorochrome-conjugated secondary antibodies (see 
Table 8, 4.1.5) + 5 µg/mL Hoechst 33258 (Life Technologies), diluted in Blocking buffer, for 30 min at 
37 °C and 30 min at RT. After washing for 5 min in 0.1% (v/v) Triton X-100/ PBS+ solution and 2x 5 
min in PBS+, slides were briefly immersed in dH
2
O and mounted using Fluorescent Mounting Medium 
(Dako).
Sections were analyzed employing an Olympus AX-70 fluorescence microscope equipped with a 
OSIS F View CCD camera and the accompanying cell^R software (Olympus). Images were processed 
with Adobe Photoshop CS5. For proliferation analysis after BrdU or Ki67 staining complete sections 
were imaged using a Cell Observer fluorescence microscope equipped with a AxioCam MRm and the 
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accompanying ZEN software (Zeiss). The number of BrdU/ Ki67-positive keratinocytes was determined 
with Fiji software and expressed relative to the corresponding BM length as determined by Collagen 
VII co-staining (proliferation index). The proliferation index was plotted as mean of 2 sections per OTC 
of 2-3 individual cultures. Statistical significance was calculated by performing a One-way ANOVA 
+ Dunnett’s Multiple Comparison Test that compared each treatment modality to the corresponding 
control.
(b) Immunofluorescence of OTC whole-mount preparations
Whole-mount samples (prepared and fixed as described in 4.2.5.3c) were incubated during the whole 
procedure in 24-well plates with the basal cell layer floating on top of 200 µL liquid. All steps were 
carried out at RT on a horizontal shaker (70-100 rpm). To quantify proliferation by BrdU-staining, 
samples were treated with 2 M HCl for 25 min followed by washing in Wash buffer 1 (see Table 4, 
4.1.2) for 4x 10 min. Thereafter, samples were blocked with Blocking solution (see Table 4, 4.1.2) for 
1 h at 100 rpm. Samples were incubated with anti-BrdU antibody over night at RT and 70 rpm. The 
24-well plate was additionally sealed with Parafilm (Pechiney Plastic Packaging). On day 2, samples 
were washed in Wash buffer 2 for 5x 45 min at 100 rpm. Then, samples were incubated with anti-mouse 
IgG-Cy3 antibody + 5 µg/mL Hoechst 33258, diluted in 0.5% Triton X-100/ PBS solution, over night at 
RT and 70 rpm. Again, plates were sealed with Parafilm. On day 3, samples were washed in Wash buffer 
2 for 5x 45 min. Afterwards, the samples were placed on microscopic slides with the basal cell layer 
facing away from the glass. The whole-mounts were embedded with Fluorescent Mounting Medium 
and analyzed using a Cell Observer fluorescence microscope equipped with a AxioCam MRm and the 
accompanying ZEN software (Zeiss). Each whole-mount was entirely imaged and the number of all 
cells (Hoechst positive) and BrdU-positive cells was determined with Fiji to calculate the percentage 
of proliferation. The mean proliferation of 5,000 cells per data point and OTC was plotted. Statistical 
significance was calculated by performing a One-way ANOVA + Dunnett’s Multiple Comparison Test 
that compared each treatment modality to the corresponding control.
4.2.11 In situ zymography (Gelatinase assay)
To visualize in situ MMP-activity, the quenched fluorescin-labeled DQ-gelatin (EnzChek Gelatinase/
Collagenase Assay Kit, Life Technologies) was employed. Upon cleavage of the Gelatin substrate, 
quenching is released and fluorescence signals can be visualized. Therefore, 10x Gelatinase assay 
buffer was prepared according to the manufacturer’s protocol: 0.5 M Tris-HCl, 1.5 M NaCl, 50 mM 
CaCl
2
, 2 mM sodium azide, pH 7.6. Cryostat sections of OTCs (see 4.2.5.3b) were incubated in 1x 
Gelatinase assay buffer supplemented with 50 µg/mL DQ-gelatin and 5 µg/mL Hoechst 33258 for 60 
min at RT. Sections were washed 2x 5 min in PBS and subsequently fixed in 80% (v/v) methanol for 
5 min at 4 °C followed by acetone dehydration for 2 min at -20 °C. Air-dried sections were mounted 
using Fluorescent Mounting Medium (Dako) and immediately examined employing an Olympus AX-
70 fluorescence microscope equipped with a OSIS F View CCD camera and the accompanying cell^R 
software (Olympus). Fluorescence was documented using equal exposure times for all sections.
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4.2.12 Mutation analysis of genomic DNA
To analyze genomic DNA of keratinocytes representing different stages of skin carcinogenesis for 
frequently occurring mutations, DNA was isolated from cultured cells and the quality was confirmed by 
NanoDrop spectroscopic measurement as well as by Agarose gel electrophoresis. Thereafter, a somatic 
mutation PCR array was performed using a LightCycler 480 Instrument II (Roche).
4.2.12.1 Isolation of genomic DNA
Cell pellets of 5x 106 cells, prepared by trypsinization as described (see 4.2.1.2), were lysed and processed 
with the QIAamp DNA Mini Kit (QIAGEN) including Protease plus RNase A digestion according to 
the manufacturer’s instructions. Elution of the genomic DNA was performed with 200 µL nuclease free 
water (QIAGEN) and the concentration was determined with a NanoDrop ND-1000 spectrophotometer 
(Thermo Fischer Scientific). The quality was confirmed by measuring the OD260/OD280 (approx. 1.8) 
and OD260/OD230 (approx. 1.7) by a NanoDrop ND-1000. DNA integrity was confirmed by Agarose 
gel electrophoresis. DNA was stored at -80 °C.
4.2.12.2 Agarose gel electrophoresis of genomic DNA
Genomic DNA quality can be assessed by detecting DNA fragments larger than 2 kb in length with some 
fragments greater than 10 kb. This was analyzed by separating the genomic DNA according to the size 
using Agarose gel electrophoresis. Therefore, 1% (w/v) agarose was solubilized in 1x TBE (see Table 4, 
4.1.2) and boiled with 0.01% (v/v) SYBR Safe DNA gel stain, allowing detection of the DNA. 500 ng 
of each isolation was mixed with DNA loading dye (3x, see Table 4, 4.1.2), loaded onto the polymerized 
agarose gel in 1x TBE and separated at 100 V (constant). Lambda DNA-Hind III Ladder (4 µL per lane) 
was used as marker. DNA fragments as well as the ladder were visualized by irradiation at 254 nm. For 
all DNA isolations, DNA integrity was confirmed.
4.2.12.3 Somatic mutation PCR array
The Human Skin Cancer qBiomarker Somatic Mutation PCR Array (QIAGEN) allows profiling of the 78 
most frequent somatic mutations in human skin cancer samples. The array includes mutations within the 
following genes: BRAF, CDKN2A, CTNNB1, FGFR3, GNAQ, HRAS, KIT, KRAS, NRAS, PIK3CA, 
PTCH1, PTEN, RB1, SMO, LKB1/STK11 and TP53. The kit was used to characterize mutations in 
HaCaT and HaCaT-RAS II-4 cells as well as in the SCC cell lines SCL-I, SCL-II, SCC-12, SCC-13, 
MET-1 and MET-4. NHEK 1 (see Table 11, 4.1.7) that do not show any somatic mutation in the analyzed 
set of genes was used to normalize the assay.
After quality and integrity control, 3 µg genomic DNA per cell type and 96-well plate was used for the 
PCR reaction using a LightCycler 480 Instrument II (Roche) according to the manufacturer’s protocol 
with the following settings: initial heating for 10 min at 95 °C and 40 cycles composed of 15 sec at 95 
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°C (ramp rate: 1 °C/sec), 60 sec at 60 °C (ramp rate: 1 °C/sec). Fluorescence was measured after each 
cycle. The crossing point (CP) of each gene in a given sample that identifies the cycle number at which 
the fluorescence signal rises above a certain threshold fluorescence was obtained using the Second 
Derivative Maximum method with High Confidence setting of the LightCycler 480 Software (Roche). 
The assay was performed in duplicates per analyzed cell line (n=2) and the mutational characterization 
was performed using the supplied Data Analysis Template Excel Sheet (QIAGEN).
4.2.13 Gene expression analysis
For investigating gene expression in monoculture cells as well as in organotypic cultures, RNA was 
isolated and transcribed to cDNA. Quantitative PCR allowed relative gene expression analysis by 
comparing target gene expression normalized to the house-keeping gene GAPDH in treated vs. untreated 
cells or OTCs.
4.2.13.1 RNA-isolation from cultured cells
Cell pellets, prepared by trypsinization (see 4.2.1.2), were lysed and processed with the QIAshredder 
Kit (QIAGEN), according to the manufacturer’s instructions. Thereafter, RNA isolation was performed 
using the RNeasy Mini Kit (QIAGEN) with an additional DNase digestion (RNase free DNase Set, 
QIAGEN). Elution of RNA was performed with 35 µL RNase-free water. The concentration was 
determined with a NanoDrop ND-1000 spectrophotometer (Thermo Fischer Scientific) and the quality 
was confirmed by measuring an OD260/OD280 > 2.0. RNA was stored at -80 °C until further use for 
reverse transcription.
4.2.13.2 RNA-isolation from OTCs
Each epidermal or dermal tissue homogenized in TRIzol Reagent (see 4.2.5.3d) was thawed and 
centrifuged for 10 min at 12,000 rpm to remove remaining cell debris or ECM. The supernatant was 
mixed with 0.2 mL chloroform (Roth) for 15 sec and incubated for 2-3 min at RT. After centrifugation 
for 15 min at 12,000 rpm, 4 °C the upper aqueous phase was carefully transferred to a fresh tube. RNA 
was precipitated by adding 500 µL isopropyl alcohol per 600 µL transferred solution, incubation for 10 
min at RT and centrifugation for 10 min at 12,000 rpm, 4 °C. The pellet was washed with 1 mL of 75% 
(v/v) ethanol, precipitated by centrifugation for 10 min at 9,000 rpm, 4 °C, air-dried and dissolved in 
nuclease-free water. The concentration was determined with a NanoDrop ND-1000 spectrophotometer 
(Thermo Fischer Scientific) and the quality was confirmed by measuring an OD260/OD280 > 2.0. RNA 
was stored at -80 °C until further use for reverse transcription.
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4.2.13.3 Reverse Transcription
cDNA synthesis was performed with the RevertAid H Minus First Strand cDNA Synthesis Kit (Thermo 
Fischer Scientific). In particular, 4 µg total RNA was transcribed in a 40 µL reaction mix according 
to the manufacturer’s instructions: RNA was mixed with RNase free water ad 22 µL + 2 µL oligo 
(dT)
18
 primer (1 µg/µL), followed by incubations for 5 min at 65 °C and 5 min at 4 °C. Afterwards, 8 
µL reaction buffer (5x), 4 µL dNTP mix (10 mM), 2 µL RiboLock Ribonuclease Inhibitor (10 U/µL) 
and 2 µL RevertAid H Minus M-MuLV Reverse Transcriptase (200 U/µL) were added. The reverse 
transcription was carried out at 42 °C for 1 h and was stopped by heating to 70 °C for 10 min. cDNA 
was further stored at -20 °C for real-time PCR.
4.2.13.4 Real-time/ quantitative RT-PCR (qRT-PCR)
Quantitative RT-PCR (qRT-PCR) allows the relative quantification of mRNA expression. Therefore, 
the Universal Probe Library (UPL) system (Roche) was used and qRT-PCR was performed in a 96-well 
plate based LightCycler 480 Instrument II (Roche) according to the manufacturer’s instructions. The 
primers were designed using the UPL tool (www.universalprobelibrary.com; for primers and probes 
see Table 6, 4.1.4). Each reaction consisted of a 15 µL mix in nuclease free water containing 10 µL 
LightCycler 480 master (2x), 0.4 µM forward and reverse primers (stock: 10 µM) and 0.1 µM UPL-
probe (stock: 10 µM). 50 ng cDNA in 5 µL RNase free water was added after the reaction mix into each 
well. A negative control containing water instead of cDNA was performed for each primer pair and 
every qRT-PCR was performed in technical duplicates. The reaction was incubated in a PCR 96-well 
TW-MT Plate, white (Biozym) that was sealed with Adhesive Clear qPCR Seals (Biozym), centrifuged 
at 2,000 rpm for 1 min and run according to the following: After a pre-incubation for 10 min at 95 °C, 45 
cycles were carried out, each consisting of 10 sec at 95 °C (ramp rate 4.4 °C/sec), 30 sec at 60 °C (ramp 
rate 2.2 °C/sec) and 1 sec at 72 °C (ramp rate 4.4 °C/sec). Fluorescence was measured after each cycle. 
To verify the quality of the primer/ probe combination and the efficiency of the PCR reaction, standard 
curves were performed for each primer pair using a dilution series of 100, 20, 4, 0.80 and 0.16 ng pooled 
cDNA for each target cell type.
For relative quantification, the gene of interest (target) and the housekeeping gene GAPDH (reference) 
were compared for each control and stimulated sample. For this calculation, the CP of each gene in 
a given sample that identifies the cycle number at which the fluorescence signal rises above certain 
threshold fluorescence, was obtained using the Second Derivative Maximum method of the LightCycler 
480 Software (Roche). With these CP values the ratio of the relative gene expression of control vs. treated 
sample, normalized to the housekeeping gene GAPDH, was calculated using the formula proposed by 
Pfaffl (Pfaffl, 2001). Data was displayed using linear or logarithmic scales, whereas the corresponding 
control was always set to one.
4.2.14 Protein expression and phosphorylation analysis
To determine protein expression as well as the activity of signaling pathways by phosphorylation 
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analysis of key proteins, total protein was isolated from control or treated cells and quantified by protein 
assay. Proteins were separated according to their size by SDS-Polyacrylamide gel electrophoresis 
(SDS-PAGE) and protein of interest levels were analyzed by Western-Blot using specific primary and 
secondary antibodies (see Table 7+8, 4.1.5).
4.2.14.1 Protein extraction
Thawed cell pellets harvested by detachment (see 4.2.1.2) were resuspended on ice in 150-200 µL 
freshly prepared RIPA lysis buffer (see Table 4, 4.1.2) and further incubated for 30 min at 4 °C. In 
order to pellet cell debris, the suspension was centrifuged for 20 min at 14,000 rpm, 4 °C. The protein-
containing supernatant was transferred to a fresh tube and stored at -80 °C.
4.2.14.2 Protein assay
To determine the total protein concentration of the different extractions the Pierce BCA Protein Assay 
Kit (Thermo Fischer Scientific) was used according to the manufacturer’s protocol. The lysates were 
diluted 1:10 with ddH
2
O to a total volume of 60 µL and 25 µL was added in technical duplicates to 
a 96-well plate (flat bottom). In addition, a BSA standard, ranging from 0-2,000 µg/mL total protein, 
was included. 200 µL of the supplied reaction mix was added to each protein dilution. After 30 min 
incubation at 37 °C, the optical density was determined at 595 nm using a Multiskan FC Microplate 
Photometer (Thermo Fischer Scientific). The protein concentration of the cell lysates was calculated 
according to the BSA standard curve.
4.2.14.3 SDS-PAGE
Total protein lysates were separated according to the size of individual proteins by SDS-PAGE. 
Therefore, discontinuous 10% SDS-PA gels were polymerized using the Mini-PROTEAN Tetra Cell 
system (Bio-Rad). 30 µg total protein per lane of each lysate was mixed with Protein loading dye (5x, 
see Table 4, 4.1.2), boiled for 5 min at 95 °C and loaded onto the SDS-PA gels. Rainbow Molecular 
Weight Marker (Full-Range, GE Healthcare) was loaded to estimate the corresponding molecular size. 
The protein samples were separated in a chamber filled with Running buffer (see Table 4, 4.1.2) at 200 V 
(constant) using a PowerPac HC (Bio-Rad) power supply until the dye front reached the end of the gel.
4.2.14.4 Western-Blot
SDS-PA gels were blotted on Nitrocellulose membrane (Whatman) using a Mini Trans-Blot Module 
wet transfer device (Bio-Rad) according to the manufacturer’s instructions. Accordingly, the membrane 
was activated in ddH
2
O, followed by incubation in Transfer buffer (see Table 4, 4.1.2). Blotting was 
performed in the device filled with Transfer buffer for 2.5 h at 48 V (constant) using a PowerPac HC 
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(Bio-Rad) power supply. When completed, Ponceau staining of the membrane was used to confirm the 
transfer.
The membrane was blocked in Blocking buffer (see Table 4, 4.1.2) for 90 min at RT on a rotating shaker. 
Then, the membrane was rinsed twice in PBS before incubation with the appropriate primary antibody 
(see Table 7, 4.1.5) diluted in 3% (w/v) BSA/ 0.1% (v/v) Tween 20 in PBS with 0.02% (w/v) sodium 
azide over night at 4 °C. Afterwards, unbound antibody was removed by washing 3x 10 min in Wash 
buffer (see Table 4, 4.1.2). The secondary antibody (see Table 8, 4.1.5) was diluted in Blocking buffer 
and incubated on the membrane for 45-60 min at RT on an rotating shaker. Again, unbound antibody was 
removed by incubation with Wash buffer for 3x 10 min at RT. The secondary antibodies were visualized 
using Amersham ECL Advance Western Blotting Detection Kit (GE Healthcare) with a 1:10 dilution 
of the substrate solution in ddH
2
O. The signals were detected on Medical X-ray film (FujiFilm). All 
antibody incubations were performed on a rotating shaker, whereas an orbital shaker at 250 rpm was 
utilized for the washing steps.
4.2.15 Enzyme-linked immunosorbent assay (ELISA)
To study the protein levels of CCL-2, IL-8, pro MMP-1, MMP-3 and MMP-9 in conditioned medium, 
the ELISA Kits Quantikine Human CCL-2/ MCP-1, Quantikine CXCL-8/ IL-8, Quantikine Human Pro-
MMP-1, Quantikine Human MMP-3 and Quantikine Human MMP-9 Immunoassay (all R&D Systems) 
were used. Conditioned medium was collected from treated OTCs (see 4.2.5.3e). The ELISAs were 
performed as described in the manufacturer’s protocol. Supernatants were diluted when necessary in 
the supplied solution. A Multiskan FC Microplate Photometer (Thermo-Scientific) was used to perform 
the readout at 450 nm with enabled background subtraction at 620 nm. Protein concentrations were 
calculated according to a standard curve of recombinant protein that was included in each kit. Statistical 
significance was calculated by performing a One-way ANOVA + Dunnett’s Multiple Comparison 
Test or Two-way ANOVA + Bonferroni posttest, which both compare each treatment modality to the 
corresponding controls.
4.2.16 Statistics
Depending on the obtained data One-way or Two-way Analysis of variance (ANOVA) was performed 
with or without posttest as indicated in the corresponding method section or figure legend.
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5. Results
In order to study skin carcinogenesis, different human cell lines and cultivation systems have been 
identified that display cancer progression and were employed to study the effects of Wnt/Beta-catenin 
and specific B-Raf inhibitors on the development of cSCC. A model for functional studies bases on the 
HaCaT keratinocytes, which were obtained by culturing keratinocytes of a healthy, 62 year-old donor 
under low calcium and elevated temperature allowing the spontaneous transformation. HaCaT cells 
are immortal but remain non-tumorigenic upon injection into immunodeficient mice. HaCaT cells also 
show chromosomal alterations that are characteristic for SCCs, such as loss of 3p, 9p and gain of 3q 
(Boukamp et al., 1988; Boukamp et al., 1997) as well as UV-B type-specific mutations in both alleles of 
the p53 gene (Lehman et al., 1993). Despite the unlimited growth potential, they form a structured and 
fully differentiated epidermis on nude mice and thereby, express differentiation state specific keratins 
and other markers. These properties render HaCaT cells as early stage model of skin carcinogenesis 
(Boukamp et al., 1988; Ryle et al., 1989). Transfection of the parental HaCaT cells with H-RasG12V led 
to the generations of benign-tumorigenic HaCaT-RAS A-5 and malignant-tumorigenic HaCaT-RAS II-4 
cells, representing two further steps in skin cancer progression (Boukamp et al., 1990; Mueller and 
Fusenig, 1999). Moreover, cross-talk between keratinocytes and fibroblasts, spacial distribution and 
the cellular environment are also crucial aspects to investigate that were considered when developing 
different 3D organotypic co-culture models (OTCs).
5.1 Wnt/Beta-catenin signaling in cSCC development and progression
Wnt/Beta-catenin activation is well-known in tumorigenic keratinocytes of cSCC. However, we could 
additionally detect nuclear Beta-catenin, a hallmark for Wnt pathway activity, in fibroblasts surrounding 
the tumor, suggesting a role for stromal Wnt/Beta-catenin activation in cSCC progression. Furthermore, 
global gene expression analysis of Wnt-3a stimulated NHDF revealed a strong upregulation of the 
cytokines IL-8 and CCL-2 as well as of the matrix remodeling factor MMP-1 (Sobel, Tham et al., 2015). 
Thus, potential roles of the NHDF-derived factors IL-8, CCL-2 and MMP-1 on cSCC development and/ 
or progression were investigated in monolayer cultures as well as in 3D OTCs.
5.1.1 Wnt-3a induces IL-8 and CCL-2 expression in colOTCs
To analyze the effects of Wnt-3a as well as of IL-8 and CCL-2 in a 3D environment, collagen-based 
organotypic cultures (colOTCs) were employed (Schoop et al., 1999). Therefore, NHDF were embedded 
into a Collagen type I gel and seeded into filter inserts forming a dermal equivalent. Subsequently, 
HaCaT cells were seeded on top of the dermal equivalents and were grown air-exposed, forming a 
multi-layered stratified epithelium (see 4.2.5). Wnt-3a stimulation (100 ng/mL) for 2 and 4 weeks was 
performed though the culture medium. In addition to Wnt-3a, neutralizing antibodies targeting IL-8 
(nIL-8) and CCL-2 (nCCL-2) were used to specifically inhibit effects of these cytokines.
To ask whether IL-8 and CCL-2 are indeed secreted in Wnt-3a stimulated colOTCs, conditioned medium 
was harvested over the entire culture time and analyzed by immunoassays. IL-8 protein level increased 
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with time in Wnt-3a treated cultures to 2.7 ng/mL on day 28 (Fig. 9a). CCL-2 levels reached a maximum 
of 61 ng/mL at day 24 (Fig. 9b). Although IL-8 and CCL-2 protein levels were increasing in control 
cultures as well, Wnt-3a treatment caused a significant increase of both cytokines (IL-8: P=0.039, CCL-
2: P=0.016). Interestingly, the cytokines became measurable after 7 days of OTC cultivation compared 
to a direct expression in monoculture NHDF (Sobel, Tham et al., 2015). Since IL-8 and CCL-2 are 
probably highly expressed in NHDF upon Wnt-3a stimulation also in 3D, this finding suggested that both 
cytokines are retained in the ECM of colOTCs at the early time points, before becoming measurable in 
the culture medium. Furthermore, control and Wnt-3a cultures were additionally treated with neutralizing 
antibodies. As result, IL-8 was completely eliminated in the medium of both culture types (P=0.003, 
Fig. 9a), whereas CCL-2 levels were slightly reduced in control, but significantly decreased in Wnt-3a 
cultures by nCCL-2 treatment (P=0.009, Fig. 9b).
After 2 weeks of cultivation, histological analysis revealed a thin HaCaT cell epithelium without terminal 
differentiation. Stimulation with Wnt-3a or treatment with neutralizing antibodies (nIL-8, nCCL-2) did 
not alter the epithelial morphology (Fig. 10 a-d). After 4 weeks, all epithelia increased in thickness and 
showed some differentiating layers. As control colOTCs (Fig. 10e) were comparable to cultures treated 
with nIL-8 and nCCL-2, demonstrated that the neutralizing antibodies neither altered epithelial growth 
and differentiation nor caused major toxicity (Fig. 10f). Importantly, by stimulating OTCs with Wnt-
3a for 4 weeks, HaCaT cells grew invasively into the underlying dermal equivalent (Fig. 10g). This 
was prevented by additional treatment of Wnt-3a cultures with both neutralizing antibodies (Fig. 10h) 
suggesting that IL-8 and CCL-2 facilitate invasion in some areas of colOTCs.
To analyze differentiation and invasion in more detail, indirect immunofluorescence was performed 
to investigate the late differentiation marker Filaggrin, expressed from stratum granulosum to stratum 
corneum in normal skin (Watt, 1989) as well as integrity proteins of the BM. Since Filaggrin expression 
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Figure 9 | Wnt-3a leads to IL-8 and CCL-2 secretion in colOTCs.
colOTCs were prepared by seeding HaCaT cells on top of a dermal equivalent, consisting of NHDF embedded in a 
Collagen type I matrix. HaCaT colOTCs were stimulated with Wnt-3a (100 ng/mL) for 4 weeks through the culture 
medium. In addition, neutralizing antibodies targeting IL-8 (nIL-8, 1 mg/mL) and CCL-2 (nCCL-2, 4 mg/mL) were 
used to specifically inhibit effects of these cytokines. Conditioned medium was analyzed by ELISAs for IL-8 (a) and 
CCL-2 (b). Both cytokines were significantly increased in Wnt-3a stimulated cultures. The addition of nIL-8 and 
nCCL-2 to Wnt-3a treated OTCs caused a significant reduction of IL-8 and CCL-2 levels in Wnt-3a colOTCs. [n=2, 
mean ± SD, Two-way ANOVA + Bonferroni posttest]
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and localization was not changed by any treatment after 4 weeks, terminal differentiation did not seem 
to be altered. However, more differentiation markers should be analyzed to clearly answer this question 
(Fig. 11a-c). The BM separates dermis from epidermis and is composed of many proteins including 
lamins, HSPGs and collagens, but especially of Collagen IV. Keratinocytes adhere to the BM by cell 
surface proteins like Integrin (Kalluri, 2003). An Integrin beta-4 and Collagen IV staining between 
dermis and HaCaT epithelium revealed a continuous BM in control cultures (Fig. 11a, d). Interestingly, 
Wnt-3a stimulation led to reduction of both, Integrin beta-4 and Collagen IV, suggesting that this may 
have caused invasive growth in some areas of the HaCaT colOTCs (Fig. 11b, e). Neutralizing of IL-8 
and CCL-2 in Wnt-3a treated cultures led to a similar BM as observed in control cultures (Fig. 11c, f). 
This suggested that the invasive phenotype actually correlates with IL-8 and CCL-2 expression.
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Figure 10 | Invasion in HaCaT colOTCs is triggered by Wnt-3a induced IL-8 and CCL-2.
colOTCs were prepared by seeding HaCaT cells on top of a dermal equivalent, consisting of NHDF embedded in 
a Collagen type I matrix. OTCs were stimulated with Wnt-3a (100 ng/mL) through the culture medium. In addition, 
neutralizing antibodies targeting IL-8 (nIL-8, 1 mg/mL) and CCL-2 (nCCL-2, 4 mg/mL) were used to specifically 
inhibit effects of these cytokines. FFPE sections were stained with haematoxylin/ eosin to analyze the morphology. 
a-d | After 2 weeks, cultures revealed a thin undifferentiated HaCaT cell epithelium (a). Treatment with neutralizing 
antibodies (b), Wnt-3a (c) or both (d) did not alter the epithelial morphology. e-h | After 4 weeks, control (e) and 
nIL-8 + nCCL-2 treated cultures (f) showed some stratified layers. Stimulation with Wnt-3a led to invasive growth of 
HaCaT cells (g), which was prevented by the addition of nIL-8 and nCCL-2 (h). [n=2]
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5.1.2 IL-8 and CCL-2 increase HaCaT cell proliferation
Although both, IL-8 and CCL-2 are described to trigger proliferation in various cell types (Mishra et 
al., 2011; Steude et al., 2002; Tuschil et al., 1992), the effect of these chemokines on keratinocytes 
remains largely elusive. Therefore, I asked whether Wnt-3a induced levels of both cytokines also 
increase proliferation of HaCaT cells in colOTCs after 2 weeks. To quantify proliferation, the thymidine 
analogue BrdU was added to the OTCs prior to harvest for 5 h and thereafter, epithelial whole-mounts of 
OTCs were prepared by physically separating the epidermis from the dermal equivalent. BrdU staining 
of the entire whole-mount by immunofluorescence (Fig. 12a) revealed either 13% or 19% BrdU-positive 
HaCaT cells in control or nIL-8 + nCCL-2 treated colOTCs. Wnt-3a stimulation significantly increased 
proliferation to 31% (P<0.001). Most importantly, this increase was prevented by co-treatment with the 
neutralizing antibodies, keeping HaCaT cell proliferation at the control rate of 19% (P<0.001, Fig. 12b). 
As both cytokines were simultaneously neutralized within the culture medium, either IL-8, CCL-2, or 
the combination of both was directly responsible for increased HaCaT proliferation in colOTCs.
To answer which factor induced HaCaT cell proliferation, stimulation with each cytokine or the 
combination of both was repeated in HaCaT cell proliferation in monolayer cultures. Proliferation was 
quantified employing the SYBR Green cell proliferation assay. As positive control, 10 ng/mL of the 
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Figure 11 | IL-8 and CCL-2 do not affect HaCaT cell differentiation, but reduce BM proteins.
colOTCs were prepared by seeding HaCaT cells on top of a dermal equivalent, consisting of NHDF embedded 
in a Collagen type I matrix. HaCaT colOTCs were stimulated with Wnt-3a (100 ng/mL) through the culture 
medium. In addition, neutralizing antibodies targeting IL-8 (nIL-8, 1 mg/mL) and CCL-2 (nCCL-2, 4 mg/mL) were 
used to specifically inhibit effects of these cytokines. Cryo-sections of 4 week-old cultures were fixed to analyze 
differentiation and BM integrity by immunofluorescence. a-c | Expression and localization of the late differentiation 
marker Filaggrin (green) was not altered by any treatment. [n=2] a-f | Staining for the BM markers Integrin beta-
4 (red) and Collagen IV (red) showed a continuous BM in control cultures, while Cadherin-1 (green) served as 
epithelial marker (a, d). Wnt-3a stimulation caused a reduction of Integrin beta-4 and Collagen IV (b, e), whereas 
additional treatment with nIL-8 and nCCL-2 resembled the BM staining of control cultures (c, f). [n=2]
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known mitogen EGF (Dhillon et al., 2007) led to a significant increase in HaCaT cell proliferation 
compared to unstimulated cells (P<0.001). Moreover, stimulation of HaCaT cells with 10 ng/mL IL-8 
or 100 ng/mL CCL-2 for 24–72 h, representing the protein levels determined in OTCs, caused an 
even stronger increase in proliferation (P<0.001). Interestingly, combining both factors did not further 
increase proliferation suggesting that a maximal stimulation of HaCaT cells was reached already by 
each individual factor (Fig. 13). This, clearly showed that IL-8 and CCL-2 are potent and atypical 
mitogens for keratinocytes that directly affected HaCaT cell growth in monolayer cultures and OTCs.
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Figure 12 | Wnt-3a leads to IL-8 and CCL-2-dependent increased HaCaT cell proliferation in 3D.
colOTCs were prepared by seeding HaCaT cells on top of a dermal equivalent, consisting of NHDF embedded in 
a Collagen type I matrix. HaCaT colOTCs were stimulated with Wnt-3a (100 ng/mL) through the culture medium. 
In addition, neutralizing antibodies targeting IL-8 (nIL-8, 1 mg/mL) and CCL-2 (nCCL-2, 4 mg/mL) were used to 
specifically inhibit effects of these cytokines. a | Proliferation was assessed in epithelial whole-mounts prepared by 
peeling the epithelium from the dermal equivalent of 2 week-old OTCs. The fixed whole-mounts were analyzed by 
immunofluorescence staining for BrdU (red) and nuclei (blue). b | Wnt-3a stimulated OTCs significantly increased 
proliferation of basal HaCaT cells compared to controls. Depletion of IL-8 and CCL-2 with neutralizing antibodies 
prevented this Wnt-3a effect. [n=2, box plot with median, One-way ANOVA + Dunnett’s Multiple Comparison Test]
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Figure 13 | IL-8 and CCL-2 directly 
increase HaCaT cell proliferation.
HaCaT cell monolayer cultures were 
stimulated with human recombinant EGF 
(10 ng/mL), IL-8 (10 ng/mL), CCL-2 (100 
ng/mL) or a combination of IL-8 and CCL-
2 for 24-72 h. Proliferation was quantified 
by SYBR Green cell proliferation assay. 
Stimulation with the known mitogen EGF led 
to a significantly elevation, while IL-8, CCL-
2 or the combination of both even further 
increased HaCaT cell proliferation. [n=2, 
mean ± SEM, Two-way ANOVA + Bonferroni 
posttest]
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5.1.3 Wnt-3a induces MMP expression in colOTCs
Another Wnt-3a target gene identified by global gene expression analysis in NHDF was MMP1. MMPs 
are responsible for the degradation of the ECM, a process required for tumor cell invasion (Lynch 
and Matrisian, 2002) and thus, are crucial in preparing a permissive tumor stroma. Several MMPs 
were shown to be direct Wnt target genes (Brabletz et al., 1999; Lowy et al., 2006; Takahashi et al., 
2002). As we found MMP1 to be upregulated in Wnt-3a-treated NHDF (Sobel, Tham et al., 2015), 
I investigated whether MMP1 triggered invasive growth of non-tumorigenic HaCaT cells. First, the 
expression of pro MMP-1 was analyzed by immunoassay of conditioned colOTC medium. As result, 
pro MMP-1 accumulated over the cultivation period of 4 weeks in HaCaT control colOTCs, reaching 
a maximum of 1,005 ng/mL. At the same time, Wnt-3a stimulation significantly increased secretion of 
pro MMP-1 to 1,320 ng/mL (P=0.033, Fig. 14a). Using DQ-Gelatin in situ zymography to directly assay 
for active MMPs in colOTCs sections, demonstrated a low gelatinolytic activity (green) in the dermal 
equivalents of controls, while Wnt-3a-treatment 
caused an increased MMP-activity (Fig. 14b, 
c). Additionally, Wnt-3a-treated OTCs stained 
strongly with an antibody that specifically 
detects Collagenase-cleaved Collagen type I 
and II compared to control cultures (Figs. 14e, 
f), thus, confirming an active matrix degradation 
by MMP-1. Importantly, IL-8 and CCL-2 
neutralization in Wnt-3a stimulated cultures 
reduced neither pro MMP-1 levels, which was 
still significantly increased (1,554 ng/mL after 4 
weeks) compared to control cultures (P=0.006, 
Fig. 14a), nor MMP-activity (Fig. 14d) or levels 
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Figure 14 | Wnt-3a causes pro MMP-1 secretion 
and MMP-activity in HaCaT colOTCs.
HaCaT colOTCs were stimulated with Wnt-3a (100 
ng/mL) through the culture medium. In addition, 
neutralizing antibodies targeting IL-8 (nIL-8, 1 mg/
mL) and CCL-2 (nCCL-2, 4 mg/mL) were used to 
specifically inhibit effects of these cytokines. a | 
Conditioned medium was analyzed by ELISA for pro 
MMP-1 protein levels during 28 days of cultivation. 
Wnt-3a treatment significantly increased pro MMP-1 
secretion compared to controls. Wnt-3a effects on pro 
MMP-1 were not altered by depletion of IL-8 and CCL-
2. [n=2, mean ± SD, Two-way ANOVA + Bonferroni 
posttest] b-d | In situ zymography to analyze MMP-
activity in 4 week-old cryo-conserved HaCaT 
colOTCs revealed only weak gelatinolytic activity 
(green) in control OTCs (b). Stimulation with Wnt-
3a strongly increased gelatinolytic activity (c), which 
was not reduced by IL-8 and CCL-2 neutralization 
(d). [n=3]. e-g | In agreement, immunofluorescence 
for collagen cleavage products in 4 week-old cultures 
demonstrated a strong accumulation of cleaved 
collagen (red) only in sections of Wnt-3a-treated 
cultures (f), but not in untreated OTC sections (e). 
This was not altered by nIL-8 and nCCL-2 (g). [n=2]
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of Collagen cleavage (Fig. 14g). Importantly, these findings did not reflect the invasive behavior of 
HaCaT cells in colOTCs, which was dependent on increased IL-8 and CCL-2 levels (Fig. 10), but 
demonstrated that MMP upregulation is a direct effect of Wnt-3a.
Since the presence of myofibroblasts or CAFs within the tumor stroma was frequently associated 
with tumor progression (Mishra et al., 2011), I asked whether myofibroblasts or CAFs play a role in 
tumorigenesis in vivo or in invasion of colOTCs. By immunofluorescence staining of sections with the 
myofibroblast marker alpha-Smooth muscle actin (alpha-SMA) signals relating to blood vessels were 
detected in normal human skin (Fig. 15a, b) and human cSCCs (Fig. 15c, d). However, neither in vivo 
nor in control (Fig. 15e, f) or Wnt-3a stimulated colOTCs (Fig. 15g, h) alpha-SMA positive stromal 
cells were detected, arguing that CAFs do not play a role in MMP secretion and HaCaT cell invasion or 
human cSCC progression.
Taken together, these findings argue for two distinct mechanisms. On one hand, Wnt/Beta-catenin 
activation of NHDF led to MMP expression, secretion and activation, which is frequently involved 
in an invasive phenotype. On the other hand, invasion of HaCaT cells grown on colOTCs was clearly 
dependent on Wnt-3a induced and NHDF secreted IL-8 and CCL-2. However, both mechanisms may 
also work in concert.
5.1.4 Wnt-3a stimulation of fdmOTCs leads to invasion of HaCaT-RAS A-5 cells
In order to confirm the observed invasive phenotype, fibroblast-derived matrix OTCs (fdmOTCs) as a 
more stable OTC model that is not prone to self-degradation was employed. After 4 weeks of fdmOTCs 
growth, HaCaT cells formed a well-differentiated parakeratotic epithelium (Fig. 16a, b). Under these 
more stringent conditions, however, neither control nor Wnt-3a stimulated HaCaT fdmOTCs showed 
invasive growth (Fig. 16c, d). Besides non-tumorigenic HaCaT cells, the invasive behavior of H-RasG12V-
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Figure 15 | Myofibroblasts are not present in Wnt 3a-treated OTCs or cSCC.
a-d | Immunofluorescence staining for the myofibroblast marker alpha smooth muscle actin (alpha-SMA, green) 
revealed pericytes surrounding blood vessels in sections of normal human skin (a, b) and human cSCCs cryo-
sections (c, d). e-h | Immunofluorescence co-staining of alpha-SMA (green) with the BM marker Collagen IV (red) 
in 2 and 4 week-old fixed cryo-sections did not show myofibroblasts in control (e, f) and Wnt-3a-stimulated OTCs 
(g, h).
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transfected benign-tumorigenic HaCaT-RAS A-5 cells was also analyzed. HaCaT-RAS A-5 fdmOTCs 
formed a more hyperplastic epithelium showing less terminal differentiation as HaCaT fdmOTCs (Fig. 
16e, f). When stimulating these cultures with Wnt-3a, HaCaT-RAS A-5 cell differentiation was slightly 
increased. Most importantly, cells grew invasively into the dermal equivalent (Fig. 16g, h), showing 
that Wnt-3a led to invasion of benign-tumorigenic keratinocytes only in fdmOTCs. Thus, whether 
exclusively benign-tumorigenic or also non-tumorigenic cells grew invasively strongly depended on the 
stability of the employed OTC model.
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Figure 16 | Wnt-3a causes invasion of HaCaT-RAS A-5, but not of HaCaT cells in fdmOTCs.
fdmOTCs were prepared by allowing NHDF to build an ECM before seeding HaCaT or HaCaT-RAS A-5 cells, 
resulting in a stable OTC model that is not prone to self-degradation. fdmOTCs were stimulated with Wnt-3a (100 
ng/mL) through the culture medium for 4 weeks. FFPE sections were stained with haematoxylin/ eosin to analyze 
the morphology. a-d | Non-tumorigenic HaCaT cells formed a well-differentiated parakeratotic epithelium (a, b). 
Under the fdmOTC conditions, Wnt-3a stimulated did not induce invasive growth (c, d). e-h | Benign-tumorigenic 
HaCaT-RAS A-5 cells formed a more hyperplastic epithelium showing low levels of terminal differentiation (e, f). 
Wnt-3a stimulation increased differentiation and invasion into the dermal equivalent (g, h). [n=3]
5. Results
54
5.1.5 Wnt ligands, IL-8, CCL-2 and MMP-1 in Beta-catenin positive cSCCs
To determine the relevance of these findings, the expression of Wnt ligands as well as of the Wnt/Beta-
catenin induced factors IL-8, CCL-2 and MMP-1 was investigated in human primary cSCCs. First, 
WNT2 and WNT3 mRNA expression was analyzed by in situ hybridization. While normal skin was 
generally negative for WNT2 and WNT3 transcripts (Fig. 17a, d), cSCCs showed focal WNT2 and 
WNT3 mRNA expression (blue) within the tumor-stroma (Fig. 17b-c, e-f). In agreement, Wnt-3 protein 
could not be detected by immunofluorescence in normal skin (Fig. 17g), but was stained positive within 
the Vimentin positive cSCC stroma (Fig. 17h, i). This demonstrated that Wnt ligands are present in the 
stroma of some Wnt/Beta-catenin activated cSCCs.
Second, in situ hybridization for IL8 and CCL2 in normal human skin, revealed strong signals of both 
cytokines in sebaceous glands and hair follicles (blue, Fig. 18a, d). When analyzing the cSCC sections, 
high levels of both IL8 and CCL2 were additionally expressed within the tumor stoma (Fig. 18b-c, e-f), 
arguing that both cytokines are indeed expressed in some Wnt/Beta-catenin positive tumors and most 
likely act in concert. Third, high stromal MMP-1 levels (Fig. 18g, h) and MMP-cleaved collagen (Fig. 
18i, j) could also be confirmed by immunofluorescence in cSCCs in situ, thereby supporting that MMP-1 
is also expressed in vivo and contributes to matrix degradation and remodeling.
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Figure 17 | WNT2 and WNT3 are expressed in Wnt/Beta-catenin positive cSCC.
Wnt/Beta-catenin positive cryo-conserved cSCC sections were analyzed for the presence of Wnt ligands a-f | In situ 
hybridization revealed WNT2 (b, c) and WNT3 (e, f) in the tumor-stroma of some cSCCs (blue), but not in normal 
skin (a, d). g-i | Immunofluorescence confirmed an increased Wnt-3 (red) expression within the Vimentin (green) 
positive tumor stroma (h, i) compared to normal skin (g).
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Figure 18 | Effector genes IL8, CCL2 and MMP1 are expressed in Wnt/Beta-catenin positive cSCC.
Wnt/Beta-catenin positive cryo-conserved cSCC sections were analyzed for the expression of the Wnt-3a induced 
genes IL8, CCL2 and MMP1. a-f | In situ hybridization showed high amounts of IL8 (b, c) and CCL2 (e, f) in the 
tumor-stroma of some cSCCs (blue) compared to normal skin (a, d). g-j | Immunofluorescence demonstrated a 
strong accumulation of MMP-1 (red) within the Keratin-14 (K14, green)-negative tumor stroma (g, h). Staining for 
MMP-cleaved collagen (red) confirmed MMP activity within the K14 (green)-negative cSCC stroma (i, j).
5. Results
56
5.2 The B-Raf inhibitor Vemurafenib in cSCC progression
Besides the canonical Wnt signaling pathway, additional pathways may play a role in cSCC development 
and progression. It was recently described in melanoma therapy using the specific B-RafV600E inhibitor 
Vemurafenib (VEM) that cSCCs represent a frequently observed and early adverse effect. Moreover, 
it was hypothesized that a paradoxical MEK-ERK MAPK hyper-activation by Vemurafenib in BRAF 
wild-type melanoma cells also represents the mechanism underlying cSCC development (Halaban et 
al., 2010; Hatzivassiliou et al., 2010). Thus, Vemurafenib-induced and Ras-Raf-MEK-ERK MAPK 
pathway dependent or independent effects could drive keratinocyte transformation, as well.
5.2.1 HaCaT and SCC cell lines does not reveal BRAF mutations
In order to determine the importance of activating BRAF and RAS mutations in cSCCs as well as to 
identify a suitable model system for the analysis of Vemurafenib induced cutaneous effects, frequent 
somatic mutation were analyzed. Besides the HaCaT carcinogenesis progression model, cSCC cell 
lines isolated directly from human tumors were included. The MET1-4 cell lines were isolated from 
the primary cSCC, two recurrences and a metastasis of the same patient (Proby et al., 2000). These 
cells carry a number of cSCC characteristic chromosomal changes and mutations except for TP53, thus 
allowing to study p53-independent mechanisms in skin carcinogenesis and metastasis (Boukamp, 2005; 
Popp et al., 2000). Moreover, SCL-I (Boukamp et al., 1982), SCL-II (Tilgen et al., 1983), SCC-12, 
SCC-13 (Rheinwald and Beckett, 1981) that were also isolated from primary human cSCCs display later 
stages in carcinogenesis.
The PCR-based array allowed the analysis of 78 frequently reported somatic mutations in human skin 
cancer within the genes BRAF, CDKN2A, CTNNB1, FGFR3, GNAQ, HRAS, KIT, KRAS, NRAS, 
PIK3CA, PTCH1, PTEN, RB1, SMO, LKB1/STK11 and TP53. NHEK of a young donor and from a 
sun-protected body site that unlikely carry any of the listed mutations were used to normalize the PCR 
array. When analyzing parental non-tumorigenic HaCaT cells as well as malignant tumorigenic HaCaT-
RAS II-4 cells, the known TP53 mutations p.H179Y and p.R282W could be detected, confirming the 
specificity of the assay. The third known TP53 mutation p.281 was not included in the assay and thus, 
not detected (Lehman et al., 1993). Besides TP53 mutations, HaCaT-RAS II-4 cells also showed the 
expected HRAS mutation p.G12V (Boukamp et al., 1990), but no additional common mutation. The 
SCC cell lines SCL-I and SCL-II have the known TP53 mutations p.197STOP and p.N132K, respectively. 
SCC-12 cells have the TP53 mutation p.V216G and the HRAS mutation p.G12L, which were also not 
part of the employed array. In SCC-13 cells the TP53 mutation p.E258K could be confirmed (Popp et 
al., 2002) and a so-far unpublished HRAS mutation p.G12D was identified. Surprisingly, MET-1 cells 
originating from a primary SCC did not show any mutation, while MET-4 cells established from a lymph 
node metastasis of the same tumor showed an unknown CDKN2A (p16) mutation p.W110* (Table 12).
Thus, HaCaT, SCL-I and SCL-II cells showed TP53 mutations only while HaCaT-RAS II-4, SCC-12 
and SCC-13 harbor additional HRAS mutations. The MET-1 and MET-4 cells had neither TP53 nor 
RAS mutations but MET-4 showed a so-far unknown CDKN2A (p16) mutation. Most importantly, all 
cell lines were negative for the typical BRAF mutations and only some revealed RAS mutations, thus 
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showing that especially BRAF mutations are in contrast to melanoma not involved in cSCC development. 
Having shown that TP53 but not BRAF mutations are frequently found in cSCCs, non-tumorigenic 
HaCaT cells displaying this genotype were chosen as model system to study Vemurafenib effects on 
keratinocytes cells. As benign-tumorigenic HaCaT-RAS A-5 and malignant-tumorigenic HaCaT-RAS 
II-4 cells showed an additional RAS mutation, these cells allowed studying the involvement of Ras in 
Vemurafenib induced cSCCs.
5.2.2 MEK-ERK signaling can be stimulated in HaCaT and HaCaT-RAS II-4 
cells
Furthermore, we asked whether a normal activation of the Ras-Raf-MEK-ERK MAPK pathway by 
EGFR stimulation is possible in HaCaT and HaCaT-RAS II-4 cells. Therefore, cells were staved for 40 
h in growth medium without FBS and stimulated with either the specific EGFR-inducer EGF (2 ng/mL) 
or FBS (10%)-containing growth medium. Subsequent activation of MEK, ERK and the related MAPK 
p38 as well as of the adjacent PI3K-PTEN-Akt pathway by phosphorylation was analyzed by Western-
Blot.
 
TP53 (p53) HRAS CDKN2A (p16) 
Base 
change 
Amino 
acid 
change 
Base 
change 
Amino 
acid 
change 
Base 
change 
Amino 
acid 
change 
HaCaT 
(immortalized) 
c.535C>T 
 
c.844C>T 
4p.H179Y 
3p.281 
4p.R282W 
- - - - 
HaCaT A-5 
(benign) 
c.535C>T 
 
c.844C>T 
3p.H179Y 
3p.281 
3p.R282W 
c.35G>T 3p.G12V 
- - 
HaCaT II-4 
(malignant) 
c.535C>T 
 
c.844C>T 
4p.H179Y 
3p.281 
4p.R282W 
c.35G>T 4p.G12V   
SCL-I 
(moderate 
differentiation) 
c. C>T 1p.197STOP 
- - - - 
SCL-II 
(low 
differentiation) 
c. T>G 1p.N132K 
- - - - 
SCC-12 
(high 
differentiation) 
c. T>G 1p.V216G c. CC>TT 1p.G12L 
- - 
SCC-13 
(high 
differentiation) 
c.772G>A 2p.E258K c.35G>A p.G12D 
- - 
MET-1 
(primary SCC) - - - - - - 
MET-4 
(metastasis) - - - - 
c.330G>A p.W110* 
 
Table 12 | Mutation analysis of HaCaT variants and SCC cell lines.
1Adopted from, 2confirmed by Popp et al., 2002/ 3Adopted from, 4confirmed by Lehmann et al. 1993 or 
Boukamp et al. 1990/ newly detected mutation.
5. Results
58
In HaCaT cells, stimulation with EGF led to a strong phosphorylation of MEK1/2 and ERK1/2 
already after 15 min and lasted for more than 60 min compared to the baseline after starvation (0 min). 
Importantly, total MEK and ERK protein levels remained unchanged. Stimulation with growth medium 
+ FBS also caused MEK1/2 and ERK1/2 phosphorylation after 15 min, but showed a weaker and shorter 
effect on Ras-Raf-MEK-ERK pathway activation compared to EGF stimulation. A weak increase in 
phosphorylated p38 was also noted after 45-60 min of stimulation, while phosphorylated Akt was not 
reproducibly affected (Fig. 19a). A longer treatment showed that both, EGF and FBS stimulated MEK/
ERK, but not p38 MAPK phosphorylation for more than 6 h (Fig. 19b).
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Figure 19 | EGF and FBS stimulate MEK-ERK signaling in HaCaT and HaCaT-RAS II-4 cells.
HaCaT and HaCaT-RAS II-4 cells were staved for 40 h in growth medium without FBS and stimulated with either 
the EGFR ligand EGF (2 ng/mL) or FBS (10%)-containing growth medium. MEK, ERK, p38 MAPK and PI3K-PTEN-
Akt pathway activation was monitored over 6 h by Western-Blot. a, b | In HaCaT cells, EGF and FBS stimulation 
caused a strong MEK-ERK phosphorylation after 15 min (a) that was observed for more than 6 h (b), while total 
MEK and ERK protein levels remained unchanged. A weak but not reproducible increase in phosphorylated p38 and 
Akt was also noted (a, b). c, d | In HaCaT-RAS II-4 cells, the baseline MEK-ERK activation was increased compared 
to HaCaT cells. EGF or FBS stimulation caused MEK and ERK phosphorylation after 15 min (c) that remained 
increased until reaching 3 h (d) and was not as strong as in HaCaT cells. [n=2]
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In HaCaT-RAS II-4 cells, the baseline MEK-ERK activation was increased compared to HaCaT cells. 
By stimulation with either EGF or growth medium + FBS, MEK and ERK phosphorylation was also 
observed after 15 min and remained increased until reaching 3 h. Again, phosphorylated p38 was slightly 
increased after stimulation and phosphorylated levels of Akt remained unchanged (Fig. 19c, d). Thus, 
EGF and FBS stimulated EGFR as well as downstream signaling to MEK1/2 and ERK1/2 in HaCaT and 
at lower levels also in HaCaT-RAS II-4 cells.
5.2.3 Treatment of HaCaT cells with the B-Raf inhibitor Vemurafenib does not 
cause toxicity
In order to study Vemurafenib on keratinocytes, toxicity was assessed by apoptosis assay. Vemurafenib 
is generally solubilized in DMSO and was used in different studies on melanoma cells at a concentration 
of 0.01-50 µM, while it is commonly at 1 µM for the investigation of signaling pathways in cell culture 
(Comin-Anduix et al., 2010; Søndergaard et al., 2010; Yu et al., 2011). To determine apoptosis, HaCaT 
cells were stimulated for 24 and 48 h with 1, 10 or 50 µM Vemurafenib or the corresponding DMSO 
concentrations 0.01, 0.1 or 0.5% (v/v) as control. After trypsinization, FITC-labeled Annexin V binding 
to the phospholipid phosphatidylserine at the outer cell membrane layer identified early apoptosis, while 
PI that entered the cell marked late apoptotic/ dead cells. Staining was analyzed by FACS for each 
cell, plotted (Fig. 20a) and quantified accordingly. Celastrol, a known inducer of apoptosis in HaCaT 
cells (Zhou et al., 2011), was used as positive control. Compared to untreated control cells, Celastrol 
induced a minor increase in overall apoptosis from 13.1 to 16.9% apoptotic cells at 2.2 µM and a 
significant increase to 77.4% at 8.8 µM after 24 h of treatment (P<0.01). In contrast, increasing DMSO 
or Vemurafenib concentrations induced apoptosis after neither 24 h (Fig. 20b) nor 48 h of treatment (Fig. 
20c). Thus, 0.01-5 µM Vemurafenib could be used for subsequent experiments.
5.2.4 Vemurafenib long-term stimulation does not alter apoptosis but causes 
partial G1/G0 phase arrest of HaCaT cells
Since short-term hyper-activation of MEK-ERK signaling in HaCaT cells did not show any toxicity, 
I asked whether such an effect is observed in continuously stimulated HaCaT cells. For this reason, 
HaCaT cells were cultivated in growth medium and growth medium supplemented with 0.5% (v/v) 
DMSO, 1 µM or 5 µM Vemurafenib for 9 weeks. As cells reached confluency under control conditions 
after 7 days, all conditions were split every week and 0.5x 106 cells were routinely reseeded per 10 
cm culture dish and condition. (Fig. 21a). After 5 weeks of continuous treatment, HaCaT cells were 
stimulated for another 24 h to determine apoptosis. FACS analysis revealed an overall apoptosis rate of 
15% in DMSO treated HaCaT cells. In contrast, apoptosis was significantly increased to 90% by treating 
the same cells for 24 h with 8.8 µM Celastrol confirming the specificity of the assay (P<0.05). Treatment 
for 5 weeks + 24 h with either 1 µM or 5 µM Vemurafenib did not result in significant changes in HaCaT 
cell apoptosis compared to DMSO treated cells (Fig. 21b, c).
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To determine whether cell cycle progression was altered by continuous Vemurafenib stimulation in 
HaCaT cells, a cell cycle measurement was performed after 5 or 9 weeks. Therefore, HaCaT cells were 
fixed and the cell cycle phases were distinguished according to the DNA content of each cell by FACS 
analysis (Fig. 22a). After 5 weeks + 24 h, control and DMSO treated HaCaT cells showed approx. 
44% G1/G0, 35% S and 18.0% G2 phase. By 1 µM/ 5 µM Vemurafenib stimulation, G1/G0 phase was 
Figure 20 | Vemurafenib does not induce apoptosis in HaCaT cells.
Vemurafenib induced toxicity was assessed by apoptosis assay. HaCaT monolayer cultures were stimulated for 24 
and 48 h with 1, 10 or 50 µM Vemurafenib, solubilized in DMSO, or the corresponding DMSO concentration of 0.01, 
0.1 or 0.5% (v/v) as control. Celastrol (2.2 µM, 8.8 µM), as known inducer of apoptosis in HaCaT cells, served as 
positive control. Trypsinized HaCaT cells were stained with FITC-labeled Annexin V marking early apoptotic cells 
and PI detecting late apoptotic/ dead cells. a | FACS-based single cell analysis was plotted according to FITC and 
PI fluorescence. b, c | Quantification revealed a minor elevation in overall apoptosis by 2.2 µM and a significant 
increase by 8.8 µM Celastrol after 24 h, compared to untreated control cells. Increasing DMSO or Vemurafenib 
concentrations did not significantly increase apoptosis after 24 h (b) or 48 h (c). [n=2, mean ± SEM, Two-way 
ANOVA + Bonferroni posttest]
Figure 21 | Vemurafenib long-term treatment of HaCaT cells does not induce apoptosis.
Vemurafenib induced toxicity in long-term treated HaCaT monolayer cultures was assessed by apoptosis assay. a | 
HaCaT cells were continuously stimulated for 9 weeks with 0.05% (v/v) DMSO, 1 µM or 5 µM Vemurafenib. As cells 
reached confluency every 7 days, they were trypsinized and 0.5x 106 cells were reseeded per 10 cm culture dish. 
b | After 5 weeks, HaCaT cells were treated for another 24 h accordingly and stained with FITC-labeled Annexin 
V marking early apoptotic cells and PI detecting late apoptotic/ dead cells. FACS-based single cell analysis was 
plotted for FITC and PI fluorescence. c | Quantification of control cells treated for 24 h with Celastrol (8.8 µM), as 
known inducer of apoptosis in HaCaT cells, revealed a significant increase in apoptosis, compared to control cells. 
Treatment for 5 weeks + 24 h with either 1 µM or 5 µM Vemurafenib did not result in significant changes in HaCaT 
cell apoptosis. [n=2, mean ± SEM, Two-way ANOVA + Bonferroni posttest]
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increased to 47.8/ 53.1%, whereas S phase was decreased to 31.9/ 29.7% and also G2 phase cells were 
not altered/ reduced to 18.0/ 14.6%. After 9 weeks + 24 h, control and DMSO treated HaCaT cells 
showed approx. 52% G1/G0, 29% S and 17.0% G2 phase. By 1 µM/ 5 µM Vemurafenib stimulation, G1/
G0 phase also was increased to 57.4/ 56.6%, whereas S phase was decreased to 28.0/ 23.8% and also G2 
phase cells were reduced/ slightly increased to 12.8/ 18.2%. Thus, the cell cycle quantification revealed 
a small shift from G2 or S to G1/G0 phase after 5 and 9 weeks of Vemurafenib treatment (Fig. 22b), 
suggesting that Vemurafenib rather inhibited than accelerated cell cycle progression of HaCaT cells. 
However, this demonstrated that neither short-term nor long-term treatment with 1-5 µM Vemurafenib 
induced toxicity on HaCaT cells.
5.2.5 Vemurafenib abrogates MEK-ERK signaling in B-Raf-mutant melanoma 
cells but causes hyper-activation in B-Raf wild-type keratinocytes
To test the efficacy of the B-Raf inhibitor Vemurafenib at a concentration of 1 µM, I stimulated 
B-Raf p.V600E mutant A375 melanoma cells. Western-Blot analysis of phosphorylated MEK1/2 and 
ERK1/2 revealed high levels of both proteins at baseline in this tumor cell line, accounting to the 
Figure 22 | Vemurafenib rather inhibites than accelerates cell cycle progression of HaCaT cells.
Vemurafenib induced toxicity of long-term treated HaCaT monolayer cultures was assessed by cell cycle analysis. 
HaCaT cells were continuously stimulated for 9 weeks with 0.05% (v/v) DMSO, 1 µM or 5 µM Vemurafenib. As cells 
reached confluency every 7 days, they were trypsinized and 0.5x 106 cells were reseeded per 10 cm culture dish. 
a | After 5 or 9 weeks, HaCaT cells were treated for another 24 h accordingly, were fixed and stained with PI. As the 
PI intensity per cell relates to the DNA content, a FACS analysis allowed distinguishing the cell cycle phases G1/
G0, S and G2. b | After 5 weeks + 24 h or 9 weeks + 24 h, 1 µM or 5 µM Vemurafenib stimulation led to a shift from 
G2 or S to G1/G0 phase when compared to control and DMSO treated HaCaT cells. This suggested inhibited rather 
than accelerated cell cycle progression of HaCaT cells. [n=1 for each time point]
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constitutively active mutant B-Raf signaling. When adding Vemurafenib, both phosphorylated proteins 
were strongly reduced for more than 6 h compared to treatment with 0.01% (v/v) DMSO, as expected. 
The corresponding total protein load was not altered. The increase in phosphorylation of MEK, ERK, 
p38 and Akt between 1-6 h likely accounted to the addition of new growth medium, which activated 
these pathways irrespective of the treatment. Comparable effects were also observed in subsequent 
Western-Blot experiments. However, phosphorylated p38 and Akt were not reproducibly affected by 
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Figure 23 | MEK-ERK signaling is blocked by Vemurafenib in mutant, but hyper-activated in wild-
type B-Raf cells.
B-RafV600E-mutant A375 melanoma cells and B-Rafwild-type HaCaT cells were stimulated with 1 µM or 0.01% (v/v) 
DMSO as control in FBS-containing growth medium for 6 h. MEK, ERK, p38 MAPK and PI3K-PTEN-Akt pathway 
activation was monitored by Western-Blot. a, b | A375 cells demonstrated high MEK and ERK levels at baseline 
due to mutant B-Raf signaling. By Vemurafenib, both phosphorylated proteins were strongly reduced for more 
than 6 h compared to treatment with DMSO. The corresponding total protein was not altered. p38 and Akt did 
not show Vemurafenib specific effects (a). This confirmed that Vemurafenib abrogates downstream signaling by 
monomeric B-RafV600E (b). [n=2] c-f | HaCaT cells demonstrated a low basal MEK-ERK activity. When stimulated 
with Vemurafenib, levels of phosphorylated MEK and ERK were increased after 30 min for more than 6 h. p38 and 
Akt activation accounted to fresh growth medium (c). Accordingly, B-Rafwild-type, both hypothesized models require a 
Ras mutation or receptor tyrosine kinases (RTKs) signaling (d, e). Poulikakos (2010) suggested a low Vemurafenib 
concentration as third requirement that blocks and conformationally alters one Raf subunit leading hyper-activation 
of the second (d). Alternatively, Heidorn and Hatzivassiliou (2010) proposed that Vemurafenib resolves the B-Raf 
auto-inhibitory state allowing Ras-dependent dimer formation and MEK-ERK hyper-activation (e). [n=2]
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Vemurafenib (Fig. 23a). This shows that a concentration of 1 µM Vemurafenib is indeed sufficient 
to specifically block downstream signaling from monomeric B-RafV600E to MEK and ERK in A375 
melanoma cells (Fig. 23b).
In contrast to A375 cells, HaCaT cells showed a low basal MEK-ERK activation. When stimulating 
HaCaT cells with Vemurafenib, levels of phosphorylated MEK and especially ERK increased as soon 
as after 30 min and persisted for more than 6 h reaching a maximum after 1 h post treatment. Again, 
the related signaling pathways p38 and Akt were activated over time under both conditions, which 
accounted to pathway stimulation by growth medium rather than being a Vemurafenib-specific effect 
(Fig. 23c). As suggested by the pathway hyper-activation hypothesis initially described in BRAFwild-type 
melanoma cells, Vemurafenib leads to pathway activation rather than inhibition (Hatzivassiliou et al., 
2010) also in BRAFwild-type HaCaT cells. Accordingly, upon upstream activity via EGFR or Ras and a low 
Vemurafenib concentration only one subunit of the B-Raf/B-Raf or B-Raf/C-Raf dimer is stochastically 
blocked leading to conformational changes that likely hyper-activated the second subunit (Poulikakos 
et al., 2010) (Fig. 23d). An alternatively hypothesis suggests the release of the B-Raf auto-inhibitory 
state by Vemurafenib leading to increased downstream signaling through MEK and ERK, as well 
(Hatzivassiliou et al., 2010; Heidorn et al., 2010) (Fig. 23e).
To test whether Vemurafenib itself is capable of hyper-activating MEK-ERK signaling or requires 
upstream activity through EGFR or Ras, HaCaT cells were starved in medium without FBS for 48 h and 
stimulated with 1 µM Vemurafenib only or in combination with 2 ng/mL EGF for 1 and 3 h. Compared 
to DMSO treatment, Vemurafenib caused a weak, while EGF stimulation mediated a strong MEK-
ERK phosphorylation after 1 h that further increased and was maintained for more than 3 h. Combined 
stimulation with Vemurafenib and EGF further increased MEK and ERK phosphorylation above the 
levels of each individual stimulation. p38 MAPK and Akt revealed some activation, which could not 
be reproducibly linked to EGF or Vemurafenib. This argued that B-Raf upstream activity increases the 
hyper-activation effect of Vemurafenib also in HaCaT keratinocytes (Fig. 24a). Thereafter, effects of 
higher Vemurafenib concentrations on HaCaT cells in growth medium were investigated by adding 1, 10 
or 50 µM Vemurafenib to the cells for 1 or 3 h. Compared to 0.5% (v/v) DMSO, 1 µM Vemurafenib led to 
ERK activation after 1 and 3 h. 10 µM Vemurafenib mediated a strongly increased ERK phosphorylation 
after 1 h, which was not maintained at 3 h. Even more interesting, 50 µM led to a reduced response at 1 h 
compared to 10 µM, which was also not maintained for 3 h. Again, neither p38 nor Akt phosphorylation 
were reproducibly affected (Fig. 24b). This suggested that Vemurafenib concentrations between 10 and 
50 µM lead to the binding of both subunits of a Raf dimer, thus, preventing signaling through MEK and 
ERK. Therefore, Vemurafenib concentrations below 10 µM were used in the subsequent experiments.
As Vemurafenib induced MEK-ERK hyper-activation in HaCaT cells, I asked whether BRAFwild-type 
NHEK, HaCaT-RAS A-5 and HaCaT-RAS II-4 cells respond also with pathway activation. Again, 
keratinocytes were stimulated with either 1 µM Vemurafenib or 0.01% (v/v) DMSO in growth medium 
for 6 h. Two different normal keratinocytes, NHEK 1 and NHEK 2, responded with increased levels of 
phosphorylated MEK and ERK after 30 min with a peak at 1 h of Vemurafenib stimulation, compared to 
the corresponding control at each time point. Importantly, total MEK and ERK protein levels remained 
unchanged (Fig. 25a, b). Even H-RasG12V transfected and benign-tumorigenic HaCaT-RAS A-5 cells 
responded similarly to Vemurafenib with ERK phosphorylation after 30 min and a maximum level after 
1 h (Fig. 25c). HaCaT-RAS II-4 cells showed a strong MEK and ERK phosphorylation after 30 min 
5. Results
65
of treatment that was maintained for more than 6 h at a similar level (Fig. 25d). In case of control and 
Vemurafenib, MEK, ERK p38 and Akt phosphorylation increased over time due to pathway activation 
by fresh growth medium, whereas only MEK and ERK were also reproducibly hyper-activated by 
Vemurafenib (Fig. 25a-d). Taken together, Vemurafenib abrogated signaling through MEK and ERK 
in B-RafV600E mutant A375 cells, but increased MEK-ERK signaling in all analyzed B-Rafwild-type 
keratinocytes irrespective of RAS mutations or the stages in skin carcinogenesis. Moreover, pathway 
upstream activity and Vemurafenib concentration below 10 µM seemed to promote a solid response in 
HaCaT cells.
5.2.6 MEK-ERK hyper-activation does not increase proliferation of keratinocytes
Activation of MEK-ERK signaling was frequently linked to increased cell proliferation (Dhillon et al., 
2007). As Vemurafenib mediated MEK-ERK hyper-activation in keratinocytes, this may subsequently 
lead to increased cell proliferation. Therefore, NEHK, HaCaT and HaCaT-RAS A-5 cells were stimulated 
with different Vemurafenib concentrations or 0.05% (v/v) DMSO. Since B-Raf upstream activity was 
found to increase Vemurafenib induced MEK-ERK hyper-activation, keratinocytes were cultured and 
stimulated in growth medium. A subsequent SYBR Green-based cell proliferation assay revealed for 
NHEK cultured in Derma Life a normal growth behavior with slow proliferation onset during 0-24 
Figure 24 | MEK-ERK activation is increased by EGF, but not by high Vemurafenib concentrations.
a | HaCaT cells were starved for 48 h and stimulated by either 1 µM Vemurafenib only or in combination with 
2 ng/mL EGF for 1-3 h. MEK, ERK, p38 or Akt-activation were analyzed by Western-Blot. Compared to DMSO 
treatment, Vemurafenib caused a weak and EGF stimulation a strong MEK-ERK phosphorylation after 1 h that 
increased and persisted for more than 3 h. Combined stimulation further increased MEK and ERK phosphorylation 
above the individual level. p38 MAPK and Akt revealed some not reproducible regulation. [n=2] b | Effects of higher 
Vemurafenib concentrations were analyzed by adding 1, 10 or 50 µM Vemurafenib in growth medium to HaCaT 
cells for 1 or 3 h. Compared to 0.5% (v/v) DMSO, 1 µM Vemurafenib led to a higher ERK activation after 1 and 3 h. 
10 µM Vemurafenib led to an increased ERK phosphorylation after 1 h, which was not maintained at 3 h, while 50 
µM caused a reduced response at 1 h and no detectable effect after 3 h. Neither p38 nor Akt phosphorylation were 
reproducibly affected. [n=2]
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h that increased to a hyper-proliferative growth between 24-72 h. Stimulation with either DMSO, 0.1 
and 0.01 µM Vemurafenib did not show an effect on NHEK proliferation as initial cell numbers of 
7,300 cells at 0 h generally increased to approx. 20,000 cells after 24 h, to approx. 60,000 cells after 
48 h and to 90,000 cells after 72 h. In contrast, stimulation with 1 µM or 5 µM Vemurafenib led to a 
dose-dependent and significant inhibition of growth (P<0.05). Treatment with 1 µM revealed a maximal 
cell number of approx. 14,000 cells after 48 h, while 5 µM Vemurafenib prevented growth of NHEK 
(Fig. 26a). HaCaT cells grew generally slower than NHEK by reaching approx. 47,000 cells after 72 
h under control conditions. The lag-phase between 0-24 h was also observed, however, growth kept 
similar kinetics thereafter without showing a hyper-proliferative phase. Moreover, 1 µM or 5 µM did 
Figure 25 | Vemurafenib triggers MEK-ERK hyper-activation in NHEK and HaCaT-RAS cells.
Keratinocytes were stimulated with either 1 µM Vemurafenib or 0.01% (v/v) DMSO in growth medium for 6 h and 
MEK, ERK, p38 or Akt-activation were analyzed by Western-Blot. a, b | Two different normal keratinocytes, NHEK 1 
(a) and NHEK 2 (b), responded to Vemurafenib with increased levels of phosphorylated MEK and ERK after 30 min 
compared to controls, whereas total MEK and ERK protein levels remained unchanged. Other signaling pathways 
were not affected by Vemurafenib. [n=1 per NHEK donor] c, d | HRAS transfected HaCaT-RAS A-5 (c) and HaCaT-
RAS II-4 cells (d) responded to Vemurafenib with ERK phosphorylation after 30 min that was maintained for more 
than 6 h (d). MEK, ERK p38 and Akt phosphorylation increased due to growth medium replacement. [n=2]
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not affect this growth rate (Fig. 26b). HaCaT-
RAS A-5 cells did not show a lag-phase, but 
hyper-proliferative growth already between 0-24 
h, which was continued with similar kinetics. 
Under DMSO treatment, HaCaT-RAS A-5 
cells grew to approx. 111,000 cells within 72 h 
of cultivation. Similarly to HaCaT cells 1 or 5 
µM Vemurafenib did alter the growth kinetics 
showing comparable cell numbers at each time 
point compared to control cells. To ask whether 
low Vemurafenib concentrations lead to an 
increased proliferative response by binding only 
one subunit of a B-Raf/ C-Raf dimer, HaCaT-
RAS A-5 cells were stimulated with 0.01 and 0.1 
µM Vemurafenib. However, none Vemurafenib 
concentration revealed significant changes in 
proliferation (Fig. 26c). Thus, Vemurafenib-
induced hyper-activation did not lead to elevated 
cell proliferation in NHEK, HaCaT and HaCaT-
RAS A-5 cells, but rather prevented growth of 
NHEK at higher concentrations.
5.2.7 Long-term Vemurafenib treatment leads to increased keratinocyte 
differentiation
KAs and cSCCs occurred within a median time of 8 weeks melanoma patients treated with Vemurafenib 
(Anforth et al., 2013). Since short-term treatment with Vemurafenib leads to MEK-ERK hyper-
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Figure 26 | Vemurafenib does not increase 
proliferation in keratinocytes.
Keratinocytes were stimulated using different 
Vemurafenib concentrations or 0.05% (v/v) DMSO. 
After 0-72 h, cells were lysed and incubated with a 
SYBR Green solution that stained DNA. Cell number 
was determined by correlating the fluorescence 
measurement of each well to a standard plate with 
defined cell counts. a | NHEK in Derma Life showed 
a normal growth behavior with slow proliferation 
during 0-24 h and hyper-proliferative growth between 
24-72 h. Stimulation with either DMSO, 0.01 and 0.1 
µM Vemurafenib did not show an effect on growth. 
Stimulation with 1 µM or 5 µM Vemurafenib led to a 
dose-dependent and significant inhibition of growth. 
[n=2] b | HaCaT cells grew slower than NHEK and did 
not show a hyper-proliferative phase. 1 µM or 5 µM 
did not affect the growth. [n=2] c | HaCaT-RAS A-5 
cells demonstrated hyper-proliferation directly after 
seeding. Compared to DMSO treatment, 0.01, 0.1, 1 or 
5 µM Vemurafenib did alter the growth kinetics. [n=2, 
mean ± SD, Two-way ANOVA + Bonferroni posttest]
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activation, but did not increase proliferation of keratinocytes, I asked whether similar as in vivo a 
continuous stimulation is required cause downstream effects. Therefore, HaCaT/ HaCaT-RAS A-5 cells 
were cultivated in growth medium and growth medium supplemented with 0.05% (v/v) DMSO, 1 µM 
or 5 µM Vemurafenib for 9 or 5 weeks, respectively, and cell numbers were monitored. As cells reached 
confluency under control conditions after 7 days, all conditions were split every week and 0.5x 106 cells 
were routinely reseeded per 10 cm culture dish and condition.
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Figure 27 | Continuous Vemurafenib stimulation increases differentiation rather than proliferation.
HaCaT or HaCaT-RAS A-5 cells were cultivated in growth medium supplemented with 0.05% (v/v) DMSO, 1 µM or 
5 µM Vemurafenib for either 9 or 5 weeks. As cells reached confluency under control conditions every 7 days, cells 
were trypsinized and 0.5x 106 cells were reseeded per 10 cm culture dish and condition. a, b | After 7 weeks, light 
microscopic evaluation of HaCaT cells revealed that 5 µM Vemurafenib leads to earlier and increased differentiation 
compared to DMSO treated cells (a). This was also reflected by the cell numbers as control, DMSO and 1 µM 
stimulated cells were comparable, while 5 µM Vemurafenib decreased the cell numbers (b). [n=1] c, d | After 5 
weeks, light microscopic evaluation of HaCaT-RAS A-5 revealed smaller differences in differentiation between 
DMSO and Vemurafenib treated cells compared to HaCaT cells (c). The cell numbers were comparable among all 
cultivation conditions (d). [n=1]
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A light microscopic evaluation of 7 weeks continuously stimulated HaCaT cells revealed that 5 µM 
Vemurafenib leads to earlier and increased differentiation compared to DMSO treated cells (Fig. 27a). 
Interestingly, this was also reflected in the cell numbers obtained after the weekly split of the HaCaT 
cells. Control, DMSO and 1 µM Vemurafenib stimulated cells revealed similar numbers of 6.8x 106 cells 
per 10 cm dish and week, thus, demonstrating a similar proliferation rate. In contrast, 5 µM Vemurafenib 
reduced the cell number to 3.5x 106 cells per 10 cm dish (Fig. 27b), arguing that Vemurafenib triggers 
differentiation in combination with a reduced proliferation in HaCaT cells. To determine whether 
Vemurafenib also affects differentiation of HaCaT-RAS A-5, these cells were cultivated for 5 weeks in 
growth medium and in growth medium containing 0.05% (v/v) DMSO, 1 µM or 5 µM Vemurafenib. 
A morphological analysis by light microscopy revealed smaller differences in differentiation between 
DMSO and Vemurafenib treated HaCaT-RAS A-5 cells compared to HaCaT cells. However, a tendency 
towards accelerated differentiation through Vemurafenib was generally observed (Fig. 27c). Throughout 
the different conditions, a mean cell number of 7.5x 106 per 10 cm dish was determined after each week 
(Fig. 27d), showing that HaCaT-RAS A-5 proliferation was not affected by Vemurafenib at all.
Taken together, Vemurafenib long-term stimulation of HaCaT cells did not cause increased proliferation, 
but rather led to an accelerated differentiation. In contrast, HaCaT-RAS A-5 cell numbers did not change 
by any treatment, which was also reflected in a weaker acceleration of differentiation. Importantly, cSCCs 
induced by Vemurafenib in melanoma cells were also described to be well-differentiated (Anforth et al., 
2013; Anforth et al., 2015), which may be resembled by accelerated differentiation of HaCaT cells.
5.2.8 Vemurafenib caused genetic selection of HaCaT cells
As cSCCs are observed in Vemurafenib treated patients within weeks, prolonged exposure of keratinocytes 
could lead to either genotoxicity or the selection of a subclone that both may facilitate tumorigenesis. 
Accelerated differentiation of HaCaT monolayer cultures was only observed after several weeks of 
continuous exposure to Vemurafenib also implying a selection of a HaCaT cells. To address this question, 
HaCaT cells were continuously treated with 0.05% (v/v) DMSO, 1 µM or 5 µM Vemurafenib and subjected 
to a multiplex fluorescence in situ hybridization (M-FISH) analysis performed in cooperation with Prof. 
Dr. Anna Jauch (Heidelberg University Hospital). Interestingly, the Vemurafenib treated HaCaT cells 
remained genetically very similar to the control (DMSO) cells. Comparison of numerical aberrations 
for the individual chromosomes demonstrated a very similar profile with only a few deviations. When 
specifically comparing the aberration profile of the control cells with that of Vemurafenib treated HaCaT 
cells, it became obvious that Vemurafenib rather favored the selection of a preexisting subpopulations 
instead of novel aberrations. In particular, we detected a Vemurafenib dose-dependent gain of i(1q) 
carrying genes like S100, RASSF5, MAPKAPK2, TP53BP, WNT3A and WNT9A. Second, HaCaT 
cells showed a loss of i(17p) containing genes including TP53, MAP2K4, MAPK7 and RASD1. Third, 
we observed a dose-dependent translocation of (2)t(2;8) leading to a gain of MYC (Fig. 28). Thus, these 
data suggest that a potential mechanism of Vemurafenib in keratinocytes may be selection of preexisting 
subpopulations with a genetic makeup prone for tumorigenicity. Whether Vemurafenib is selecting for 
specific changes has yet to be determined.
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5.2.9 Vemurafenib stimulation of scaOTCs increases HaCaT cell differentiation
In monolayer cultures, I could detect that Vemurafenib robustly hyper-activated MEK-ERK signaling in 
BRAFwild-type keratinocytes reflecting different stages in skin carcinogenesis. However, besides increased 
differentiation and a genetic selection pressure triggered by Vemurafenib, downstream effects explaining 
SCC progression remained elusive. The 3D organization may also be crucial for Vemurafenib induced 
carcinogenesis. Therefore, scaffold-based organotypic cultures (scaOTCs) were employed providing 
optimal growth and differentiation conditions for keratinocytes through the interaction with NHDF 
embedded in a Fibrin matrix. These cultures are stable for several months, allowing a longer follow-up 
of Vemurafenib stimulation compared to colOTCs. After one week submersed pre-cultivation, HaCaT 
cells were seeded on top of the dermal equivalent and grown air-exposed, forming a multi-layered 
stratified epithelium (Fig. 29a). To investigate the consequences under in vivo-like conditions, epithelial 
growth and stratification was allowed for 2 weeks to mimic the situation in patient’s skin before 
treatment with Vemurafenib. As the Vemurafenib half-life in MM patients was assessed to be 51.6 h 
(Funck-Brentano et al., 2015), medium containing Vemurafenib or DMSO was replaced every 2-3 days. 
After 2 weeks (w 2+2), 4 weeks (w 2+4) or 7 weeks (w 2+7) of treatment, cultures were harvested 
(Fig. 29b). A macroscopic evaluation of these cultures showed that control cultures (Fig. 29c, d) were 
comparable to DMSO cultures after 2+4 weeks (Fig. 29e, f), implying that DMSO does not influence 
growth and differentiation of keratinocytes. In contrast, scaOTCs treatment with 1 µM (Fig. 29g, h) or 
5 µM Vemurafenib (Fig. 29i, j) implied increased differentiation, but caused a dose-dependent loss in 
vitality of HaCaT cells.
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Figure 28 | Vemurafenib mediates genetic selection of HaCaT cells.
HaCaT cells were continuously treated with 0.05% (v/v) DMSO, 1 µM or 5 µM Vemurafenib for 5 weeks and 
subjected to a multiplex fluorescence in situ hybridization (M-FISH) analysis. Vemurafenib treated HaCaT cells 
remained genetically similar to the control, although Vemurafenib favored the selection of a preexisting subpopulation 
showing gain of i(1q), loss of i(17p) and dose-dependent translocation of (2)t(2;8) leading to a gain of MYC. [n=1]
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Histological analysis of the scaOTCs demonstrated that HaCaT cells formed a multilayered and rather 
disorganized epithelium revealing parakeratotic stratification from 2+2 to 2+4 weeks under control 
conditions (Fig. 30a, e). After 2+7 weeks, 2 viable basal cell layers remained with numerous cornfield 
layers on top (Fig. 30i). 0.05% (v/v) DMSO did not affect growth and morphology of keratinocytes under 
these 3D conditions, showing that DMSO treated cultures could serve as proper control for Vemurafenib 
cultures (Fig. 30b, f, j). Treatment with 1 µM Vemurafenib accelerated terminal differentiation of HaCaT 
cells as early as after 2 weeks compared to DMSO or control cultures (Fig. 30c). This effect was also 
observed at later harvest points (2+4, 2+7 weeks/ Fig. 30g, k) and comparable when treating the cultures 
for 2+2 or 2+4 weeks with 5 µM Vemurafenib (Fig. 30d, h). Viable basal cells could be observed under 
each condition even after 2+7 weeks of cultivation. Importantly, treatment for 2+7 weeks with 5 µM 
Vemurafenib caused an early invasion phenotype (Fig. 30l). Taken together, this first study confirmed 
in an in vivo-like environment the absence of toxic effects, but accelerated differentiation triggered by 
Vemurafenib in HaCaT cells. In addition, Vemurafenib may favor invasive growth of HaCaT cells, 
which required further investigations.
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Figure 29 | Stimulation of HaCaT scaOTCs with Vemurafenib.
a, b | scaOTCs consisted of a Cellulose scaffold and a Fibrin matrix with embedded NHDF, which formed the dermal 
equivalent. After 1 week submersed pre-cultivation of NHDF, HaCaT cells were seeded and grown air-exposed. 
Epithelial growth and stratification was allowed for 2 weeks to mimic the in vivo situation before treatment with 
0.05% (v/v) DMSO, 1 µM or 5 µM Vemurafenib for another 2, 4 or 7 weeks. c-j | A macroscopic evaluation after 2+4 
weeks showed that controls (c, d) were comparable to DMSO cultures (e, f). scaOTCs treated with 1 µM (g, h) or 5 
µM Vemurafenib (i, j) revealed increased differentiation and a dose-dependent loss in vitality of HaCaT cells. [n=2]
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5.2.10 Vemurafenib stimulation of fdmOTCs
Since especially keratinocyte invasion is highly dependent on its environment and scaOTCs used in the 
first 3D experiments do not provide an ECM composition and height perfectly suited for invasion studies, 
the fibroblast-derived matrix-based organotypic cultures (fdmOTCs) were employed for subsequent 
experiments. This model makes use of a ECM secreted by NHDF that additionally shows increased 
vertical space to monitor invasive behavior of keratinocytes (Berning et al., 2015) (Fig. 31a). In order 
to generate fdmOTCs, NHDF were cultivated submersed for 4 weeks in FDM medium to generate the 
fibroblast-derived matrix. Afterwards, keratinocytes displaying different stages in skin carcinogenesis 
were also grown air-exposed on top for 2 weeks to resemble the pre-treatment situation in patients. 
Thereafter, stimulation with 1 µM, 5 µM Vemurafenib or 0.05% (v/v) DMSO was performed for 1 (2+1 
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Figure 30 | Vemurafenib accelerates terminal differentiation of HaCaT scaOTCs.
scaOTCs consisted of a Cellulose scaffold and a Fibrin matrix with embedded NHDF, which formed the dermal 
equivalent. HaCaT cells were seeded on top and grown air-exposed. Epithelial growth and stratification was allowed 
for 2 weeks to mimic the in vivo situation before treatment with 0.05% (v/v) DMSO, 1 µM or 5 µM Vemurafenib. 
FFPE sections were stained with haematoxylin/ eosin to analyze the morphology. a, e, i | After 2+2 to 2+4 weeks, 
control cultures revealed a multilayered and disorganized epithelium with parakeratotic stratification (a, e). After 2+7 
weeks, two viable basal cell layers remained with numerous cornfield layers (i). b, f, j | DMSO did not affect growth 
and morphology of HaCaT cells. c, g, k | Treatment with 1 µM Vemurafenib accelerated terminal differentiation of 
HaCaT cells after at each time point compared to the control. d, h, l | The accelerated differentiation was confirmed 
by 5 µM Vemurafenib (d, h, l). After 2+7 weeks, 5 µM Vemurafenib caused an early invasion phenotype (l). [n=2]
5. Results
73
weeks), 3 (2+3 weeks) and 5 weeks (2+5 weeks), since Vemurafenib effects on scaOTCs were already 
observed after 2 and 4 weeks (Fig. 31b).
5.2.10.1 Vemurafenib stimulates differentiation and invasion of keratinocytes
NHEK fdmOTCs formed an organized but hyperplastic, well-stratified and orthokeratotic epithelium 
after 2+1 weeks of DMSO treatment (Fig. 31c). After 2+3 weeks, the basal cells were still organized 
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Figure 31 | Vemurafenib accelerates terminal differentiation of NHEK fdmOTCs.
a, b | fdmOTCs were prepared by NHDF cultivation for 4 weeks to generate a fibroblast-derived matrix (fdm), 
before keratinocyte seeding. The fdmOTC model makes use of an ECM secreted by NHDF that is more stable and 
shows increased vertical space to monitor invasive behavior (a). Epithelial growth and stratification was allowed for 
2 weeks to mimic the in vivo situation and thereafter, cultures were treated with 0.05% (v/v) DMSO, 1 µM or 5 µM 
Vemurafenib for another 1, 3 or 5 weeks (b). FFPE sections were stained with haematoxylin/ eosin to analyze the 
morphology. c, f, i | After 2+1 weeks, NHEK fdmOTCs revealed an organized, hyperplastic, orthokeratotic, well-
stratified epithelium (c). After 2+3 weeks, basal cells were organized, but the number of layers was reduced together 
with an accumulation of stratum corneum (f), which was more pronounced after 2+5 weeks (i). This demonstrated 
the typical shift from a hyperplastic to a homeostatic epithelium. d, g, j | Treatment with 1 µM Vemurafenib slightly 
increased differentiation. e, h, k | Stimulation with 5 µM Vemurafenib further reduced vital layers and led to an 
accumulation of stratum corneum already after 2+1 weeks (e). [n=2]
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but a reduction in the number of vital layers together with an accumulation of stratum corneum were 
observed. This displayed the typical shift from a hyperplastic to a homeostatic epithelium that is also 
found in wounded normal skin (Fig. 31f). The progression towards a homeostatic epithelium could be 
followed until 2+5 weeks (Fig. 31i). Treatment with 1 µM Vemurafenib did not reveal morphological 
changes of the epithelium compared to control cultures. However, due to the large stratum corneum in 
control cultures, small effects on differentiation could likely not be visualized (Fig. 31d, g, j). Stimulation 
of NHEK with 5 µM Vemurafenib led to a reduction in vital layers and an accelerated accumulation of 
stratum corneum already after 2+1 weeks (Fig. 31e, h, k). A vital epithelium was preserved under all 
conditions, confirming that Vemurafenib did not hinter long-term regeneration of NHEK (Fig. 31i, j, k).
HaCaT fdmOTCs showed a multi-layered but little cornified and parakeratotic epithelium after 2+1 
weeks (Fig. 32a). Differentiation improved by 2+3 weeks (Fig. 32d), however, long-term regeneration 
was hampered by terminal differentiation of the cultures. After 2+5 weeks, barely a vital HaCaT cell 
could be observed below the differentiated layers (Fig. 32g). Treatment with 1 µM Vemurafenib showed 
a similar morphology compared to DMSO treated cultures after 2+1 weeks (Fig. 32b). However, after 
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Figure 32 | Vemurafenib accelerates terminal differentiation of HaCaT fdmOTCs.
fdmOTCs were prepared by NHDF cultivation for 4 weeks to generate a fibroblast-derived matrix (fdm), before 
HaCaT cell seeding. Epithelial growth and stratification was allowed for 2 weeks to mimic the in vivo situation 
and thereafter, cultures were treated with 0.05% (v/v) DMSO, 1 µM or 5 µM Vemurafenib for another 1, 3 or 5 
weeks. FFPE sections were stained with haematoxylin/ eosin to analyze the morphology. a, d, g | After 2+1 weeks, 
HaCaT fdmOTCs cultures showed a multi-layered, parakeratotic and slightly cornified epithelium (a). Differentiation 
improved by 2+3 weeks (d), which also prevented long-term regeneration of the cultures after 2+5 weeks (g). 
b, e, h | Treatment with 1 µM Vemurafenib showed no change after 2+1 weeks (b), but led to a reduction in vital 
layers and increased HaCaT cell differentiation after 2+3 weeks (e). Long-term regeneration was prevented as 
only differentiated layers remained after 2+5 weeks (h). c, f, i | 5 µM Vemurafenib caused elevated differentiation 
after 2+1 weeks (c), which further increased at cost of vital layers by 2+3 weeks (f). After 2+5 weeks, terminal 
differentiation of all vital HaCaT cell layers was observed (i). [n=2]
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2+3 weeks of treatment, Vemurafenib caused a reduction in vital layers together with an increase in 
HaCaT cell differentiation (Fig. 32e). Similar to DMSO treated cultures, long-term regeneration was 
prevented as only differentiated layers remained after 2+5 weeks (Fig. 32h). 5 µM Vemurafenib already 
mediated increased differentiation after 2+1 weeks (Fig. 32c), which subsequently increased at cost of 
vital layers by 2+3 weeks (Fig. 32f). After 2+5 weeks, long-term regeneration was prevented by terminal 
differentiation of all vital HaCaT cell layers (Fig. 32i).
HaCaT-RAS A-5 fdmOTCs established a multilayered hyper-proliferative and orthokeratotic epithelium 
after 2+1 weeks with more cell layers as observed in NHEK and HaCaT fdmOTCs (Fig. 33a). After 
2+3 weeks, the epithelium showed less organization and increased differentiation with a discrete 
stratum corneum (Fig. 33d). However, after 2+5 weeks, the epithelium showed parakeratosis and 
became atrophic leaving only some vital cells within the basal layers (Fig. 33g). Treatment with 1 
µM Vemurafenib already caused accelerated differentiation revealing a orthokeratotic epithelium 
after 2+1 weeks (Fig. 33b). After 2+3 weeks, accelerated differentiation was still observed leading 
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Figure 33 | Vemurafenib causes differentiation and invasion of HaCaT-RAS A-5 fdmOTCs.
fdmOTCs were prepared by NHDF cultivation for 4 weeks to generate a fibroblast-derived matrix (fdm), before 
HaCaT-RAS A-5 cell seeding. Epithelial growth and stratification was allowed for 2 weeks to mimic the in vivo 
situation and thereafter, cultures were treated with 0.05% (v/v) DMSO, 1 µM or 5 µM Vemurafenib for another 1, 
3 or 5 weeks. FFPE sections were stained with haematoxylin/ eosin to analyze the morphology. a, d, g | After 2+1 
weeks, HaCaT-RAS A-5 fdmOTCs established a multilayered hyper-proliferative and orthokeratotic epithelium (a). 
After 2+3 weeks, the epithelium showed less organization and increased differentiation with a discrete stratum 
corneum (d). At 2+5 weeks, the epithelium showed parakeratosis and became atrophic (g). b, e, h | Treatment 
with 1 µM Vemurafenib caused accelerated differentiation after 2+1 weeks (b), which was still observed after 2+3 
weeks, although a shift orthokeratosis to parakeratosis was observed (e). A highly cornified but vital epithelium 
was detected after 2+5 weeks (h). 1 µM Vemurafenib also caused HaCaT-RAS A-5 cell invasion into the dermal 
equivalent. After 2+1 weeks, early invasive buds were observed (b) leading to complete invasive growth after 2+3 
weeks (e). c, f, i | Treatment with 5 µM Vemurafenib led to similar effects, including accelerated differentiation and, 
a shift from orthokeratosis to parakeratosis (c, f, i). 5 µM Vemurafenib also caused HaCaT-RAS A-5 cell invasion 
into the underlying dermal equivalent (f, i). [n=2]
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to large amounts of terminally differentiated layers, however, revealing a shift from orthokeratosis 
to parakeratosis (Fig. 33e). Especially after 2+5 weeks, a highly cornified epithelium and still vital 
parakeratotic HaCaT-RAS A-5 epithelium was observed (Fig. 33h). Treatment with 5 µM Vemurafenib 
led to similar effects, including accelerated differentiation, a shift from orthokeratosis to parakeratosis 
as well as the generation of a highly differentiated, but vital epithelium after 2+5 weeks (Fig. 33c, f, i). 
Besides that, both, 1 µM and 5 µM Vemurafenib treatment caused HaCaT-RAS A-5 cell invasion into the 
underlying dermal equivalent. After 2+1 weeks of treatment, early invasive buds were observed leading 
to complete invasive growth after 2+3 weeks. Interestingly, signs of atrophy were observed after 2+5 
weeks at invasion sites (Fig. 33e, h, f, i).
Taken together, treatment with Vemurafenib led to an accelerated differentiation accompanied by a 
reduction of vital layers in all analyzed keratinocytes. Importantly, Vemurafenib stimulation of benign-
tumorigenic HaCaT-RAS A-5 cells caused invasive growth together with an improved viability after 
2+5 weeks.
5.2.10.2 Vemurafenib mediates ERK hyper-activation in fdmOTCs
To correlate the observed accelerated differentiation, but especially the invasion of HaCaT-RAS A-5 
cells to a potential Vemurafenib induced MEK-ERK hyper-activation also OTCs, sections of HaCaT and 
HaCaT-RAS A-5 fdmOTCs were analyzed for ERK phosphorylation by immunohistochemistry (IHC). 
DMSO treated HaCaT and HaCaT-RAS A-5 cultures showed some cytoplasmic ERK phosphorylation 
(brown) with a tendency for basal keratinocytes after 2+3 weeks (Fig. 34a, c). At the same time, 
Vemurafenib treatment (5 µM) strongly increased ERK phosphorylation in all vital layers of the HaCaT 
epithelium and demonstrated activation in the underlying NHDF (Fig. 34b). Moreover, Vemurafenib also 
induced ERK phosphorylation throughout the HaCaT-RAS A-5 epithelium (Fig. 34d). This showed that 
Vemurafenib leads to MEK-ERK hyper-activation in BRAFwild-type keratinocytes as well as in HaCaT and 
HaCaT-RAS A-5 fdmOTCs, which likely mediated the observed effects in differentiation and invasion.
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Figure 34 | Vemurafenib 
triggers MEK-ERK hyper-
activation in fdmOTCs.
fdmOTCs were prepared by NHDF 
cultivation for 4 weeks to generate 
a fibroblast-derived matrix (fdm), 
before HaCaT or HaCaT-RAS A-5 
cell seeding. Epithelial growth and 
stratification was allowed for 2 
weeks to mimic the in vivo situation 
and thereafter, cultures were 
treated with 0.05% (v/v) DMSO 
or 5 µM Vemurafenib for another 
3 weeks. Ras-Raf-MEK-ERK 
pathway activity was analyzed by 
performing immunohistochemistry 
(IHC) for ERK phosphorylation 
on FFPE fdmOTCs. a, b | DMSO 
treated HaCaT cultures showed some cytoplasmic ERK phosphorylation (brown) after 2+3 weeks (a). Vemurafenib 
strongly increased ERK phosphorylation, thus pathway activation, in all vital layers and demonstrated activation in 
the underlying NHDF (b). c, d | DMSO treated HaCaT-RAS A-5 cultures showed ERK phosphorylation (brown) in 
the basal cell layer (c). Vemurafenib induced ERK phosphorylation throughout the epithelium (d). [n=2]
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5.2.10.3 Differentiation but not proliferation is accelerated by Vemurafenib 
fdmOTCs
Although MEK-ERK activation is commonly coupled to growth (Dhillon et al., 2007), proliferation 
was not detected in monolayer cultures. As 3D organization and interaction with NHDF may be crucial 
mediators, proliferation upon Vemurafenib treatment was assessed in 2+3 week-old fdmOTCs. Therefore, 
NHEK as well as TP53 and HRAS-mutant HaCaT-RAS A-5 cultures as two opposing cell types were 
stained by immunofluorescence for the proliferation marker Ki67. Staining for the BM marker Collagen 
VII revealed the epidermal-mesenchymal border and allowed calculating a proliferation index that 
correlates the number of proliferating cells to the corresponding BM length. As result, NHEK cultures 
showed some basal proliferation without major differences in Ki67 staining between DMSO (Fig. 35a), 
1 µM (Fig. 35b) or 5 µM Vemurafenib treated cultures (Fig. 35c). Quantification showed a proliferation 
index of approx. 4.1 irrespective of the treatment condition (Fig. 35g). HaCaT-RAS A-5 fdmOTCs 
generally showed suprabasal Ki67-positive cells (Fig. 35d), which may account to the slightly increased 
proliferation index of 5.6 compared to NHEK cultures (Fig. 35g). Upon Vemurafenib stimulation (1 
µM or 5 µM), HaCaT-RAS A-5 cells revealed accumulations of proliferative cells at invasion sites 
demonstrating that proliferation is not homogeneously distributed over the entire culture (Fig. 35e, 
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Figure 35 | Keratinocyte proliferation is not induced by Vemurafenib in fdmOTCs.
fdmOTCs were prepared by NHDF cultivation for 4 weeks to generate a fibroblast-derived matrix (fdm), before 
keratinocyte seeding. Epithelial growth and stratification was allowed for 2 weeks to mimic the in vivo situation 
and thereafter, cultures were treated with 0.05% (v/v) DMSO, 1 µM or 5 µM Vemurafenib for another 3 weeks. To 
assess proliferation, cryo-conserved and fixed sections of NHEK 2 and HaCaT-RAS A-5 cultures were stained for 
the proliferation marker Ki67 and the BM component Collagen VII by immunofluorescence. a-f | NHEK cultures 
showed some basal proliferation without major differences in Ki67 staining between DMSO (a), 1 µM (b) or 5 µM 
Vemurafenib treated cultures (c). HaCaT-RAS A-5 fdmOTCs generally showed suprabasal Ki67-positive cells (d). 
Vemurafenib stimulation led to the accumulation of proliferative cells at invasion sites (e, f). g | Co-staining with 
Collagen VII allowed calculating a proliferation index by correlating the number of proliferating cells to the BM 
length. Neither HaCaT nor HaCaT-RAS A-5 cells revealed significant differences in the proliferative index upon 
Vemurafenib. [n=2, mean ± SEM, One-way ANOVA + Dunnett’s Multiple Comparison Test]
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f). Therefore, 1 µM and 5 µM Vemurafenib increased the proliferation index to either 36.3 or 17.7. 
However, none of these results revealed significant differences in proliferation (Fig. 35g).
In order to confirm the increased differentiation upon Vemurafenib as observed in histological staining, 
2+3 week-old fdmOTC cryo sections were analyzed for differentiation markers by immunofluorescence. 
Staining was performed for the early differentiation marker Keratin-10, expressed in the stratum 
spinosum up to the stratum corneum, as well as for the late differentiation marker Filaggrin, expressed 
from stratum granulosum to stratum corneum in human skin. NHEK control fdmOTCs revealed 
Keratin-10 in all epithelial layers besides the stratum basale as expected for normal cells (Fig. 36a). 
Treatment with 1 µM or 5 µM Vemurafenib even increased the number of the differentiated layers (Fig. 
36b, c). HaCaT cells showed Keratin-10 staining only in the uppermost epidermal layers confirming a 
low differentiation profile, as described by histology (Fig. 36d). 1 µM and 5 µM Vemurafenib increased 
tissue organization and the number of Keratin-10 positive cell layers, thus differentiation (Fig. 36e, 
f). Compared to HaCaT cultures, HaCaT-RAS A-5 control fdmOTCs showed increased differentiation 
(Fig. 36g). Again, Vemurafenib seemed to improve tissue organization revealing a more organized 
suprabasal distribution of Keratin-10 positive cell layers, while invasive buds were not stained. Although 
Vemurafenib treated HaCaT-RAS A-5 cultures showed accelerated differentiation in the histological 
sections, this effect could not be confirmed by Keratin-10 immunofluorescence. Control and treated 
cultures showed a similar Keratin-10 expression. However, the Keratin-10 positive layers may be more 
compact in Vemurafenib cultures compared to the control (Fig. 36h, i).
Furthermore, the late differentiation maker Filaggrin was detected in the stratum granulosum and 
stratum corneum of control NHEK fdmOTCs, as expected for normal cells (Fig. 36j). Treatment 
with Vemurafenib led to an increased terminal differentiation as determined by the higher number 
of Filaggrin positive layers (Fig. 36k, l). HaCaT fdmOTCs generally showed very low levels of late 
differentiation compared to NHEK (Fig. 36m). Vemurafenib treatment led, if at all, to a minor increase in 
Filaggrin levels compared to DMSO control cultures (Fig. 36n, o). In contrast, HaCaT-RAS A-5 control 
cultures demonstrated higher Filaggrin levels compared to HaCaT fdmOTCs (Fig. 36p). Vemurafenib 
slightly increased suprabasal Filaggrin at 1 µM, which was further increased showing locally elevated 
concentrations when stimulated with 5 µM. Invasion sites remained negative also for Filaggrin (Fig. 
36q, r). In addition to immunofluorescence staining, NHEK and HaCaT-RAS A-5 fdmOTC epithelia 
were also separated from the dermal equivalents by Dispase incubation to perform RNA isolation and 
qRT-PCR analysis of FLG mRNA expression. In NHEK fdmOTCs, 5 µM Vemurafenib treatment caused 
a 2.4-fold increased FLG expression compared to DMSO cultures after 2+1 weeks. Thereafter, FLG 
expression levels decreased to 0.6-fold after 2+3 weeks. A similar FLG upregulation was also detected 
in HaCaT-RAS A-5 fdmOTCs, however, showing 0.7-fold regulation after 2+1 weeks, followed by a 
delayed upregulation of 2.6-fold after 2+3 weeks (Fig. 36s). Together, this confirmed that Vemurafenib 
directly accelerated differentiation also in fdmOTCs, while keratinocyte proliferation was not altered.
5.2.10.4 Gelatinolytic activity is increased by Vemurafenib
The BM was analyzed in fdmOTCs by immunofluorescence staining for the BM component Collagen IV 
in order to investigate the mechanism of HaCaT-RAS A-5 invasion. In NHEK fdmOTCs, Collagen IV 
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was detected at the BM as well as throughout the dermal ECM after 2+3 weeks (Fig. 36j). Interestingly, 
Collagen IV levels remained constant by stimulation with 1 µM (Fig. 36k), but showed a slight decrease 
by 5 µM Vemurafenib (Fig. 36l). HaCaT fdmOTCs generally showed lower Collagen IV levels especially 
directly under the epithelium (Fig. 36m). 1 µM and 5 µM Vemurafenib treatment caused a reduction in 
Collagen IV levels compared to DMSO control cultures (Fig. 36n, o). Furthermore, HaCaT-RAS A-5 
control cultures revealed a strong Collagen IV signal across the dermal equivalent with an accumulation 
at the BM (Fig. 36p), which was reduced by Vemurafenib treatment (Fig. 36q, r).
Invasion is commonly associated with MMPs. To determine whether MMP-activity is involved in the 
observed reduction of Collagen IV in Vemurafenib treated fdmOTCs as well as the invasive phenotype 
of HaCaT-RAS A-5 cultures, a Gelatinase assay was performed on cryo-sections of invasively growing 
HaCaT-RAS A-5 fdmOTC. Control HaCaT-RAS A-5 fdmOTCs demonstrated a low fluorescence signal 
(green) after 2+5 weeks, arguing for an overall weak Gelatinase cleavage and thus, for a low MMP-
Figure 36 | Keratinocyte differentiation is accelerated by Vemurafenib in fdmOTCs.
fdmOTCs were prepared by NHDF cultivation for 4 weeks to generate a fibroblast-derived matrix (fdm), before 
NHEK, HaCaT or HaCaT-RAS A-5 cell seeding. Epithelial growth and stratification was allowed for 2 weeks to 
mimic the in vivo situation and thereafter, cultures were treated with 0.05% (v/v) DMSO, 1 µM or 5 µM Vemurafenib 
for another 1 or 3 weeks. a-i | To analyze keratinocyte differentiation, cryo-sections of 2+3 week-old fdmOTC were 
fixed and analyzed for differentiation markers by immunofluorescence. In NHEK the early differentiation marker 
Keratin-10 (green) was detected in all epithelial layers besides the stratum basale, as in normal skin (a). Treatment 
with 1 µM or 5 µM Vemurafenib increased the number of the differentiated layers (b, c). HaCaT cells showed 
Keratin-10 staining only in the uppermost epidermal layers (d). 1 µM and 5 µM Vemurafenib increased tissue 
organization and the number of Keratin-10 cell layers (e, f). HaCaT-RAS A-5 control fdmOTCs showed increased 
differentiation (g). Vemurafenib improved Keratin-10 organization likely leading to differentiated layers with increased 
density (h, i). [n=2] j-r | The late differentiation maker Filaggrin (green) was detected in the stratum granulosum and 
corneum of control NHEK fdmOTCs (j), while Vemurafenib increased the number of Filaggrin positive layers (k, l). 
HaCaT fdmOTCs generally showed low terminal differentiation (m). Vemurafenib treatment led to a minor increase 
in Filaggrin (n, o). HaCaT-RAS A-5 control cultures demonstrated higher Filaggrin levels as HaCaT fdmOTCs (p) 
and Vemurafenib slightly increased suprabasal Filaggrin in a dose-dependent manner (q, r). The BM component 
Collagen IV (red) was detected in NHEK fdmOTCs at the BM as well as throughout the dermal ECM (j), remained 
constant by 1 µM (k), but slightly decreased by 5 µM Vemurafenib (l). HaCaT fdmOTCs revealed low Collagen IV 
levels (m). 1 µM and 5 µM Vemurafenib treatment caused a reduction (n, o). HaCaT-RAS A-5 cultures revealed 
a strong Collagen IV signal with an accumulation at the BM (p), which was reduction by Vemurafenib treatment 
(q, r). [n=2] s | NHEK and HaCaT-RAS A-5 fdmOTC epithelia were separated from the dermal equivalents by 
Dispase incubation and subjected to RNA isolation and qRT-PCR analysis. In NHEK fdmOTCs, 5 µM Vemurafenib 
increased FLG expression at 2+1 weeks, whereas levels declined thereafter. A delayed FLG upregulation was 
detected in HaCaT-RAS A-5 fdmOTCs showing a downregulation after 2+1 weeks followed by an upregulation after 
2+3 weeks. [n=1]
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Figure 37 | Gelatinolytic activity 
is increased by Vemurafenib 
in HaCaT-RAS A-5 fdmOTCs.
fdmOTCs were prepared by NHDF 
cultivation for 4 weeks to generate 
a fibroblast-derived matrix (fdm), 
before HaCaT-RAS A-5 cell seeding. 
Epithelial growth and stratification 
was allowed for 2 weeks to mimic 
the in vivo situation and thereafter, 
cultures were treated with 0.05% 
(v/v) DMSO or 5 µM Vemurafenib 
for another 5 weeks. An in situ 
zymography was performed on 
unfixed cryo-section to investigate 
the MMP-activity. Control cultures 
demonstrated a low fluorescence 
signal (green), implying a low MMP-
activity (a, b). Vemurafenib caused a strong increase in fluorescence signal especially within the invasive areas 
(c, d). [n=2]
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activity (Fig. 37a, b). In contrast, Vemurafenib caused a strong increase in fluorescence signal especially 
within the invasive areas of the HaCaT-RAS A-5 epithelium (Fig. 37c, d). Thus, an elevated MMP-
activity upon Vemurafenib correlated with Collagen IV degradation and invasion of HaCaT-RAS A-5 
cells.
5.2.11 MEK-ERK hyper-activation is mediated by Vemurafenib in NHDF
To investigate whether Vemurafenib triggered the release of paracrine factors by NHDF leading to 
invasive growth of HaCaT-RAS A-5 cells, we first asked if Vemurafenib indeed hyper-activated MEK-
ERK signaling also in NHDF monolayer cultures of two individual donors. Western-Blot analysis 
revealed increased phosphorylation of MEK and ERK after 30 min Vemurafenib stimulation (1 µM) that 
reached a maximal induction after 1-3 h and was subsequently declining. NHDF stimulated with DMSO 
(0.01%) also showed some increased MEK and ERK phosphorylation, which could be correlated to 
the addition of fresh growth medium at the time of stimulation. While Akt signaling was not altered, 
a reproducible p38 phosphorylation was monitored after 30 min of Vemurafenib stimulation. Since 
MEK, ERK and p38 regulations were similar in both NHDF strains, we excluded donor-specific effects 
(Fig. 38a, b). Thus, this data demonstrated that Vemurafenib-induced MEK-ERK hyper-activation is not 
only triggered in BRAFwild-type keratinocytes, but also in NHDF. As both, keratinocytes and NHDF were 
activated by Vemurafenib, the observed HaCaT-RAS A-5 invasion could indeed result either from direct 
keratinocyte stimulation or secreted factors derived from activated NHDF.
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Isolation: 08.02.1996Isolation: 04.04.2007-IFigure 38 | Vemurafenib triggers MEK-ERK hyper-activation also in NHDF.
NHDF monolayer cultures were stimulated with either 1 µM Vemurafenib or 0.01% (v/v) DMSO in growth medium 
for 6 h and MEK, ERK, p38 or Akt-activation were analyzed by Western-Blot. Stimulation of two different normal 
human dermal fibroblasts, NHEK 1 (a) and NHEK 2 (b), with DMSO showed some increased MEK and ERK 
phosphorylation, which could be accounted to the addition of fresh growth medium. Vemurafenib mediated MEK 
and ERK hyper-phosphorylation after 30 min, which reached a maximum after 1-3 h and subsequently declined. 
While Akt signaling was not altered, a reproducible p38 phosphorylation was monitored after 30 min of Vemurafenib 
stimulation. [n=1 per NHDF donor]
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5.2.12 Vemurafenib activation of NHDF and invasion in fdmOTCs
To address the role of Vemurafenib-activated NHDF on HaCaT-RAS A-5 invasion, NHDF were 
pre-treated with Vemurafenib for 3 weeks during fdm generation. The treatment was discontinued 
immediately before seeding of HaCaT-RAS A-5 cells, allowing the accumulation of potential fibroblast-
derived factors that may act on the keratinocytes (Fig. 39a). After another 3 weeks, cultures pre-treated 
with 0.05% (v/v) DMSO showed several undifferentiated cell layers and a BM without signs of invasion 
(Fig. 39b). Pre-treatment with 1 µM or 5 µM Vemurafenib did not strongly affect differentiation, as 
expected, but caused a disorganization of the BM in a dose-dependent manner (Fig. 39c, d). This early 
invasive phenotype may point either to a role of Vemurafenib activated NHDF or alternatively to 
Vemurafenib which was retained in the ECM and directly acted on HaCaT-RAS A-5 cells.
In order to determine genes, which are expressed in response to Vemurafenib, NHDF monolayer 
cultures were stimulated with 1 µM or 5 µM Vemurafenib for 8 h and 24 h. Subsequently, RNA was 
subjected to expression analysis for known growth factors (TGFA, TGFB1, TGFB3, IL1A, IL1B, HGF, 
CSF2, FGF7, FGF10), cytokines of the fibroblast secretome (IL6, IL8, CCL2, CXCL10, CXCL12) 
and matrix remodeling factors (MMP1, MMP3, MMP9, MMP14). The activation of Wnt/Beta-catenin 
signaling (AXIN2) or the p21 pathway (CDKN1A) as well as expression of the myofibroblast marker 
(alphaSMA) were also determined. Normalization was performed using GAPDH as house-keeping gene 
and fold-changes were expressed by comparing 1 µM 
or 5 µM Vemurafenib treatment of NHDF to 0.05% 
(v/v) DMSO stimulation. To our surprise, none of the 
genes showed regulation beyond 2-fold after 8 and 24 
h (Fig. 40a). As the tissue organization may play a role 
in gene regulation also in respect to treatment with 
Vemurafenib, NHDF was allowed to form a dermal 
equivalent (fdm). After an initial phase of 1 week, 
NHDF were constantly stimulated with Vemurafenib 
for another 3 weeks in FDM medium. Compared to 
monolayer cultures, a few distinct gene regulations 
were detected including a 3.7-fold downregulation 
of TGFA by 5 µM Vemurafenib as well as a 2.1-
fold upregulation of CSF2 by 1 µM Vemurafenib. 
However, in agreement with 2D cultures, I did not 
observe major gene regulations also in 3D (Fig. 40b). 
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Figure 39 | fdmOTC pre-treatment with Vemurafenib 
leads to BM disorganization.
a | fdmOTCs were prepared by NHDF cultivation for 4 
weeks to generate a fibroblast-derived matrix (fdm). During 
the last 3 weeks of fdm generation, NHDF were treated 
with 0.05% (v/v) DMSO, 1 µM or 5 µM Vemurafenib, before 
HaCaT-RAS A-5 cell seeding. Cultivation with growth 
medium only was performed for another 3 weeks. b-d | 
FFPE and haematoxylin/ eosin stained sections of control 
cultures showed several undifferentiated cell layers and a 
BM without signs of invasion (b). Pre-treatment with 1 µM 
or 5 µM caused BM disorganization in a dose-dependent 
manner (c, d). [n=3]
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Since TGF-alpha acts as growth factor and is routinely added to fdmOTCs after seeding HaCaT cells, 
a TGFA downregulation in NHDF can be excluded as reason for invasive growth. Therefore, only 
CSF2, other faintly regulated or non-investigated factors remained as potential paracrine acting factors 
inducing HaCaT-RAS A-5 invasion, which requires further investigations.
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Figure 40 | Vemurafenib does not regulate gene expression in 2D and 3D cultured NHDF.
NHDF were stimulated with 0.05% (v/v) DMSO, 1 µM or 5 µM Vemurafenib. RNA was subjected to expression 
analysis for known growth factors (TGFA, TGFB1, TGFB3, IL1A, IL1B, HGF, CSF2, FGF7, FGF10), cytokines 
of the fibroblast secretome (IL6, IL8, CCL2, CXCL10, CXCL12) and matrix remodeling factors (MMP1, MMP3, 
MMP9, MMP14). Activation of Wnt/Beta-catenin (AXIN2) or p21 pathways (CDKN1A) and the myofibroblast marker 
(alphaSMA) were also investigated. Normalization was performed using GAPDH as house-keeping gene and fold-
changes were expressed by comparing 1 µM or 5 µM Vemurafenib treatment of NHDF to DMSO stimulation. 
a | NHDF stimulation in monolayer cultures for 8 and 24 h did not show regulation beyond 2-fold. b | NHDF was 
allowed to form a dermal equivalent (fdm) within 4 weeks, which was constantly stimulated during the last 3 weeks 
with Vemurafenib or DMSO in FDM medium. Gene expression analysis showed that Vemurafenib led to TGFA 
downregulation and a minor CSF2 upregulation only. [n=2, mean ± SD]
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5.2.13 Vemurafenib upregulates MMP1 and MMP3 in keratinocytes
While Vemurafenib caused only minor changes in gene regulation of NHDF, a direct gene regulation in 
keratinocytes leading invasive growth of HaCaT-RAS A-5 cells became more likely. Similarly to NHDF, 
NHEK, HaCaT and HaCaT-RAS A-5 cells were stimulated with 1 µM, 5 µM Vemurafenib or DMSO as 
control in monolayer cultures. RNA was subjected to qRT-PCR for a gene regulation analysis of growth 
factors (TGFA, TGFB1, TGFB3, IL1A, IL1B), matrix remodeling factors (MMP1, MMP3, MMP9, 
MMP14) and differentiation-associated genes (KRT10, FLG, IVL). Moreover, activation of Wnt/Beta-
catenin (AXIN2) or the p21 pathway (CDKN1A), EGF receptor expression (EGFR) and EMT (SNAI2) 
were also analyzed. Normalization was performed using GAPDH and fold-changes were expressed by 
comparing 1 µM or 5 µM Vemurafenib treatment of keratinocytes to 0.05% (v/v) DMSO stimulation. 
NHEK upregulated IL1A and IL1B by 2.6 or 2.9-fold, the differentiation marker IVL, expressed in 
late stratum spinosum and stratum granulosum, by 4.7 or 7.7-fold, FLG by 1.4 or 2.2-fold as well 
as slightly KRT10 upon 1 µM or 5 µM Vemurafenib treatment for 24 h, respectively. IVL, FLG and 
KRT10 upregulation further confirmed the direct role of Vemurafenib in keratinocyte differentiation. In 
addition, MMP1 and MMP3 were induced by 1 µM or 5 µM Vemurafenib in a dose-dependent manner 
already after 8 h by either 2.0 or 4.3-fold and 2.6 or 2.9-fold, but even stronger after 24 h of stimulation 
leading to 28 or 62-fold MMP1 and 20 or 51-fold MMP3 upregulation, respectively (Fig. 41a).
Also HaCaT cells showed 2.0-2.2-fold upregulation of IL1A and IL1B by Vemurafenib after 8 and 24 h, 
but in contrast to NHEK no regulation of differentiation genes was detected. Furthermore, 1 µM or 5 µM 
Vemurafenib induced MMP1 in a dose-dependent manner by 3.6 or 6.1-fold (8 h) and 3.9 or 5.5-fold (24 
h), respectively. MMP3 was also induced reaching 3.2 or 6.4-fold (8 h) and 3.6 or 5.0-fold (Fig. 41b). In 
HaCaT-RAS A-5 cells 1 µM or 5 µM Vemurafenib led to a 1.7 or 1.9-fold (8 h) and 2.2 or 2.6-fold (24 
h) induction of TGFA, respectively, which was slightly stronger compared to NHEK and HaCaT cells. 
IL1A was induced by 1.8 or 1.9 (8 h) and 2.3 or 2.5-fold (24 h), while IL1B levels were increased by 
1.7 or 1.6-fold (8 h) and 2.6 or 3.0-fold (24 h). No differentiation genes were regulated in HaCaT-RAS 
A-5 cells. However, MMP1, MMP3 and MMP9 showed a dose-dependent upregulation by 1 µM or 5 
µM Vemurafenib. While MMP9 showed a 1.9 or 2.3-fold regulation only after 24 h, MMP1 was 3.6 or 
5.1-fold (8 h)/ 3.8 or 8.6-fold (24 h) and MMP3 3.1 or 5.2-fold (8 h)/ 1.5 or 2.8-fold (24 h) upregulated, 
respectively (Fig. 41c).
To assess whether Vemurafenib induced gene regulated only temporarily or can be observed over a 
prolonged time, HaCaT monolayer cultures were continuously stimulated for 4 and 8 weeks. After 
another 8 h of the corresponding stimulation, HaCaT cells were subjected to qRT-PCR analysis. After 
8 weeks + 8 h with 1 µM or 5 µM Vemurafenib, IL1A was either 2.4-fold or 1.6-fold upregulated. Also 
MMP1 was 1.8 or 4.6-fold upregulated after 4 weeks, which declined to 1.0 or 2.5-fold regulation 
after 8 weeks. MMP3 was 2.0 or 18.4-fold upregulated after 4 weeks and the levels remained at 2.3 or 
5.3-fold after 8 weeks of stimulation, respectively. In contrast to HaCaT cell short-term stimulation, 
TGFA showed a 2.0-fold upregulation by 1 µM Vemurafenib after 8 weeks. Importantly, levels of 
the differentiation-associated genes were increased by 5 µM Vemurafenib reaching for KRT10 3.4 
or 4.2-fold and for FLG 3.6 or 2.5-fold upregulation after 4 or 8 weeks, respectively. In contrast to 
NHEK monolayer cultures, IVL was not regulated (Fig. 42). Thus, the gene expression data of the 
keratinocytes confirmed for NHEK a direct and early as well as for HaCaT cells a direct but delayed 
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effect of Vemurafenib on keratinocyte differentiation. Furthermore, the induction of MMP1, MMP3 
and MMP9 by Vemurafenib was detected in all analyzed keratinocytes, ranging from normal to benign-
tumorigenic cells. This rendered these matrix remodeling factors as possible trigger for HaCaT-RAS 
A-5 cell invasion. As Vemurafenib induced MEK-ERK hyper-activation in all analyzed keratinocytes, 
the observed gene expression is most likely dependent on this pathway activity.
Figure 41 | Vemurafenib shows distinct gene regulation pattern in keratinocytes.
Keratinocytes were stimulated with 0.05% (v/v) DMSO, 1 µM, 5 µM Vemurafenib in monolayer cultures for 8 and 
24 h. RNA was subjected to qRT-PCR-based gene expression analysis of growth factors (TGFA, TGFB1, TGFB3, 
IL1A, IL1B), matrix remodeling factors (MMP1, MMP3, MMP9, MMP14) and differentiation-associated genes 
(KRT10, FLG, IVL). Activation of Wnt/Beta-catenin (AXIN2) or p21 pathway (CDKN1A), EGF receptor expression 
(EGFR) and EMT (SNAI2) were also investigated. Normalization was performed using GAPDH and fold-changes 
were expressed by comparing 1 µM or 5 µM Vemurafenib to DMSO stimulation. a | NHEK upregulated IL1A, IL1B, 
IVL, FLG and KRT10 mostly after 1 µM or 5 µM Vemurafenib stimulation. In addition, MMP1 and MMP3 were 
highly induced in a dose-dependent manner after 8 h, but even stronger after 24 h. b | HaCaT cells showed some 
upregulation of IL1A, IL1B, but a major induction of MMP1 and MMP3 by Vemurafenib starting after 8 h. c | HaCaT-
RAS A-5 cells revealed induction of TGFA, IL1A and IL1B at lower levels. MMP1, MMP3 and MMP9 showed a 
dose-dependent upregulation by 1 µM or 5 µM Vemurafenib. [n=2, mean ± SD]
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Figure 42 | Vemurafenib induced gene regulation is maintained in HaCaT cells.
HaCaT monolayer cultures were continuously stimulated with 0.05% (v/v) DMSO, 1 µM, 5 µM Vemurafenib for 4 
and 8 weeks. After another 8 h corresponding stimulation, RNA was subjected to qRT-PCR-based gene expression 
analysis of growth factors (TGFA, TGFB1, TGFB3, IL1A, IL1B), matrix remodeling factors (MMP1, MMP3, MMP9, 
MMP14) and differentiation-associated genes (KRT10, FLG, IVL). Activation of Wnt/Beta-catenin (AXIN2) or p21 
pathway (CDKN1A), EGF receptor expression (EGFR) and EMT (SNAI2) were also investigated. As result, IL1A 
and TGFA were slightly elevated by Vemurafenib only after 8 weeks + 8 h. After 4 and 8 weeks, Vemurafenib 
upregulated MMP9 and especially MMP1 + MMP3. Expression of the differentiation-associated genes KRT10 and 
FLG was increased by 5 µM Vemurafenib after 4 or 8 weeks + 8 h. [n=1]
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5.2.14 Cobimetinib prevents MEK-ERK hyper-activation and gene regulation by 
Vemurafenib
In melanoma patients, the resistance development to the B-RafV600E inhibitor Vemurafenib is counteracted 
by additionally administering a MEK inhibitor like Cobimetinib (COBI) (Queirolo et al., 2015). We made 
use of the co-treatment with Cobimetinib in order to block the Vemurafenib induced MEK-ERK hyper-
activation downstream at MEK in order to ask which keratinocyte phenotypes are indeed dependent on 
MEK-ERK activity.
To determine the Cobimetinib concentration that was sufficient to block the Vemurafenib induced 
hyper-activation, but without causing major toxicity, monolayer cultures were treated with different 
Cobimetinib concentrations to analyze effects on MEK and ERK signaling. In particular, HaCaT-RAS 
A-5 cells were stimulation with 0.15% (v/v) DMSO, 1 µM or 5 µM Vemurafenib in combination with 
0, 0.01, 0.1 or 1 µM Cobimetinib for 4 h. Western-Blot analysis revealed ERK phosphorylation by 
treatment with 1 µM and 5 µM Vemurafenib compared to DMSO treatment. ERK activation by 1 µM 
Vemurafenib was blocked by adding 0.01 µM Cobimetinib. However, this Cobimetinib concentration 
was not sufficient to prevent ERK phosphorylation in combination with 5 µM Vemurafenib. A reduction 
of this hyper-activation to control levels was achieved by 0.1 µM Cobimetinib. Moreover, increasing 
concentrations of Cobimetinib led to an accumulation of phosphorylated MEK, but not total MEK. This 
effect was even stronger in combination with Vemurafenib and thus, likely reflected the MEK inhibitor 
mechanism, which did not allow further ERK phosphorylation by MEK leading to an accumulation of 
phosphorylated MEK. Hyper-activation of signaling through Vemurafenib further increased this effect 
(Fig. 43). Since the combination of 5 µM Vemurafenib with 0.1 µM Cobimetinib completely blocked 
pathway activation at the level of MEK, this concentration was used for subsequent experiments.
Subsequently, the response of Cobimetinib co-treatment and thereby, the MEK-ERK specificity of 
Vemurafenib induced gene expression was assessed in HaCaT-RAS A-5 monolayer cultures by qRT-
PCR. Normalization was performed using GAPDH and fold-changes were expressed by comparing 
each treatment to the DMSO control set to one. As shown before (see Fig. 41), Vemurafenib (5 µM) 
upregulated the growth factors TGFA, IL1A and IL1B by 2-4-fold (8 or 24 h) compared to the control. 
The cytokine IL-8 was included in the analysis, as it mediated proliferation of HaCaT cells (see Figs. 
12+13 and Sobel, Tham et al. 2015). Also IL8 and was similarly upregulated by Vemurafenib after 8 and 
24 h. Importantly, the co-treatment with 0.1 µM Cobimetinib caused a downregulation of these genes. 
VEM [5 µM]VEM [1 µM] control
D
M
S
O
– –
kDa
HaCaT-RAS A-5 (4 h)
38
38
38
COBI
38
38
P-MEK1/2
P-ERK1/2
MEK1/2
ERK1/2
GAPDH
DMSO: 0.15% | COBI: 0.01, 0.1, 1 µM
Figure 43 | Cobimetinib prevents 
Vemurafenib induced MEK-ERK hyper-
activation.
HaCaT-RAS A-5 cells were stimulation with 0.15% 
(v/v) DMSO, 1 or 5 µM Vemurafenib in combination 
with 0, 0.01, 0.1 or 1 µM Cobimetinib for 4 h. Western-
Blot analysis revealed ERK phosphorylation by 
Vemurafenib treatment. Co-treatment with 0.1 µM 
Cobimetinib prevented Vemurafenib induced ERK 
phosphorylation. Additionally, Cobimetinib led to an 
accumulation of phosphorylated MEK, but not total 
MEK, which was more pronounced with increasing 
Cobimetinib concentrations or in combination with 
Vemurafenib. This likely reflected a block in ERK 
phosphorylation by MEK. [n=1]
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Furthermore, inhibition of basal MEK activity by Cobimetinib (0.1 µM) led to a similar downregulation 
as the combination treatment. The matrix remodeling factor MMP1 was 3.0 or 2.1-fold upregulated by 
Vemurafenib after 8 or 24 h, respectively, while Cobimetinib co-treatment caused a downregulation. 
Furthermore, MMP3 revealed a 6.8-fold upregulation after 8 h, which was downregulated by additionally 
adding Cobimetinib, while a 2.3-fold downregulation was detected by Vemurafenib treatment after 24 h. 
MMP9 was either 4.6 or 3.4-fold upregulated by Vemurafenib stimulation after 8 or 24 h, respectively, 
while Cobimetinib co-treatment prevented this effect. Interestingly, whereas MMP1, MMP3 and 
MMP9 were regulated by both inhibitors, MMP14 gene expression did not respond to any treatment. 
Additionally, the differentiation marker KRT10 did not respond to Vemurafenib, but Cobimetinib co-
treatment caused a 1.8 or 2.7-fold upregulation after 8 or 24 h, respectively. FLG did not respond to 
Vemurafenib or Cobimetinib (Fig.44a).
Since NHEK cultured in Derma Life showed a very high MMP1 and MMP3 gene induction upon 
Vemurafenib, I tested whether this effect depends on calcium level regulating keratinocyte differentiation. 
Therefore, HaCaT-RAS A-5 cells were shifted for 9 days from FBS and calcium containing growth 
medium to the defined low-calcium medium Derma Life. This resulted in basal HaCaT-RAS A-5 cells 
that did not differentiate upon reaching confluency (Fig. 44c). Expression analysis demonstrated that 
TGFA, IL1A, IL1B and IL8 were upregulated by Vemurafenib, while combination treatment with 
Cobimetinib resulted in a downregulation comparable to HaCaT-RAS A-5 cells in calcium-containing 
growth medium. Importantly gene expression of MMP1 (15 or 155-fold), MMP3 (13 or 15-fold) and 
MMP9 (3.5 or 14-fold) was highly increased by Vemurafenib after either 8 or 24 h. Again, MMP14 
expression remained unchanged by any treatment demonstrating that it is not regulated by MEK-ERK 
MAPK signaling. Cobimetinib also prevented the induction of MMP1, MMP3 and MMP9 and led to a 
gene downregulation compared to the DMSO control. KRT10 levels were either not altered after 8 h or 
downregulated by Vemurafenib after 24 h compared to DMSO treated HaCaT-RAS A-5 cells. However, 
Cobimetinib increased KRT10 by either 4 or 64-fold (8 or 24 h). Similarly, FLG was not altered by 
Vemurafenib, but 1.6 or 2.1-fold upregulated (8 or 24 h) by Cobimetinib treatment suggesting toxicity 
related differentiation (Fig. 44b).
A possible reason for the higher induction of especially MMP1 in HaCaT-RAS A-5 cells grown in Derma 
Life vs. growth medium is a lower basal gene expression in Derma Life. Hence, the relative differences 
in mRNA levels were calculated between DMSO treated HaCaT-RAS A-5 cells cultured in Derma 
Life and DMEM+FBS. TGFA, IL1B, MMP3, MMP9 and MMP14 revealed a similar basal expression 
under both conditions. IL1A was not altered after 8 h, but 34-fold higher expressed in cells grown in 
Derma Life 24 h after replacing the medium. Although Derma Life generally induces IL1A expression, 
this difference was not reflected in the regulation by Vemurafenib in Derma Life vs. DMEM+FBS. 
Importantly, MMP1 demonstrated a 26 or 71-fold lower basal expression in HaCaT-RAS A-5 grown 
in Derma Life 8 or 24 h post medium-change, respectively (Fig. 44d), thus implying a higher range for 
Vemurafenib induced gene upregulation.
Taken together, 0.1 µM Cobimetinib prevented Vemurafenib-induced MEK-ERK hyper-activation in 
HaCaT-RAS A-5 cells confirming that the Vemurafenib increased gene expression especially of MMP1, 
MMP3 and MMP9 was most likely dependent on ERK-activity and specific for keratinocytes.
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5.2.15 Vemurafenib and Cobimetinib combination treatment of fdmOTCs
To determine whether the two major Vemurafenib induced phenotypes differentiation and invasion 
depend on MEK-ERK hyper-activation in fdmOTCs, Cobimetinib was used to abrogate signaling via 
ERK and thus, restore the epithelial morphology.
5.2.15.1 Cobimetinib treatment is tolerated in HaCaT-RAS A-5 fdmOTCs
Toxicity by Cobimetinib was assessed in HaCaT-Ras A-5 cells because they showed major gene 
regulation as well as strong changes in differentiation and invasion upon Vemurafenib. For this purpose, 
2 week-old HaCaT-RAS A-5 fdmOTCs were treated with 0.06% (v/v) DMSO as control, 0.1 µM or 1 
µM Cobimetinib for 3 weeks (Fig. 45a). In control cultures, HaCaT-RAS A-5 cells formed the typical 
multilayered and hyper-proliferative epithelium with a disorganized BM (Fig. 45b). Treatment with 0.1 
µM Cobimetinib resembled the control, although the number of epithelial layers was reduced and parts 
of the epithelium became atrophic (Fig. 45c). Cobimetinib at a concentration of 1 µM caused complete 
atrophy of the epithelium, leaving only few vital cell islands. Interestingly, NHDF appeared to be only 
slightly affected in their number by Cobimetinib (Fig. 45d), demonstrating that high Cobimetinib 
concentrations are toxic for epithelial development only. As 0.1 µM Cobimetinib revealed only a limited 
toxicity and was proven to be sufficient to block ERK hyper-activation as well as Vemurafenib induced 
gene induction in vitro, this concentration was subsequently employed.
5.2.15.2 Combination treatment prevents ERK hyper-activation, differentiation 
and invasion
In order to determine the role of ERK activation as well as the presence of a Ras mutation in Vemurafenib 
mediated epithelial invasion and differentiation, fdmOTCs with non-tumorigenic HaCaT as well as 
Figure 44 | Vemurafenib gene regulation depends on ERK-activity in HaCaT-RAS A-5 cells.
HaCaT-RAS A-5 monolayer cultures were stimulated with 0.06% (v/v) DMSO and 5 µM Vemurafenib alone or 
in combination with 0.1 µM Cobimetinib for 8 and 24 h. RNA was subjected to qRT-PCR for a gene expression 
analysis of growth factors (TGFA, IL1A, IL1B, IL8), matrix remodeling factors (MMP1, MMP3, MMP9, MMP14) 
and differentiation-associated genes (KRT10, FLG). Normalization was performed using GAPDH and fold-changes 
were expressed by comparing each treatment to the DMSO control set to one. a | All growth factors and matrix 
remodeling factors were increased by Vemurafenib after 8 and 24 h, while MMP3 was only unregulated after 8 h. 
Co-treatment with 0.1 µM Cobimetinib caused downregulation of these genes compared to DMSO stimulated cells. 
Inhibition of basal MEK activity by Cobimetinib (0.1 µM) led to a similar downregulation. MMP14 was not regulated 
by any treatment. The differentiation marker KRT10 did not respond to Vemurafenib, but Cobimetinib co-treatment 
led to an upregulation after 8 or 24 h, while FLG was not regulated. b, c | HaCaT-RAS A-5 cells were shifted for 9 
days to the low-calcium medium Derma Life, resulting in cells that did not differentiate upon reaching confluency 
(c). Expression analysis demonstrated that Vemurafenib induced gene regulation was comparable to high-calcium 
growth medium and combination treatment with Cobimetinib also resulted in a downregulation of these genes. 
MMP1 was strongly upregulated by Vemurafenib especially in Derma Life, which was turned to a downregulation 
by combination treatment. KRT10 was downregulated by Vemurafenib, while Cobimetinib highly increased KRT10 
after 24 h stimulation. MMP14 and FLG expression remained unchanged (b). d | The differential expression between 
control cultures in Derma Life and DMEM+FBS was calculated 8 and 24 h after replacing the respective medium. 
TGFA, IL1B, MMP3, MMP9 and MMP14 revealed a similar basal expression, while IL1A was higher expressed in 
HaCaT-RAS A-5 cells grown in Derma Life after 24 h. MMP1 demonstrated highly increased expression in cells 
grown in Derma Life after 8 or 24 h, implying a higher range for Vemurafenib induced gene upregulation. [n=2, mean 
± SD, normalized to DMSO control, log2 scale]
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with H-RasG12V-transfected benign-tumorigenic HaCaT-
RAS A-5 cells were prepared. Cultures were grown for 
2 weeks to resemble a multilayered and differentiated 
epithelium before stimulating with either 0.06% (v/v) 
DMSO, 5 µM Vemurafenib, 0.1 µM Cobimetinib or the 
combination of both inhibitors for another 1-3 weeks 
(Fig. 46a, b).
Histological characterization of HaCaT control cultures 
revealed the generation of a multilayered and disorganized 
epithelium showing parakeratotic stratification after 
2+1 weeks (Fig. 46c). Treatment with Cobimetinib 
abolished terminal differentiation and reduced the 
number of cell layers, implying some toxicity (Fig. 
46d). As observed earlier, Vemurafenib accelerated differentiation at the cost of vital HaCaT cell layers 
(Fig. 46e). Co-treatment with Cobimetinib prevented Vemurafenib accelerated differentiation restoring 
the epithelium of control cultures with fewer differentiation (Fig. 46f). After 2+3 weeks, control cultures 
further stratified, while reducing the number of vital layers (Fig. 46g). Cobimetinib mono-treatment 
prevented terminal differentiation, but at the same time caused some atrophy of the epithelium (Fig. 
46h). Vemurafenib stimulation further accelerated differentiation of HaCaT cells compared to controls, 
accompanied by a reduction in vital layers. Basal cells were even more organized compared to controls, 
but without showing invasive growth (Fig. 46i). The combination treatment prevented Vemurafenib 
induced differentiation, but caused atrophy that became stronger compared to 2+1 week-old cultures 
(Fig. 46j). Moreover, IHC was performed to visualize the level of ERK hyper-activation in 2+3 week-
old HaCaT fdmOTCs. In control cultures, some basal ERK phosphorylation was observed (brown, Fig. 
46k). Cobimetinib led to a complete loss of ERK phosphorylation demonstrating its specificity to inhibit 
MEK and confirming the employed inhibitor concentration (Fig. 46l). Vemurafenib strongly increased 
ERK phosphorylation in basal HaCaT cells and NHDF directly underneath the epithelium showing 
that Vemurafenib mediates MEK-ERK hyper-activation also in fdmOTCs (Fig. 46m). Importantly, 
Cobimetinib co-treatment reduced ERK phosphorylation below the level of control cultures (Fig. 46n), 
thus preventing ERK-dependent effects by Vemurafenib.
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Figure 45 | High Cobimetinib concentrations cause 
epithelial atrophy in HaCaT-RAS A-5 fdmOTCs.
a | fdmOTCs were prepared by NHDF cultivation for 4 weeks 
to generate a fibroblast-derived matrix (fdm), before HaCaT-
RAS A-5 cell seeding. Epithelial growth and stratification 
was allowed for 2 weeks to mimic the in vivo situation and 
thereafter, cultures were treated with 0.06% (v/v) DMSO, 0.1 
µM or 1 µM Cobimetinib for another 3 weeks. b-d | FFPE 
sections were stained with haematoxylin/ eosin to analyze 
the morphology. DMSO treated HaCaT-RAS A-5 cells formed 
the typical multilayered and hyper-proliferative epithelium with 
a disorganized BM (b). Treatment with 0.1 µM Cobimetinib 
resembled the control, although the number of epithelial 
layers was reduced (c). 1 µM Cobimetinib caused complete 
atrophy of the epithelium, leaving only few vital cell islands. 
NHDF appeared to be only slightly affected by Cobimetinib 
(d). [n=3]
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Figure 46 | Vemurafenib induced differentiation depends on ERK-activity in fdmOTCs.
a, b | fdmOTCs were prepared by NHDF cultivation for 4 weeks to generate a fibroblast-derived matrix (fdm), 
before keratinocyte seeding (a). Epithelial growth and stratification was allowed for 2 weeks to mimic the in vivo 
situation and thereafter, cultures were treated with 0.06% (v/v) DMSO, 5 µM Vemurafenib, 0.1 µM Cobimetinib or 
the combination of both inhibitors for another 1 or 3 weeks (b). c-j | FFPE sections were stained with haematoxylin/ 
eosin to analyze the morphology. After 2+1 weeks, HaCaT control cultures generated the typical multilayered and 
disorganized epithelium showing parakeratotic stratification (c). Treatment with Cobimetinib abolished terminal 
differentiation and reduced the number of cell layers (d). Vemurafenib accelerated differentiation at the cost of 
vital cell layers (e), while co-treatment with Cobimetinib prevented differentiation (f). After 2+3 weeks, controls 
further stratified (g). Cobimetinib prevented terminal differentiation and caused some atrophy (h). Vemurafenib 
stimulation accelerated differentiation and led to increased organization of basal cells (i), which was prevented by 
Cobimetinib co-treatment (j). [n=3] k-n | Immunohistochemistry (IHC) of FFPE sections was performed to visualize 
ERK phosphorylation in 2+3 week-old HaCaT fdmOTCs. IHC without antibody did not result in any defined signal 
(not shown). Some basal ERK phosphorylation (brown) was observed in control cultures (k). Cobimetinib led to 
a complete loss of ERK phosphorylation demonstrating its specificity (l). Vemurafenib strongly increased ERK 
phosphorylation in basal HaCaT cells and NHDF (m), which was prevented by Cobimetinib co-treatment (n). [n=3]
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HaCaT-RAS A-5 control fdmOTCs formed the typical multi-layered, disorganized and hyperplastic 
epithelium lacking cornification after 2+1 weeks (Fig. 47a). Cobimetinib treated cultures resembled 
controls without showing toxicity (Fig. 47b). In contrast, Vemurafenib treatment caused terminal 
differentiation as well as an increased basal disorganization (Fig. 47c). Cobimetinib co-treatment restored 
the epithelial morphology of controls by preventing both, accelerated differentiation and pre-invasive 
behavior (Fig. 47d). After 2+3 weeks, HaCaT-RAS A-5 control epithelia were very similar compared 
to the 2+1 weeks cultures (Fig. 47e). Also Cobimetinib treated cultures remained largely unchanged, 
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Figure 47 | Vemurafenib induced differentiation/ invasion depends on ERK-activity in fdmOTCs.
fdmOTCs were prepared by NHDF cultivation for 4 weeks to generate a fibroblast-derived matrix (fdm), before 
HaCaT-RAS A-5 seeding. Epithelial growth and stratification was allowed for 2 weeks to mimic the in vivo situation 
and thereafter, cultures were treated with 0.06% (v/v) DMSO, 5 µM Vemurafenib, 0.1 µM Cobimetinib or the 
combination of both inhibitors for another 1 or 3 weeks. a-h | FFPE sections were stained with haematoxylin/ eosin 
to analyze the morphology. After 2+1 weeks, HaCaT-RAS A-5 control fdmOTCs formed the typical multi-layered, 
disorganized and hyperplastic epithelium lacking cornification (a). Cobimetinib treated cultures resembled controls 
without showing toxicity (b). Vemurafenib caused terminal differentiation as well as increased basal disorganization 
(c), but Cobimetinib co-treatment restored the control epithelial morphology (d). After 2+3 weeks, control epithelia 
(e) and Cobimetinib cultures remained unchanged (f). Vemurafenib stimulated cultures demonstrated increased 
differentiation and cells grew invasively into the dermal equivalent (g). Both, accelerated differentiation and invasion 
were prevented by Cobimetinib co-treatment (h). [n=3] i-l | Immunohistochemistry (IHC) of FFPE sections was 
performed to visualize ERK phosphorylation in 2+3 week-old HaCaT-RAS A-5 fdmOTCs. IHC without antibody did 
not result in any defined signal (not shown). HaCaT-RAS A-5 control fdmOTCs revealed basal ERK phosphorylation 
(i). Cobimetinib prevented ERK activation (j). Vemurafenib stimulation led to a strong increase in epithelial ERK 
phosphorylation (k), which was prevented by Cobimetinib, restoring basal ERK activation (l). [n=3]
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showing only minor toxicity compared to HaCaT cultures (Fig. 47f). Vemurafenib stimulated cultures 
demonstrated further increased differentiation including the appearance of horn pearls. Moreover, cells 
grew invasively into the dermal equivalent, which was also described in an earlier experiment after 2+3 
weeks of treatment (Fig. 47g). Importantly, accelerated differentiation and even invasion were prevented 
by Cobimetinib co-treatment (Fig. 47h). When analyzing phosphorylated ERK levels of the different 
cultures by IHC, HaCaT-RAS A-5 fdmOTCs also showed a basal ERK phosphorylation (Fig. 47i). 
Cobimetinib completely prevented ERK activation showing its specificity also in HaCaT-RAS A-5 cells 
(Fig. 47j). In contrast, Vemurafenib stimulation led to a tremendous increase in ERK phosphorylation 
compared to control cultures that was observed throughout the culture, but especially present at invasive 
sites (Fig. 47k). Combination treatment with Cobimetinib prevented invasion, and also restored basal 
ERK activation of control cultures (Fig. 47l).
Taken together, Vemurafenib mediated ERK hyper-activation in HaCaT and HaCaT-RAS A-5 
fdmOTCs was retained at basal levels by Cobimetinib co-treatment. Furthermore, Vemurafenib-induced 
differentiation as well as invasion of HaCaT-RAS A-5 cells was prevented by Cobimetinib co-treatment. 
This suggested that both phenotypes indeed depend on Vemurafenib induced MEK-ERK activity, 
whereas the Ras mutation of HaCaT-RAS A-5 cells may be additionally required for invasive growth.
5.2.15.3 Keratinocyte differentiation and MMP-activity depends on ERK-signaling
For an in-depth analysis of proliferation, differentiation and invasion in response to Vemurafenib and 
Cobimetinib treatment, immunofluorescence was performed. First, proliferation was determined by 
staining for incorporated BrdU in HaCaT and HaCaT-RAS A-5 cultures. Therefore, the number of 
BrdU-positive cells of entire fdmOTC sections was calculated relative to the corresponding BM length, 
as measured by Collagen IV staining (proliferation index). In HaCaT fdmOTCs, a proliferation index 
of 1.8 was determined after 2+3 weeks. Vemurafenib (5 µM) increased proliferation to 2.9, which was 
reduced by Cobimetinib (0.1 µM) co-treatment to 0.7. However, none of these changes were significant. 
HaCaT-RAS A-5 control cultures revealed a proliferation index of 10.4, confirming the higher basal 
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Figure 48 | Proliferation 
of keratinocytes is not 
affected by ERK-activity in 
fdmOTCs.
fdmOTCs were prepared by 
NHDF cultivation for 4 weeks 
to generate a fibroblast-derived 
matrix (fdm), before seeding 
keratinocytes. Epithelial growth 
and stratification was allowed 
for 2 weeks to mimic the in vivo 
situation and thereafter, cultures 
were treated with 0.06% (v/v) 
DMSO, 5 µM Vemurafenib only 
or in combination with 0.1 µM 
Cobimetinib for another 3 weeks. 
Keratinocyte proliferation was 
determined by staining cryo-sections for incorporated BrdU and quantified by calculating the number of BrdU-
positive cells relative to the BM length, measured by Collagen IV co-staining (proliferation index). Neither in HaCaT 
nor in HaCaT-RAS A-5 cells, proliferation was significantly altered by Vemurafenib or Cobimetinib compared to 
control cultures. [n=3, mean, One-way ANOVA + Dunnett’s Multiple Comparison Test]
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proliferation compared to HaCaT cells. Vemurafenib (5 µM) or Cobimetinib (0.1 µM) co-treatment 
decreased proliferation to either 6.7 or 7.0, but none of the effects were considered significant. This 
confirmed that Vemurafenib was not affecting proliferation of keratinocytes irrespective of a RAS 
mutation (Fig. 48).
Second, keratinocyte differentiation upon treatment was investigated by staining for the late differentiation 
marker Filaggrin. After 2+3 weeks, DMSO stimulated cultures showed low levels of Filaggrin on top of 
the epithelium (Fig. 49a). Filaggrin signal was increased in Vemurafenib stimulated cultures accounting 
for the increased differentiation (Fig. 49b). By combination treatment with Cobimetinib, Filaggrin 
levels were strongly reduced leaving only one positive cell layer on the culture (Fig. 49c). HaCaT-
RAS A-5 fdmOTCs also demonstrated only some Filaggrin-positive suprabasal cell layers (Fig. 49d). 
Vemurafenib led to a tremendous increase in Filaggrin-positive cells layers including the formation 
of horn pearls within the epithelium, accounting for an accelerated differentiation (Fig. 49e). This 
observation also correlated with a decrease in HaCaT-RAS A-5 proliferation upon Vemurafenib (see 
Fig. 48). As observed by histology, the addition of Cobimetinib largely prevented Filaggrin deposition, 
resembling control cultures (Fig. 49f), thus confirming a ERK-dependent acceleration of HaCaT and 
HaCaT-RAS terminal differentiation also at a molecular level.
Third, co-staining with the BM maker Collagen IV revealed a strong signal at the BM separating HaCaT 
cells and NHDF as well as throughout the dermal equivalent. However, Collagen IV staining was 
altered by neither Vemurafenib nor Cobimetinib co-treatment (Fig. 49a-c). HaCaT-RAS A-5 control 
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Figure 49 | Vemurafenib induced 
accelerated differentiation 
depends on ERK-activity in 
fdmOTCs.
fdmOTCs were prepared by NHDF 
cultivation for 4 weeks to generate 
a fibroblast-derived matrix (fdm), 
before HaCaT or HaCaT-RAS A-5 
seeding. Epithelial growth and 
stratification was allowed for 2 
weeks to mimic the in vivo situation 
and thereafter, cultures were treated 
with 0.06% (v/v) DMSO, 5 µM 
Vemurafenib only or in combination 
with 0.1 µM Cobimetinib for another 
3 weeks. Immunofluorescence 
staining of cryo-conserved and 
fixed sections was performed to 
investigate terminal differentiation 
by Filaggrin and BM integrity by 
Collagen IV expression. a-c | HaCaT 
control cultures showed low levels 
of Filaggrin (green) (a). Filaggrin 
signal was increased in Vemurafenib 
stimulated cultures (b), which was 
strongly reduced by Cobimetinib 
combination treatment (c). Staining for Collagen IV (red) in HaCaT cultures revealed a strong signal at the BM and 
throughout the dermal equivalent (a) that was not altered by Vemurafenib or Cobimetinib (b, c). d-f | HaCaT-RAS 
A-5 control fdmOTCs demonstrated some Filaggrin-positive suprabasal cell layers (d). Vemurafenib led to a strong 
increase in Filaggrin-positive cells layers (e), which was prevented by Cobimetinib co-treatment (f). HaCaT-RAS 
A-5 control cultures demonstrated a strong Collagen IV signal throughout the dermal equivalent (d). Vemurafenib 
slightly decreased overall Collagen IV levels (e) that was restored by Vemurafenib + Cobimetinib co-treatment (f). 
[n=3]
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fdmOTCs demonstrated a stronger Collagen IV signal throughout the dermal equivalent (Fig. 49d). By 
Vemurafenib treatment, a slight decrease in overall Collagen IV levels was observed together with a 
complete degradation at invasive islands (Fig. 49e). Vemurafenib + Cobimetinib co-treatment revealed 
a stronger overall Collagen IV staining especially at the BM without any signs of invasion (Fig. 49f). As 
we detected an ERK-dependent decrease of Collagen IV in some cultures, Collagen VII was analyzed 
as second BM marker. Immunofluorescence of 2+3 week-old HaCaT control fdmOTCs demonstrated 
a continuous Collagen VII pattern at the BM that was not altered by Vemurafenib or Vemurafenib + 
Cobimetinib (Fig. 50a-c). In HaCaT-RAS A-5 control cultures, Collagen VII also revealed a continuous 
but weaker staining at the BM (Fig. 50d). By Vemurafenib treatment, Collagen VII became a largely 
discontinuous. This was also observed at sites that did not show single cell invasion (Fig. 50e). In contrast, 
Cobimetinib co-treatment demonstrated a strong Collagen VII pattern without any BM disruption (Fig. 
50f). This showed that Collagen IV and VII degradation is also dependent on ERK activity. Since BM 
degradation correlated with invasion only in HaCaT-RAS A-5 fdmOTCs, we speculate that the RAS 
mutation plays in concert with the ERK-activity in mediating tumor progression.
5.2.15.4 MMP expression and activation are mediated through on ERK-activity 
in fdmOTCs
As Vemurafenib-induced MEK-ERK hyper-activation led to MMP1, MMP3 and MMP9 gene expression 
in monolayer cultured keratinocytes, I asked whether these matrix remodeling factors also correlate with 
the observed Collagen degradation. Therefore, MMP-1, MMP-3 and MMP-9 secretion was determined 
in 2+3 week-old cultures by ELISA of 48 h conditioned medium. HaCaT fdmOTCs revealed a basal level 
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Figure 50 | Vemurafenib 
induced ERK-activity results 
in a disrupted BM of fdmOTCs.
fdmOTCs were prepared by NHDF 
cultivation for 4 weeks to generate 
a fibroblast-derived matrix (fdm), 
before HaCaT or HaCaT-RAS A-5 
seeding. Epithelial growth and 
stratification was allowed for 2 
weeks to mimic the in vivo situation 
and thereafter, cultures were 
treated 0.06% (v/v) DMSO, 5 µM 
Vemurafenib only or in combination 
with 0.1 µM Cobimetinib for another 
3 weeks. Immunofluorescence 
staining of cryo-conserved and 
fixed sections was performed to 
investigate BM integrity by Collagen 
VII expression and localization. 
a-c | HaCaT control cultures 
revealed a continuous Collagen 
VII pattern (green) at the BM that 
was not altered by Vemurafenib or 
Vemurafenib + Cobimetinib. d-f | In 
HaCaT-RAS A-5 control cultures, 
Collagen VII revealed a continuous 
staining at the BM (d). Vemurafenib 
treatment led to discontinuous Collagen VII signals at the BM (e), which was restored to a strong Collagen VII 
pattern without any disruption by Cobimetinib co-treatment (f). [n=3]
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of 9.4 ng/mL pro MMP-1, which remained unchanged by Cobimetinib mono-treatment. Vemurafenib (5 
µM) significantly increased the pro MMP-1 levels to 14.1 ng/mL (P<0.05). Furthermore, the combination 
treatment of 5 µM Vemurafenib and 0.1 µM Cobimetinib led to a significant reduction to 6.1 ng/mL pro 
MMP-1, which is even below the level of control cultures (P<0.01). A MMP-3 concentration of 5.7 ng/
mL was detected in HaCaT control cultures that was not significantly changed by treatment with any 
inhibitor. A MMP-9 level of 12.6 ng/mL was determined in control fdmOTCs. MMP-9 was significantly 
downregulated by any treatment, but mainly in the presence of Cobimetinib suggesting a dependence on 
ERK activity (P<0.01, Fig. 51a).
HaCaT-RAS A-5 control fdmOTCs revealed a pro MMP-1 secretion of 27.1 ng/mL, demonstrating a 3-fold 
higher pro MMP-1 secretion as HaCaT cultures. By Cobimetinib treatment, the levels were significantly 
decreased to 4.2 ng/mL pro MMP-1 (P<0.01). Vemurafenib caused a significant upregulation of pro 
MMP-1 to 39.2 ng/mL (P<0.01). Importantly, combined treatment with Vemurafenib and Cobimetinib 
led to a significant pro MMP-1 reduction from Vemurafenib stimulated cultures to 17.5 ng/mL (P<0.01), 
D
M
S
O
 [0
.0
6%
] 2+3 weeksc
V
E
M
 [5
 µ
M
] d
V
E
M
 +
 C
O
B
I
300 µmDQ-Gelatin [1 h]
e
HaCaT-RAS A-5 fdmOTCa
H
aC
aT
 fd
m
O
TC
0
10
20
30
40
50
M
M
P 
se
cr
et
io
n 
[n
g/
m
L] DMSO [0.06%]
VEM [5 µM]
COBI [0.1 µM]
VEM + COBI
pro MMP-1 MMP-3 MMP-9
P<0.01
P<0.05
P<0.01
ns
2+3 weeks [48 h]
b
H
aC
aT
-R
A
S
 A
-5
 fd
m
O
TC
M
M
P 
se
cr
et
io
n 
[n
g/
m
L]
pro MMP-1 MMP-3 MMP-9
0
10
20
30
40
50
P<0.01
P<0.05
P<0.01
P<0.01
P
<0.01
P<0.01
Figure 51 | ERK-activity causes MMP expression and activation in fdmOTCs.
fdmOTCs were prepared by NHDF cultivation for 4 weeks to generate a fibroblast-derived matrix (fdm), before 
HaCaT or HaCaT-RAS A-5 seeding. Epithelial growth and stratification was allowed for 2 weeks to mimic the in vivo 
situation and thereafter, cultures were treated with 0.06% (v/v) DMSO, 5 µM Vemurafenib, 0.1 µM Cobimetinib or the 
combination of both inhibitors for another 3 weeks. a, b | MMP-1, MMP-3 and MMP-9 secretion was determined in 
2+3 week-old cultures by ELISA of 48 h conditioned medium. In HaCaT fdmOTCs pro MMP-1 remained unchanged 
by Cobimetinib mono-treatment. Vemurafenib significantly increased pro MMP-1, which was even reduced below 
the level of control cultures by Cobimetinib co-treatment. MMP-3 was not significantly altered and MMP-9 was 
significantly downregulated by any treatment in HaCaT cultures (a). HaCaT-RAS A-5 control fdmOTCs revealed 
a 3-fold higher pro MMP-1 secretion than HaCaT cultures, which was significantly decreased by Cobimetinib. 
Vemurafenib significantly upregulated pro MMP-1, which was reduced to control level by Cobimetinib co-treatment. 
MMP-3 was not altered by Cobimetinib, but it was significantly upregulated by Vemurafenib. Cobimetinib combination 
treatment caused a significant decrease from Vemurafenib levels. MMP-9 was significantly downregulated by any 
treatment (b). [n=3, mean ± SD, One-way ANOVA + Dunnett’s Multiple Comparison Test] c-e | In situ zymography 
to analyze MMP-activity in HaCaT-RAS A-5 fdmOTCs revealed only weak gelatinolytic activity (green) in control 
cultures (c). Vemurafenib treatment increased fluorescence signals in the epithelium and at invasive sites showing 
increased MMP-activity (d) that was reduced to the level of control cultures by Cobimetinib co-treatment (e). [n=3]
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which did not reach the reduction by Cobimetinib mono-treatment. HaCaT-RAS A-5 cultures secreted 
4.3 ng/mL MMP-3, which was not altered by Cobimetinib. However, Vemurafenib significantly increased 
MMP-3 levels to 6.8 ng/mL (P<0.05). Combination treatment caused again a significant decrease from 
Vemurafenib levels to 2.9 ng/mL MMP-3 (P<0.01). Moreover, MMP-9 revealed a basal expression of 
13.8 ng/mL in control cultures and was significantly downregulated by any treatment but especially by 
Cobimetinib. As MMP-9 was generally downregulated by treatment, it does not seem to be involved in 
the invasive phenotype (P<0.01, Fig. 51b). Taken together, HaCaT-RAS A-5 fdmOTCs showed higher 
basal MMP secretion than HaCaT cultures. However, Vemurafenib increased pro MMP-1 secretion in 
both, confirming the increased MMP1 gene expression of 2D cultures. MMP-3 showed similar levels 
in both cell types, but was only upregulated by Vemurafenib in HaCaT-RAS A-5 fdmOTCs. Most 
importantly, co-treatment with Cobimetinib reduced MMP-1 in both cell types and MMP-3 in HaCaT-
RAS A-5 cells below the level of control cultures demonstrating that MMP-1 and MMP-3 are direct 
target genes of ERK signaling.
Since Vemurafenib upregulated MMP-1 and MMP-3 in HaCaT-RAS A-5 fdmOTCs, the activity of 
MMPs was investigated by a in situ zymography. 2+3 week-old control cultures showed a weak epithelial 
staining (Fig. 51c). Under Vemurafenib treatment, elevated fluorescence signals in the epithelium and 
at invasive sites corresponded to increased MMP-activity (Fig. 51d). Cobimetinib co-treatment reduced 
the fluorescence signal approximately to the level of control cultures (Fig. 51e), suggesting that MMP 
activation was also dependent on ERK signaling in HaCaT-RAS A-5 cultures. Thus, ERK-dependent 
Collagen degradation as well as MMP expression, secretion and activity correlated with invasive growth 
of HaCaT-RAS A-5 cells.
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6. Discussion
The number of cSCC is constantly increasing worldwide (Molho-Pessach and Lotem, 2007). Although 
the local resection of skin tumors is mostly possible, undetected cSCCs become life threatening as 
soon as tumor cells metastasize. Aggressive tumor growth and metastasis is particularly observed 
for immunosuppressed transplant recipients (Euvrard et al., 2003). As mechanisms leading to cSCC 
initiation and progression are not yet fully understood, the roles of two most likely involved signaling 
pathways were investigated in detail. First, I characterized a novel Wnt/Beta-catenin dependent 
fibroblast activation contributing to cSCC progression. Second, as specific B-Raf inhibitors cause cSCC, 
I investigated the contribution of Vemurafenib and the Ras-Raf-MEK-ERK MAPK pathway in tumor 
development and progression.
6.1 Stromal Wnt/Beta-catenin activation in cSCC progression
Previous studies focused on deregulation of Wnt signaling in cSCC tumor cells (Brasanac et al., 2005; 
Doglioni et al., 2003; Lyakhovitsky et al., 2004; Malanchi et al., 2008; Papadavid et al., 2002). In addition, 
we detected Wnt/Beta-catenin activation in stromal fibroblasts and subsequent analyses revealed that 
deregulation of Wnt signaling in NHDF acted to both, increase epithelial cell proliferation and remodel 
the adjacent stroma. Thus, aberrant Wnt signaling may not only be important for the autocrine regulation 
of the tumor cells, but also act in a paracrine fashion within the tumor microenvironment to promote 
skin carcinogenesis. In particular, Wnt-3a stimulated NHDF to secrete the cytokines IL-8 and CCL-2, 
which positively affected HaCaT cell proliferation, as well as the matrix remodeling factor MMP-1 that 
actively degraded ECM and BM, thereby promoting invasive growth of keratinocytes.
6.1.1 Activation of stromal Wnt/Beta-catenin signaling
A constitutive activate Wnt/Beta-catenin was already previously reported in chemically induced murine 
SCCs (Bhatia and Spiegelman, 2005). Wnt pathway activation in the stroma is also not restricted to skin 
cancer. Sano and co-workers found Wnt-induced signaling within the stroma of human mucinous cystic 
neoplasms of the pancreas, suggesting a general role of canonical Wnt signaling in tumor development 
(Sano et al., 2014). How canonical Wnt signaling is induced in tumor cells and stromal fibroblasts is still 
controversially discussed. Previously, it was shown that fibroblasts secrete R-spondin-2, an activator of 
the Wnt/Beta-catenin signaling, contributing to epithelial thickening in a skin OTC model for keloid 
pathology (Chua et al., 2011). Samuel et al. showed that a Rho/ROCK pathway-dependent activation 
of Beta-catenin in mouse skin resulted in epithelial hyper-proliferation and skin thickening. They also 
found activated ROCK in 90% of human cSCCs (Samuel et al., 2011). Kaler and co-workers provided 
evidence for macrophage-derived IL-1 beta as a potential inducer of Wnt/Beta-catenin signaling in 
colon cancer cells in vitro (Kaler et al., 2009).
Importantly, nuclear Beta-catenin is not distributed homogeneously in cSCCs (Sobel, Tham et al., 
2015) or colon carcinomas. In the latter, it was detected at the invasive front, thereby underlining the 
importance of the stroma to provide signals for the tumor cells that drive tumor progression (Brabletz 
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et al., 1998). Similarly, Vermeulen et al. observed a high Wnt activity in tumor cells located close to 
stromal myofibroblasts. They suggested that the myofibroblast-derived HGF is an activator of Wnt/
Beta-catenin signaling (Vermeulen et al., 2010). In this study, the expression of WNT2 and WNT3 
mRNA as well as of Wnt-3 protein was detected in the microenvironment of a subset of human Beta-
catenin positive cSCCs in situ, suggesting an alternative mechanism for an activated Wnt pathway in 
cSCC progression. However, the involvement CAFs was excluded in vitro and in vivo as we detected 
myofibroblasts in neither Wnt-3a stimulated colOTCs nor Beta-catenin activated human cSCCs.
6.1.2 IL-8 and CCL-2 increase HaCaT cell proliferation
We identified IL-8 and CCL-2 as two candidates for Wnt/Beta-catenin induced paracrine factors by 
NHDF leading to epithelial proliferation. Accordingly, functional studies of keratinocytes in vitro 
demonstrated that keratinocytes express the receptors for IL-8 and CCL-2 (Sobel, Tham et al., 2015) 
and showed increased proliferation when stimulated with either IL-8 or CCL-2. In agreement with 
the literature (Luger and Schwarz, 1990; Michel et al., 1992; Steude et al., 2002; Tuschil et al., 1992), 
IL-8 caused a significantly increased proliferation in monolayer HaCaT cells. CCL-2 is also known to 
increase endothelial cell (Okada et al., 2009) and mammary carcinoma cell proliferation (Conti and 
Rollins, 2004). Both, IL-8 and CCL-2 even led to a comparable response as the known mitogen EGF. 
Interestingly, co-stimulation with CCL2 and IL-8 did not further increase proliferation over the individual 
stimulation, arguing that a maximal level of proliferation was reached. In 3D HaCaT colOTCs, Wnt-3a 
stimulation also elevated IL-8 and CCL-2 levels that went along with a significantly increased HaCaT 
cell proliferation. Interestingly, besides increased proliferation, Wnt-3a stimulation showed only weak 
effects on epithelial morphology of HaCaT colOTCs and fdmOTCs. Furthermore, Wnt-3a stimulated 
colOTC were treated with neutralizing antibodies for CCL-2 and IL-8 in order to specifically prevent 
effects of both factors. Inhibiting IL-8 and CCL-2 indeed prevented the hyper-proliferative response of 
the HaCaT cells in Wnt-3a stimulated colOTCs, proving that IL-8 and CCL-2 were responsible for the 
increased proliferation. Importantly, as we detected a similar expression pattern for IL8 and CCL2 in 
human Beta-catenin positive cSCCs in situ, both chemokines likely stimulate keratinocyte proliferation 
in concert in vivo, as well.
In mouse models, fibroblast-derived CCL-2 was shown to recruit and activate tumor-associated 
macrophages (TAMs), which further secrete growth-, survival- and angiogenic factors, thereby promoting 
tumor growth (Condeelis and Pollard, 2006; Lewis and Pollard, 2006). CCL-2 was associated with the 
recruitment of TAMs also in ovarian-, esophageal- and gastric carcinomas (Negus et al., 1997; Ohta 
et al., 2002, 2003). In breast cancer, high levels of CCL-2 within the tumor stroma enhanced primary 
tumor progression as well as metastasis in a macrophage-dependent and independent manner (Hembruff 
et al., 2010). In the OTC model consisting of NHDF and HaCaT cells only, additional pro-tumorigenic 
effects by CCL-2 involving the immune system cannot be determined. Thus, an additional activation of 
the immune system may or may not enhance tumorigenic effects by CCL-2.
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6.1.3 Stromal Wnt/Beta-catenin activation promotes keratinocyte invasion
Besides the cytokines IL-8 and CCL-2, the ECM remodeling protein MMP-1 was also upregulated in 
Wnt-3a stimulated monolayer cultures of NHDF. In agreement, Wnt-3a stimulated colOTCs revealed 
significantly increased pro MMP-1 levels in the conditioned medium, which correlated with elevated 
gelatinolytic activity and increased levels of cleaved collagen, demonstrating that MMPs were activated 
upon Wnt-3a stimulation. Importantly, these effects were not altered by IL-8 and CCL-2 neutralization 
showing an independent regulation of MMP-1 in Wnt-3a stimulated NHDF. Since MMP1 has TCF/
LEF promoter binding sites (Clark et al., 2008), expression is probably directly regulated by the Wnt/
Beta-catenin pathway. Thus, MMP-1 revealed a similar regulation as MMP7, MMP14 and MT3-MMP, 
which have already been described to be direct Wnt target genes in many cancer types (Brabletz et al., 
1999; Crawford et al., 1999; Lowy et al., 2006; Takahashi et al., 2002). Importantly, MMP-1 and cleaved 
collagen were also found to be highly elevated in Beta-catenin activated human cSCCs, underlining the 
relevance of this mechanism for cSCC in situ.
High expression of MMP-1 was frequently reported for tumor and stromal cells as well as for many cell 
lines derived from primary cSCCs (Airola and Fusenig, 2001; Gray et al., 1992; Haider et al., 2006) and 
MMP-1 activity is well-known for providing a pro-migratory and pro-invasive environment (Kalluri, 
2003; Lynch and Matrisian, 2002; Mueller and Fusenig, 2004). By Wnt-3a stimulation of colOTCs, 
we observed a reduction of the BM component Collagen IV and its epidermal binding protein Integrin 
beta-4, which went along with invasive growth of HaCaT cells. Importantly, Collagen IV and Integrin 
beta-4 reduction as well as invasive growth of HaCaT cells was prevented by co-treatment with IL-8 
and CCL-2 neutralizing antibodies. As MMP1 is likely a direct Wnt target gene (Clark et al., 2008), 
pro MMP-1 levels and MMP-activity remained unchanged by neutralizing IL-8 and CCL-2. Thus, an 
additional BM destructive mechanism relying on IL-8 and CCL-2 expression may cooperate with MMP 
expression in invasion of HaCaT cells, both relying on Wnt/Beta-catenin activation of NHDF. In order 
to further analyze invasive growth, fdmOTCs as a more stable OTC invasion model, which is not prone 
to self-degradation (Berning et al., 2015), were stimulated with Wnt-3a. In this model, invasive growth 
was only observed in case of the benign-tumorigenic HaCaT-RAS A-5 cells. HaCaT cells could most 
likely not overcome these more stringent culture conditions. As Wnt-3a activated NHDF increased 
proliferation and invasion, representing two well-established events in the course of carcinogenesis, 
regulation of stromal Wnt activity is important to maintain normal skin homeostasis.
Taken together, we detected deregulation of Wnt/Beta-catenin signaling in fibroblasts of the cSCC 
stroma that triggered the expression of the cytokines IL-8 and CCL-2 as well as of the matrix remodeler 
MMP-1. These factors acted by stimulating either growth of epithelial HaCaT cells in a paracrine fashion 
or by remodeling the immediate stromal environment in OTCs, allowing invasive growth of benign-
tumorigenic HaCaT-RAS A-5 cells in fdmOTCs. Since both, keratinocyte proliferation and matrix 
remodeling are prerequisites for tumor progression (Hanahan and Weinberg, 2011), our findings support 
the role of Wnt regulation in stromal fibroblasts as a crucial mechanism in cSCC progression (Fig. 52).
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6.2 Vemurafenib and epidermal Ras-Raf-MEK-ERK signaling in cSCC 
progression
Raf-MEK-ERK pathway deregulation is found in approximately one-third of human cancers (Dhillon 
et al., 2007), but especially melanoma heavily relies on its constant activity. This discovery led to the 
development of specific B-Raf inhibitors including Vemurafenib (Bollag et al., 2010) and Dabrafenib 
(Hauschild et al., 2012). However, while both inhibitors abrogated MEK-ERK signaling and prevented 
further growth of melanoma strains harboring mutated B-RafV600E/K, they paradoxically hyper-activated 
signaling via MEK-ERK in B-Rafwild-type melanoma cells. As result, a persistent MEK-ERK activation 
in B-Rafwild-type melanoma cells was shown to induce expression changes in a wide range of genes 
including IL8, increase proliferation of N-RasQ61L mutant primary melanoma cells, reduce cell adhesion 
and enhance migration in advanced lesions (Halaban et al., 2010). Furthermore, frequently adverse 
effects on epidermal cells during B-Raf inhibitor therapy like hyperkeratosis and KAs/ cSCCs were also 
hypothesized to be the caused by MEK-ERK hyper-activation (Hatzivassiliou et al., 2010; Heidorn et 
al., 2010; Poulikakos et al., 2010).
6.2.1 MEK-ERK hyper-activation in cutaneous cells
In agreement with the literature, I observed that Vemurafenib (1 µM) blocked MEK-ERK signaling 
in B-RafV600E A375 melanoma cells, while NHEK, HaCaT, HaCaT-RAS A-5 or HaCaT-RAS II-4 
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Figure 52 | Stromal Wnt/Beta-catenin in skin carcinogenesis.
Deregulated Wnt/Beta-catenin signaling in fibroblasts of the cSCC stroma triggers the expression of the matrix 
remodeler MMP-1 as well as of the cytokines IL-8 and CCL-2. While MMP-1 remodeled stroma allows invasive 
growth of benign-tumorigenic HaCaT-RAS A-5 cells in fdmOTCs (a), IL-8 and CCL-2 directly increase proliferation 
of keratinocytes and likely play an additional role in invasive growth (b). Since keratinocyte proliferation and matrix 
remodeling are prerequisites for tumor progression, these findings support the role of Wnt regulation in stromal 
fibroblasts as crucial mechanism in cSCC progression.
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cells revealed a hyper-activation of MEK-ERK signaling. Other pathways including p38 MAPK or 
Akt signaling were not reproducibly altered. In general, Ras-Raf-MEK-ERK signaling was found to 
be normally regulated and activated by EGFR stimulation in HaCaT and HaCaT-RAS II-4 cells. By 
a PCR-based mutation array, the B-Rafwild-type status concerning common mutations was confirmed in 
all analyzed keratinocytes. Besides wild-type B-Raf, both currently hypothesized hyper-activation 
models proposed the requirement of Ras activity resulting from either a mutation or activation of 
upstream pathway components (Hatzivassiliou et al., 2010). In the analyzed set of cells, the somatic 
mutation array confirmed the known H-Ras mutations p.G12V or p.G12L in HaCaT-RAS II-4 or SCC-
12 cells, respectively, while both, HaCaT-RAS A-5 and HaCaT-RAS II-4 cells were shown to have 
stably integrated the HRAS oncogene (Boukamp et al., 1990; Fusenig and Boukamp, 1998; Mueller 
and Fusenig, 1999; Rheinwald and Beckett, 1981). A so-far not described H-Ras mutation p.G12D 
was detected in SCC-13 cells. NHEK and HaCaT cells did not show common RAS-mutations, but 
Vemurafenib induced ERK phosphorylation was detected even in serum-starved HaCaT cells. However, 
EGFR co-stimulation increased MEK-ERK-activation, confirming upstream activity as MEK-ERK 
hyper-activation-promoting stimulus also in keratinocytes.
Moreover, the mechanism proposed by Poulikakos et al. suggested a low local concentration of a 
specific B-Raf inhibitor as third requirement for ERK hyper-activation. As consequence, the inhibitor 
stochastically binds and blocks only one Raf protein of a C-Raf/C-Raf homodimer or C-Raf/B-Raf 
heterodimer leading to a conformational change that trans-activates the other one causing pronounced 
downstream signaling (Poulikakos et al., 2010). In agreement, a high B-Raf inhibitor concentration above 
10 µM prevented a solid MEK-ERK hyper-activation also in HaCaT cells likely due to a simultaneous 
block of both Raf subunits. However, throughout our performed experiments, Vemurafenib related 
toxicity was detected at neither 1 µM short-term and long-term nor 50 µM short-term cultivation. 
Vemurafenib also led to MEK-ERK hyper-activation as well as to some p38 MAPK-activity in NHDF of 
two individual donors. Thus, all analyzed cutaneous cells showed MEK-ERK hyper-activation through 
Vemurafenib treatment with potential downstream effects.
6.2.2 Vemurafenib induced differentiation and invasion in OTCs and cSCCs
Melanoma patients receiving Vemurafenib develop KAs and cSCCs within a median time of 8 weeks. 
However, the development new KAs/ cSCCs were still observed after 52 weeks of treatment. Besides 
that, treatment led to the development of verrucous keratosis and hyperkeratosis (Anforth et al., 2013; 
Anforth et al., 2015). In order to characterize the involvement of Vemurafenib in cSCC tumorigenesis, I 
stimulated monolayer cultured keratinocytes representing different stages in skin carcinogenesis as well 
as 3D OTCs with Vemurafenib. Holderfield and co-workers showed that Vemurafenib treatment of wild-
type mice led to MAPK pathway activation and enhanced epidermal proliferation, but was not sufficient 
for tumorigenesis (Holderfield et al., 2014). In NHEK, Vemurafenib indeed stimulated MEK-ERK 
hyper-activation, however, this led to neither increased proliferation nor tumorigenesis in monolayer 
cultures or OTCs. Besides NHEK, MEK-ERK hyper-activation was found in all analyzed keratinocyte 
cell lines including HaCaT, HaCaT-RAS A-5 and HaCaT-RAS II-4 cells. Although MEK-ERK signaling 
is historically linked to proliferation (Dhillon et al., 2007), different Vemurafenib concentrations did not 
stimulate proliferation of HaCaT or HaCaT-RAS A-5 cells in short-term, long-term monolayer culture 
or fdmOTCs.
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Continuous Vemurafenib stimulation of HaCaT monolayer cultures for 5-9 weeks caused a cell cycle 
shift from G2 or S phase to G1/G0 phase that went along with increased differentiation. Moreover, in 
NHEK the differentiation-associated genes IVL and FLG were upregulated already 24 h after stimulation, 
supporting an early and direct differentiation induction by Vemurafenib. Importantly, KRT10 and FLG 
were upregulated in HaCaT cells after 8 weeks of continuous Vemurafenib stimulation showing a delayed 
induction of differentiation. This phenotype was also confirmed in OTCs. Accordingly, accelerated 
differentiation was confirmed in Vemurafenib treated HaCaT scaOTCs as well as in NHEK, HaCaT and 
HaCaT-RAS A-5 fdmOTCs by histology, FLG mRNA as well as by Keratin-10 and Filaggrin protein 
expression. Compared to NHEK cultures, induction of differentiation was delayed in HaCaT and HaCaT-
RAS A-5 cells. A dose-dependent effect of Vemurafenib on differentiation was not consistent among 
the different keratinocytes and OTC experiments. In HaCaT-RAS A-5 fdmOTCs, Vemurafenib even 
led to the generation of Filaggrin-positive horn pearls. Intriguingly, the in vitro-observed accelerated 
differentiation resembled development of hyperkeratosis and well-differentiated cSCCs in Vemurafenib 
receiving malignant melanoma patients (Anforth et al., 2013).
To model the effects of the Vemurafenib related B-RafV600E inhibitor PLX4720 in cSCCs, Su and co-
workers used the two-stage skin carcinogenesis mouse model. It relies on the induction of H-RasQ61L 
mutations in mouse keratinocytes by topical application of the carcinogen 7,12-dimethylbenz-(a)
anthracene (DMBA) and subsequent long-term application of the tumor promoter 12-O-tetradecanoyl-
phorbol-13-acetate (TPA) (Quintanilla et al., 1986). In this model, PLX4720 administration reduced 
tumor latency, but did not change tumor number. (Su et al., 2012), suggesting an accelerated progression 
of preexisting lesions. In the scaOTC model with a Fibrin matrix, 7 weeks of Vemurafenib treatment 
caused a potential early invasive phenotype by the non-tumorigenic HaCaT cells. However, when 
stimulating fdmOTCs, providing a more stable matrix that is not prone to self-degradation, invasion 
was not observed for NHEK or HaCaT cells. However, this treatment regime led to invasive growth 
of H-RasG12V expressing benign-tumorigenic HaCaT-RAS A-5 cells, thus, confirming an accelerated 
progression of pre-existing lesions rather than a de novo development of cSCC. While low Vemurafenib 
concentrations in the plasma of Vemurafenib patients were associated with tumor progression, no 
significant correlation between elevated plasma levels and adverse effects was detected in vivo (Funck-
Brentano et al., 2015). Similarly, a dose-dependent effect by Vemurafenib on HaCaT-RAS A-5 invasion 
was also not consistent among the different OTC experiments. At present, there are no studies showing 
B-Raf inhibitor-induced cSCC metastasis. Whether this accounts to either the close dermatological 
surveillance and early removal of these lesions (Anforth et al., 2013; Anforth et al., 2015) or a low 
tumorigenic potential of these lesions in vivo remains elusive.
6.2.3 Genetic selection by Vemurafenib and the role of Ras mutations
Vemurafenib induced invasive growth in fdmOTCs was only observed for H-RasG12V transfected 
HaCaT-RAS A-5 cells. Besides the potential requirement of an upstream activity for a lasting MEK-
ERK hyper-activation by specific B-Raf inhibitors (Hatzivassiliou et al., 2010), a predominant role 
of H-Ras and K-Ras in the pathology of KAs/ cSCCs was suggested (Frouin et al., 2014). In line 
with this, recent studies analyzed either 10 or 35 Vemurafenib induced KAs/ cSCCs and determined a 
high RAS mutation frequency of 30-60% in these lesions. The majority of mutations were H-RasQ61L 
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and K-RasG12D (Oberholzer et al., 2012; Su et al., 2012). Moreover, South et al. identified the tumor 
suppressor NOTCH1 as a highly mutated gene in Vemurafenib induced lesions, being important for 
H-Ras driven skin carcinogenesis (South et al., 2014). These results were unexpected, since RAS was 
only mutated in 12% of KAs/ cSCCs induced by the broad-spectrum kinase inhibitor Sorafenib (Arnault 
et al., 2012). Furthermore, the fact that RAS mutations were only detected in 5-15% in spontaneously 
occurring cSCCs of elderly (Boukamp, 2005) argued that Vemurafenib triggers a clonal expansion of 
RAS-mutant keratinocyte populations within a lesion that subsequently progress to a full-blown cSCCs.
In order to assay, whether continuous Vemurafenib stimulation promotes growth of certain clones, a 
M-FISH analysis of HaCaT cells was performed. After 5 weeks, Vemurafenib indeed caused a genetic 
selection of a specific HaCaT subpopulation characterized by gain of i(1q), loss of i(17q) and gain of 
MYC. However, none of these altered chromosomes carries the genes HRAS, KRAS, NRAS, NOTCH1 
or NOTCH2, suggesting that the expression of other genes was altered by Vemurafenib mediated genetic 
selection in HaCaT cells. Since accelerated differentiation was observed already shortly after onset of 
Vemurafenib stimulation in NHEK or HaCaT cells, which do not carry RAS or NOTCH mutations, this 
phenotype was independent of such a mutation. Furthermore, this implied that a RAS mutation may not 
be the only reason for the observed Vemurafenib induced invasive growth of HaCaT-RAS A-5 cells. In 
line with this, Yaktapour and co-workers observed as adverse effect in a Vemurafenib treated stage IV 
melanoma patient the development of chronic lymphocytic leukemia (CLL), which lacked any RAS 
mutation (Yaktapour et al., 2014). Thus, RAS independent pro-tumorigenic mechanisms account for the 
adverse effect by Vemurafenib also in lymphocytes.
6.2.4 Viruses and off-target effects
Whether viruses play a role for secondary tumor development in B-Raf inhibitor-treated patients is also 
controversially discussed. Falchook et al. reported the presence of Merkel cell polyomavirus (MCPyV) 
and the beta-human papillomavirus subtype 17 (HPV-17) in cSCCs of a patient receiving the specific 
B-Raf inhibitor Dabrafenib (Falchook et al., 2013). By analysis of 69 Vemurafenib/ Dabrafenib-induced 
cSCCs (29 patients), Cohen and co-workers detected no oncogenic alpha-HPV genotypes, but frequent 
beta-HPV infections. MCPyV was also detected in some lesions mostly as co-infection with beta-HPV 
(Cohen et al., 2015). In a further study of 62 Vemurafenib related tumors (44 patients), HPV DNA was 
detected in 13%, while a co-occurrence with mutated H-Ras could only be detected in one tumor. In 
contrast, Dika et al. could not observe HPV signatures in 7 Vemurafenib-induced human cutaneous 
SCCs (Dika et al., 2015) and Ganzenmueller and co-workers did not detect any human virus by next 
generation sequencing in 5 benign skin tumors (Ganzenmueller et al., 2013). A third study analyzing 27 
skin lesions of 12 Vemurafenib patients proposed that neither HPV nor human polyomavirus (HPyV) are 
involved in Vemurafenib induced adverse effects such as verrucous keratosis, KAs and SCCs (Frouin 
et al., 2014). Since we excluded the presence of HPV in the spontaneously-transformed HaCaT cells, 
the observed Vemurafenib induced effects on MEK-ERK signaling and differentiation of all analyzed 
keratinocytes as well as on HaCaT-RAS A-5 invasion were independent of a viral infection.
Off-target effects of B-Raf inhibitors affecting signaling pathways or cellular structures besides Ras-
Raf-MEK-ERK MAPK signaling could also be an explanation for the occurrence of cSCCs. However, 
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the fact that only 6-7% of patients treated with the broad-spectrum kinase inhibitor Sorafenib developed 
cSCCs after at least 3 months (Anforth et al., 2013; Arnault et al., 2009; Dubauskas et al., 2009; Robert 
et al., 2011) showed that these tumors are more frequent and arise earlier during treatment with more 
specific BRAF inhibitors. Treatment with the broad-spectrum kinase inhibitor Sunitinib, inhibiting all 
Sorafenib targets but Raf kinases, did not result in the development of any KAs or SCCs (Grimaldi et al., 
2007; Robert et al., 2011). Thus, cutaneous adverse events that develop during treatment with specific 
B-Raf inhibitors depend on the Ras-Raf-MEK-ERK pathway, arguing against off-target effects.
6.2.5 Gene regulation by Vemurafenib stimulation of cutaneous cells
Intensive tumor-stroma cross-talks via direct contacts or soluble factors are well-known events driving 
tumor progression (Mueller and Fusenig, 2004). In melanoma, B-RafV600E mutant cells activated stromal 
fibroblasts to express CXCL-12 and its receptor CXCR-4 (Whipple and Brinckerhoff, 2014), a factor 
known to increase malignancy of many cancer types (Mishra et al., 2011). Similar to Wnt/Beta-catenin 
stimulation (Sobel, Tham et al., 2015), the hyper-activation of NHDF suggested that Vemurafenib 
stimulation of NHDF could also promote the observed effects in OTCs and in vivo. As accelerated 
differentiation and genetic selection were observed in monolayer stimulation experiments, these 
phenotypes were mediated by direct stimulation of keratinocytes. Whether NHDF secreted factors play 
a role in the invasive behavior of Vemurafenib stimulated HaCaT-RAS A-5 cells can only be analyzed 
in a tissue setting, which involves the interaction of tumor and stromal cells. Gene expression analysis 
of known NHDF-derived paracrine factors including cytokines, growth factors, matrix remodeling 
factors and others did not show major regulation by Vemurafenib in NHDF. Certainly, we cannot 
exclude additional NHDF or keratinocyte-derived factors initiating a cross-talk. However, the gene 
expression data pointed towards a direct effect of Vemurafenib on keratinocytes, which subsequently led 
to increased differentiation, genetic selection as well as invasive growth also in co-culture.
To identify oncogenic factors in Vemurafenib hyper-activated epithelial cells, gene regulation of 
cytokines, growth factors, matrix remodeling factors and others was analyzed. After 24 h, Vemurafenib 
slightly upregulated IL1A and IL1B in NHEK, HaCaT and HaCaT-RAS A-5 cells. IL-1 is a well-described 
secretory factor of keratinocytes that enhances expression of growth factors in stromal cells (Maas-
Szabowski et al., 2003). TGFA and IL8 were slightly upregulated in HaCaT-RAS A-5 cell, representing 
potential factors that activate NHDF, as well. Thus, Vemurafenib may well induce a paracrine cross-
talk with NHDF that requires further investigations. Similarly, B-RafV600E mutant melanoma cells with 
constitutive active MEK-ERK signaling were shown to express higher levels the cytokines IL1B, IL6 
and IL8 than B-Rafwild-type counterparts (Whipple and Brinckerhoff, 2014), suggesting that the observed 
gene expression indeed depended on Ras-Raf-MEK-ERK activity. However, the contribution of these 
factors on the invasive phenotype remained elusive. Intriguingly, Vemurafenib induced high MMP1 and 
MMP3 expression in a dose-dependent manner in all analyzed keratinocytes. MMP9 was upregulated 
in HaCaT-RAS A-5 cells, as well. HaCaT cells that were constantly stimulated with Vemurafenib still 
demonstrated increased MMP1 and MMP3 expression after 4 and 8 weeks, revealing a stable induction 
by Vemurafenib. Furthermore, the fact that MMP9 was upregulated in HaCaT-RAS A-5 cells already 
after 24 h, while been expressed by continuously treated HaCaT cells after 4 weeks implied a delayed 
MMP9 response to Vemurafenib in HaCaT cells.
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MMP1 is normally induced in wound-edge basal keratinocytes by contact of Integrin alpha-1 beta-2 and 
dermal Collagen type I leading to p38 MAPK and ERK signaling (Rohani et al., 2014). In fibroblasts, 
Westermarck et al. detected that activation of stress-activated c-Jun N-terminal kinase and p38 pathways 
did not enhance MMP1 promoter activity (Westermarck et al., 2001), while other studies showed either 
a p38-dependent MMP1 and MMP3 mRNA stabilization (Reunanen et al., 2002) or increased MMP1 
transcription in fibroblasts (Brauchle et al., 2000). Furthermore, ERK was also described to be the major 
inducer of MMP1 expression in fibroblasts (Brauchle et al., 2000; Reunanen et al., 2002; Westermarck 
et al., 2001). Despite having detected MEK-ERK hyper-activation as well as some p38-activity, I could 
not confirm an upregulation of MMP1 in NHDF cultured in 2D and 3D. In invasive melanoma cell lines, 
MMP-1 is also constitutively expressed in a MEK-ERK dependent manner, arguing that constitutive 
activation of this pathway allows melanoma cells to acquire an invasive phenotype (Huntington et al., 
2004). In cutaneous SCCs, Van Haren et al. identified MMP-1 upregulation across multiple microarray 
studies (Van Haren et al., 2009). A recent transcriptome analysis of 10 AKs and 30 cSCCs demonstrated 
upregulation of MMP-1, MMP-10, migratory and focal adhesion genes by MAPK-activity as key event 
in the transition from AKs to cSCCs (Lambert et al., 2014). Moreover, we add MMP1 and MMP3 as 
universal target genes of Vemurafenib induced MEK-ERK-activity in keratinocytes representing different 
skin carcinogenesis stages, which correlated with invasion of benign-tumorigenic keratinocytes.
6.2.6 Ras-Raf-MEK-ERK dependence of cSCC progression
To answer whether the observed phenotypes in keratinocytes are due to a MEK-ERK induction or other 
Vemurafenib related effects, the MEK inhibitor Cobimetinib was used to block Vemurafenib effects that 
depend on ERK-activity. MEK inhibitors were developed to prevent resistance development, the major 
problem of melanoma treatment with specific B-Raf inhibitors in patients. In particular, the primary 
resistance pathway appears to be the reactivation of the parallel MAP kinases ERK, JNK and p38 by 
additional mutations, amplifications or alternative splicing. Further mechanisms of acquired resistance 
involve activation of PI3K–PTEN–Akt signaling and others. Interestingly, multiple mechanisms were 
detected within the same tumor biopsy implying a crucial contribution of tumor heterogeneity in 
resistance development (Lidsky et al., 2014; Shi et al., 2014; Sun et al., 2014). The combination of 
B-Raf and MEK inhibitors increased apoptosis and delayed onset of resistance in melanoma monolayer 
cultures and spheroids (Paraiso et al., 2010). Co-administration of Dabrafenib and Trametinib also 
enhanced the inhibition of human tumor xenograft growth in mouse models (King et al., 2013). This led 
to the investigation of a combination therapy for treatment of malignant melanoma also in clinics. As 
result, combined B-Raf and MEK inhibition improved response rates, PFS and OS compared to mono-
therapy with each inhibitor (Larkin et al., 2014a; Long et al., 2014; Robert et al., 2015).
Of importance, cutaneous adverse events were also decreased by combination treatment. In a Phase 
III clinical trial, 495 patients with previously untreated unresectable locally advanced or metastatic 
B-RafV600 mutation positive melanoma received Vemurafenib plus Cobimetinib combination therapy 
or Vemurafenib plus placebo. Combination therapy correlated with a decrease in new skin cancers and 
other hyper-proliferative skin lesions. In particular, reduction rates for KAs/ SCCs from 19% to 8% 
and hyperkeratosis from 29% to 10% were achieved (Larkin et al., 2014a). In a second Phase III trial 
comparing, Dabrafenib plus Trametinib combination therapy vs. the B-Raf inhibitor Dabrafenib alone, 
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a comparable reduction in cutaneous side effects was monitored (Long et al., 2014). Noteworthy mono-
therapy with the MEK-inhibitor Trametinib caused adverse events except for SCCs (Jang and Atkins, 
2013). These observations are consistent with the suggested pathogenesis of these lesions i.e. MEK-
ERK hyper-activation by specific B-Raf inhibitors that is abrogated at the level of MEK through the 
additional MEK inhibitor (Hatzivassiliou et al., 2010; Heidorn et al., 2010; Poulikakos et al., 2010). 
Here, 0.1 µM Cobimetinib was sufficient to prevent ERK hyper-activation by 1-5 µM Vemurafenib in 
monolayer cultures as well as in HaCaT and HaCaT-RAS A-5 fdmOTCs. Cobimetinib caused some 
toxicity at a concentration of 0.1 µM, led to major atrophy of the epithelium at 1 µM, but did not affect 
NHDF. Of interest is that HaCaT cells were more sensitive to Cobimetinib than HaCaT-RAS A-5 cells, 
which was likely due to an elevated basal ERK activity through H-RasG12V of the latter.
When co-administered, Cobimetinib prevented the Vemurafenib induced accelerated differentiation, 
which was determined by histology and Filaggrin staining, thus, confirming that this phenotype was 
indeed dependent on increased ERK signaling. Furthermore, Cobimetinib co-treatment prevented 
invasive growth of HaCaT-RAS A-5 cells in our fdmOTC model. Invasion and metastasis to different 
body sites is observed during progression of many human tumors. Several classes of proteins involved 
in tethering cells to each other or to ECM structures are altered in invasive cells (Hanahan and Weinberg, 
2000). To further unravel the invasion mechanism of HaCaT-RAS A-5 cells, I investigated changes in gene 
regulation upon Vemurafenib and Vemurafenib plus Cobimetinib co-treatment. As result, upregulation 
of Vemurafenib induced genes in HaCaT-RAS A-5 cells such as TGFA, IL1A, IL1B, IL8, MMP1 MMP3 
and MMP9 was abolished with additional Cobimetinib treatment, thus, confirming that these genes and 
in particular MMP1, MMP3 and MMP9 were upregulated through ERK-activity. Interestingly, MMP14 
expression was not affected by any inhibitor, suggesting an alternative regulation. Despite direct MEK-
ERK regulation, only pro MMP-1 secretion was upregulated by Vemurafenib in HaCaT fdmOTCs. 
Since Cobimetinib combination treatment restored control levels, this demonstrated also for HaCaT 
cells an ERK-dependent gene regulation of MMP-1. In HaCaT-RAS A-5 cells both, MMP-1 and MMP-3 
were significantly upregulated by Vemurafenib, although basal pro MMP-1 levels were already a 3-fold 
higher compared to HaCaT cells. MMP-9 secretion was downregulated by Vemurafenib in HaCaT and 
HaCaT-RAS A-5 fdmOTCs and therefore, unlikely played a role in the invasive phenotype. Moreover, 
we generally observed a lower basal level of MMP-3 compared to pro MMP-1 in HaCaT and HaCaT-
RAS A-5 fdmOTCs as described previously (Berning et al., 2015). By Cobimetinib co-treatment, MMP-
1 and MMP-3 secretion were significantly downregulated in HaCaT-RAS A-5 fdmOTCs, confirming 
the ERK-dependent expression of both MMPs. From these findings it is tempting to speculate that the 
higher MMP-1 levels and the additional induction of MMP-3 in HaCaT-RAS A-5 vs. HaCaT fdmOTCs 
may be triggered by an increased ERK-activity through H-RasG12V in HaCaT-RAS A-5 cells. Thus, the 
expressed set of MMPs appeared to be dependent on the stage in carcinogenesis and/or the presence 
of an additional RAS mutation. This may well explain the difference in invasive behavior between 
Vemurafenib stimulated HaCaT and HaCaT-RAS A-5 cells.
Besides MMP expression in 2D + 3D, gelatinolytic activity was also increased in HaCaT-RAS A-5 
fdmOTCs by Vemurafenib. As Gelatin degradation was strongly reduced by Cobimetinib co-treatment, 
we concluded that MMP secretion and activation depended on ERK-activation. Furthermore, as we 
observed increased MMP-activity and the BM components Collagen IV and Collagen VII are known 
substrates of either MMP-3+MMP-9 or MMP-1+MMP-3 (Visse and Nagase, 2003), the distribution of 
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both Collagens was determined in fdmOTCs. While Vemurafenib did not reproducibly alter both BM 
proteins in HaCaT cells, Collagen IV as well as Collagen VII appeared to be reduced by Vemurafenib 
induced ERK-activation in HaCaT-RAS A-5 fdmOTCs. This suggested that Vemurafenib induced ERK-
activation directly induced MMP-1 and MMP-3 expression, which subsequently remodeled or degraded 
BM components like Collagen IV and VII. These observations could explain the mechanism of invasion 
by HaCaT-RAS A-5 cells in fdmOTCs.
In a recent study, Vemurafenib treatment in a K5-SOS-F mouse model led to growth of preexisting 
tumors, epidermal thickening of tail, eyelids, and ears after 5-7 days. These effects were reduced by 
additional MEK inhibition using Trametinib and led the authors to conclude that Vemurafenib induced 
proliferation and de-differentiation (Doma et al., 2013). Moreover, Roh and co-workers found that 
stimulation of HaCaT cells with 2 µM Vemurafenib causes MEK-ERK phosphorylation, increased 
proliferation and invasiveness in a matrigel assay after 24 h (Roh et al., 2015). In contrast, we did not 
observe de-differentiation as the EMT marker SNAI2 was not upregulated in keratinocytes, but rather 
demonstrated highly increased differentiation by Vemurafenib treatment in all analyzed keratinocytes. 
Second, although employing Vemurafenib concentrations ranging from 1-5 µM Vemurafenib and having 
observed MEK-ERK hyper-activation, we did not detect significantly increased proliferation in NHEK, 
HaCaT or HaCaT-RAS A-5 cells in monolayer cultures or OTCs. This Vemurafenib concentration even 
prevented growth of NHEK. In agreement with both publications, we describe growth of preexisting 
keratinocyte lesions characterized by MMP expression, activation and BM degradation that promoted 
invasive growth of benign-tumorigenic human keratinocytes. Invasive growth of HaCaT cells already 
after 24 h in Matrigel as shown by Roh et al. (Roh et al., 2015) probably accounted to the presence 
of multiple growth factors and an ECM lacking complexity (Hughes et al., 2010; Vukicevic et al., 
1992). We could also demonstrate early invasive steps in HaCaT scaOTCs after 7 weeks of Vemurafenib 
stimulation, which was prevented in the fdmOTCs model due to the more stringent conditions. Similar to 
our results, Roh and co workers also identified increased MMP expression and activation by Vemurafenib 
particularly of MMP-2 and MMP-9 as possible mediators for tumor progression and invasion (Roh et al., 
2015). We did not investigate MMP-2 levels as this MMP was recently described to be highly expressed 
in unstimulated HaCaT fdmOTCs, while being downregulated in cultures with SCC cell lines (Berning, 
2015), thus questioning its contribution to tumorigenesis in the fdmOTC model. Furthermore, MMP-9 
was also upregulated by Vemurafenib in monolayer cultured HaCaT-RAS A-5 cells after 8-24 h and in 
HaCaT cells after 4-8 weeks, but we could not determine a Vemurafenib induced secretion in fdmOTCs. 
Different from Roh et al., we found MMP-1 and MMP-3 to be upregulated by ERK activation in both 
HaCaT-RAS A-5 monolayer cultures and fdmOTCs in combination with an increased MMP-activity in 
3D, thus being most likely responsible for the invasive growth.
Taken together, this study revealed that Vemurafenib mediated MEK-ERK hyper-activation in dermal 
fibroblasts and keratinocytes induced differentiation as well as MMP1 and MMP3 gene expression in 
keratinocytes. High pro MMP-1 and MMP-3 secretion especially in Vemurafenib activated benign-
tumorigenic HaCaT-RAS A-5 fdmOTCs correlated with Collagen remodeling or degradation, allowing 
invasive growth into the dermal equivalent. These effects were directly dependent on ERK-activation 
as they were prevented by co-treatment with the MEK inhibitor Cobimetinib. The invasive behavior 
of HaCaT-RAS A-5 cells was even higher in Vemurafenib compared to Wnt-3a stimulated fdmOTCs. 
Vemurafenib also mediated genetic selection pressure on HaCaT cells. A cross-talk between NHDF and 
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keratinocytes that further increased differentiation or invasion was not detected, however, cannot be 
fully excluded as Vemurafenib induced MEK-ERK hyper-activation also in these cells (Fig. 53).
6.3 Conclusion and future perspective
In this thesis, the impact of stromal Wnt/Beta-catenin as well as of Ras-Raf-MEK-ERK signaling on 
human cSCC development and progression was investigated. The performed experiments allowed 
obtaining a more detailed understanding of the oncogenic events leading to spontaneously occurring 
cSCCs. Together with aberrant Wnt signaling in tumor cells, a novel Wnt-dependent cross-talk between 
human skin carcinoma cells and their stromal fibroblasts was identified. Upon Wnt/Beta-catenin 
activation NHDF secrete proliferation and invasion inducing factors that further promote carcinogenesis. 
While this Wnt-regulatory mechanism represents a locally confined tumor-stroma cross-talk indirectly 
acting on keratinocytes, Vemurafenib-induced MEK-ERK hyper-activation was of direct consequence 
for the keratinocytes. ERK-activity subsequently triggered keratinocyte differentiation and invasive 
growth only of benign-tumorigenic keratinocytes, showing that a tumor-permissive genetic make-up is 
required for Vemurafenib-driven invasion. Interestingly, the invasion of HaCaT-RAS A-5 cells was even 
advanced in Vemurafenib compared to Wnt-3a-treated OTCs, demonstrating the power of Vemurafenib 
to cause cSCC formation within a very short time. Moreover, Vemurafenib directly caused a genetic 
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Figure 53 | Vemurafenib and Ras-Raf-MEK-ERK MAPK signaling in skin carcinogenesis.
Vemurafenib mediated MEK-ERK hyper-activation in dermal fibroblasts and keratinocytes directly induces 
differentiation (a) as well as MMP1 and MMP3 gene expression in keratinocytes. High pro MMP-1 and MMP-3 
secretion especially by Vemurafenib-activated benign-tumorigenic HaCaT-RAS A-5 cells correlates with Collagen 
remodeling/ degradation and subsequent invasive growth in fdmOTCs (b). These effects are directly dependent 
on ERK-activation as both are prevented by co-treatment with the MEK inhibitor Cobimetinib. Vemurafenib also 
mediates genetic selection of HaCaT cells (c). A cross-talk between NHDF and keratinocytes that further increases 
differentiation or invasion was not detected, but cannot be fully excluded (d).
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selection of keratinocytes. Thus, both, canonical Wnt and ERK-activity promoted tumor progression. 
A cross-talk between canonical Wnt signaling and EGFR induced Ras-Raf-MEK-ERK signaling in 
development and cancer is largely unknown. However, both pathways can transactivate one another. 
In particular, Wnt ligands can activate EGFR signaling through Frizzled, while EGFR activates Beta-
catenin via RTK-Akt pathway. EGFR was also shown to form a complex with Beta-catenin, which 
increased invasion and metastasis of cancer cells (Hu and Li, 2010). Although cross-activation was 
not discovered in this study, both investigated mechanism could cooperate in vivo to promote cSCC 
development or progression.
While monoculture experiments and organotypic cultures allow unravelling mechanisms leading to 
cSCC, it was necessary to validate the obtained results in also primary human cSCCs. Wnt-2 and Wnt-
3 ligands, Wnt pathway activation as well as IL-8, CCL-2, MMP-1 expression and collagen cleavage 
by MMPs were validated in cSCCs. Similar to our in vitro results, highly-differentiated human cSCCs 
emerged during B-Raf inhibitor therapy in vivo. Hence, these cSCCs should also be analyzed for ERK 
hyper-activation, keratinocyte differentiation, MMP expression and invasive growth on a molecular 
level in future. The role of the immune system could also not be addressed in the models used in 
this study. As it is well appreciated that precancerous lesions are under tight control of the immune 
system (Boukamp, 2005) and B-Raf signaling is central for lymphocyte regulation (Comin-Anduix et 
al., 2010), MEK-ERK hyper-activation could also render immune cells as additional players in cSCC 
tumorigenesis. A detailed understanding of the involved mechanisms would allow designing improved 
drugs with increased specificity and reduced adverse events assigned for melanoma therapy.
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